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Abstract 
 
Pharmaceutical industries aim for continuous improvement in the manufacturing 
process of producing medicines. Demands on the pharmaceutical industries are to 
produce quality products in a quick and cost effective way. Designing a robust 
crystallization process so as to produce quality crystals with the desired polymorphic 
form, morphology, size and size distribution, will contribute towards meeting these 
demands. The Food and Drug Administration regulating body encourages the 
development of quality by design (QbD) approaches, involving the use of process 
analytical technology (PAT) for the design of the crystallization process. This method 
enables the design of the crystallization process to be more flexible in terms of variation 
in operating conditions and process parameters so long as the quality of the product is 
maintained. The aim of this thesis work is to use QbD approaches involving the use of 
PAT tools and solid state analytical (SSA) techniques to increase process knowledge 
and understanding, which is required for the robust design of crystallization processes.  
 
Discovery of all possible polymorphic forms of an active pharmaceutical ingredient 
(API) is important for the design of a robust crystallization process in which product 
quality is consistent during scale up and to prevent late stage failures. This thesis work 
shows the importance of using PAT tools and SSA techniques for monitoring 
polymorphic transformations and for the discovery of new polymorphic forms that have 
not yet been reported in the literature. A range of PAT tools including the FBRM, 
turbidity probe and ATR-UV/Vis spectrometer detected polymorphic transformations 
during both cooling and antisolvent crystallization experiments using the model system 
sodium benzoate in water and a propan-2-ol (IPA)/water mixture. Information obtained 
from a range of SSA techniques provided supporting evidence for the discovery of a 
new channel hydrate, channel solvate and an anhydrous form of sodium benzoate.  
 
The problem of crusting (solid depositing on vessel walls) occurring within 
crystallization vessels has been investigated with the use of a combination of PAT tools 
and SSA techniques. The FBRM and turbidity probe detected a change occurring 
during the cooling crystallization process of para-amino benzoic acid (ABA) in ethyl 
acetate. Repeats of the experiments using the ATR-UV/Vis confirmed that the change 
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was due to crusting forming on vessel walls and not a polymorphic transformation. PAT 
tools also detected changes occurring during a pH controlled polymorphic cooling 
crystallization experiment (Chapter 9), which was subsequently confirmed by SSA 
methods to be due to the formation of a mixture of products and not a polymorphic 
transformation. This research work shows the importance of using a combination of 
PAT tools and SSA techniques for gaining a deeper understanding of the crystallization 
process and to prevent misinterpretation of results, saving both time and money. Also 
this research work highlights the need for improvement within industrial scale vessel 
design, such as vessels with variable jacket height, to prevent the problems of crusting.  
Robust MSZW measurements are obtained at laboratory scale using the model 
crystallization systems para and meta-ABA in water. PAT tools used include the 
FBRM and turbidity probe. The robust MSZW takes into consideration variation in 
process parameters including ramp rate, vessel size (1 mL and 1 L), agitator speed and 
type. This robust MSZW can be used for the design of scale up experiments (pilot plant 
and industrial scale), increasing the likelihood of producing a quality product. 
Nucleation orders used within crystallization models were determined from the MSZW 
measurements. Results showed that the nucleation order varied within different 
crystallization set-ups (vessel size and mixing conditions) using the model system meta-
ABA in water. Therefore model-based design and scale-up of crystallization processes 
must be used carefully and more detailed mechanistic models, which take into 
consideration the effect of mixing need to be designed to improve the generality and 
applicability of crystallization models. 
 
pH controlled polymorphic crystallization experiments were performed using the model 
systems meta and para-ABA in ethanol and water. A combination of 5 PAT tools were 
used in a single vessel to monitor the cooling crystallization process. PAT tools used 
include FBRM, ATR-UV/Vis, PVM, pH and a temperature probe. Various parameters 
including mixing conditions, solvent, pH of solution, strength and type of acid were 
varied to investigate the best conditions to produce salts. Results showed that careful 
selection of design parameters and salt selection is important for producing quality 
crystals of the desired morphology so as to prevent problems in downstream processing.
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Chapter 1. Introduction 
 
 1.1 Background 
 
Pharmaceutical industries aim for continuous improvement in the manufacturing 
process of producing medicines (Sistare et al., 2005). The driving force is to produce 
quality products in a quick and cost effective way (Federsel, 2009). There are many 
problems and challenges that the pharmaceutical industry faces in the current market. 
One of the demands is to reduce the time it takes from the discovery of an active 
pharmaceutical ingredient to marketing the drug. In the past the total time allocated to 
achieve this was more than 10 years but now demands require this stage to take less 
putting pressure on the designing and scaling up process (Federsel, 2009). One of the 
reasons for the increase in speed in developing new medicines is the short patent life of 
a drug (typical 20 years), giving approximately 11-12 years or less profitable period 
once launched to market (Sternitzke, 2010). Due to these demands high risk decisions 
are taken involving the scaling up the chemistry from lab to pilot plant without the full 
knowledge and understanding of the process, including kinetics, formation of 
byproducts, isolation and crystallization conditions (Federsel, 2009). This has resulted 
in late stage failures. Recent examples include a new developed drug for Alzheimer‟s 
disease (Dimebon), which showed hopeful signs after passing phase 2 clinical trials but 
failed phase 3 trials and an antidepressant drug (ebalzotan), which was discontinued 
after phase 1 trials due to the side effects in healthy volunteers (Federsel, 2009; 
Goldhill, 2010). These late stage failures contribute to a large proportion of the cost of 
producing drugs, which is estimated at a value of 802 million dollars (Schachter and 
Ramoni, 2007). Failures can also occur during the crystallization process, which is in 
effect the final purification stage of the synthesis of the API in the manufacturing 
process of medicines.  
 
Designing the crystallization process is important so as to produce crystals of desired 
polymorphic form, shape and crystal size distribution (Chen et al., 2009; Lu and Ching, 
2006; Yu et al., 2007; Yu et al., 2004; Abu Bakar et al., 2009a, Abu Bakar et al., 
2009b; Aamir et al., 2010). Purity of the compound is also an important parameter to 
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control (Braatz et al., 2002; Aamir et al., 2010). Different polymorphic forms have the 
same chemical composition but have different arrangement of molecules resulting in 
different structures. This leads to variations in morphology and physico-chemical 
properties between the different forms, including melting point, stability, solubility, 
dissolution rates and bioavailability, which can have a great effect on the quality of the 
product and can lead to problems with downstream processing (Davey and Garside, 
2000). Compounds are often crystallized as salts to overcome problems with solubility, 
dissolution rate, stability and hygroscopicity (Forbes et al., 1992, Haynes et al., 2005).  
Compounds may incorporate solvent molecules within the crystal lattice structure 
forming a hydrate or solvate. These forms are also known as pseudo-polymorphs. 
Reddy et al. (2009) reported that 50% of 254 active pharmaceutical ingredients (API‟s) 
are polymorphic. Another report stated that a new polymorphic form of a 
pharmaceutical compound used to treat HIV-1 was discovered during late stage 
development (Desikan et al., 2005), which was fortunately found in this instance to 
have no significant impact on the development of the drug. However in some cases the 
discovery of new polymorphs during late stage development or after the drug has been 
marketed can have a disastrous effect on the supply of an essential drug product as was 
found to be the case for the drug Ritonavir. Abbott Laboratories discovered a new 
polymorphic form of the drug Ritonavir after it had been on the market for two years 
(Chemburkar et al., 2000). Differences in the solubility of the two forms resulted in 
failed dissolution tests in the originally semisolid capsule, which lead to a market crisis 
(Chemburkar et al., 2000).  Production of the undesired polymorphic form would result 
in an increase in economic costs (Davey, 2003).  It is of very high importance within 
the pharmaceutical industry that all possible polymorphs, hydrates or solvates of a 
particular compound are identified and the crystallization process is controlled so that 
the desired form is produced (Bechtloff et al., 2001).  
 
To produce a quality product and prevent failures during any stage of the development 
process including crystallization, downstream processing and clinical trials, the demand 
grows towards process knowledge and understanding (Federsel, 2009). This changes 
the direction of the pharmaceutical industry towards a quality-by-design (QbD) 
approach rather than the traditionally method of quality-by-testing (Yu, 2008). 
Pharmaceutical QbD emphasises processes and product understanding and process 
control (Yu, 2008). QbD approaches within the crystallization field involve the use of 
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process analytical technology (PAT), which has been greatly promoted by the Food and 
Drug Administration (FDA) regulatory body (Yu et al., 2007). PAT tools are probe 
based methodologies in which various instruments are placed within the process stream 
for the monitoring of the crystallization process (Birch et al., 2005). These tools provide 
information about the process and product, which can be used to design a process to 
produce crystals with the desired properties. The application of these tools has lead to 
the development of novel control approaches for pharmaceutical crystallization, which 
can lead to significant product quality improvements (Nagy et al., 2008b; Zhou et al., 
2006; Abu Bakar et al., 2009a; Woo et al., 2009; Gron et al., 2003; Yu et al., 2007; 
Fevotte, 2007; Simon et al., 2009). Extensive studies have been carried out which also 
demonstrate the importance of these tools for the detection or control of polymorphic 
transformations (Simon et al.,  2009; Howard et al., 2009a; Howard et al., 2009b; 
David et al., 2004; O‟Sullivan and Glennon, 2005; Dharmayat et al., 2006; Caillet et 
al., 2008; Fevotte, 2002; Nagy et al., 2007). 
 
Process analytical tools can be used to indicate a potential polymorphic transformation, 
however a range of solid state analytical (SSA) techniques usually must also be used to 
confirm the formation of polymorphs. These techniques provide information that 
enables the different polymorphic/pseudo-polymorphic forms to be identified. Various 
combination of the SSA techniques can be used for the identification of polymorphic 
forms, including X-ray powder diffraction (XRPD), differential scanning calorimetry 
(DSC), thermal gravimetric analysis (TGA), dynamic vapour sorption (DVS) and a 
range of microscopy techniques including hot stage (HSM), optical and scanning 
electron microscope (SEM) (Brittain, 1999; Giron, 2003; Karpinski, 2006; David et al., 
2004; Giron, 1995). 
 
In industry it is often most desirable to crystallize the most stable polymorph to prevent 
polymorphic conversion during further downstream processing including filtration or 
drying, transportation and storage. This involves following a set profile within the meta-
stable zone width (MSZW) region of the phase diagram. PAT tools are used for 
obtaining MSZW values for the crystallization system at laboratory scale (Barrett and 
Glennon, 2002). There are many factors including rate of supersaturation generation, 
level of impurities and mixing conditions that affect the MSZW (Lu and Ching, 2006; 
Trifkovic et al, 2009; Barrett and Glennon, 2002). Obtaining a robust MSZW region, 
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which takes into consideration variations in process parameters, will provide the 
operating conditions so scale up of the process from laboratory scale to industrial 
production can be achieved without affecting the quality of product (Beckmann, 2000; 
Barrett and Glennon, 2002). 
 
1.2. Aims of current study 
 
The aims of the current study are included within the following points:  
 
i. To show the benefits of using a QbD approach for the investigation into 
polymorphism using one of the main model systems, sodium benzoate. PAT 
tools and SSA techniques are used to detect polymorphic transformations during 
the crystallization process and discovery of new forms of crystalline compound. 
Detection of all possible polymorphic forms earlier on in development of a drug 
can prevent late stage failures 
ii. To highlight the benefits of using a combination of PAT tools and SSA 
techniques to gain a deeper understanding of the cooling and pH controlled 
polymorphic crystallization processes using the model system para-amino 
benzoic acid in ethyl acetate and ethanol. These tools prevent the 
misinterpretation of results obtained during the crystallization process, saving 
both time and money.  
iii. To identify the common problem of crusting occurring within laboratory scale 
crystallization vessels, this emphasises the need for improvement within the 
design of pilot plant and industrial size rigs. Better vessel design would increase 
the likelihood of producing a quality product when scaling up from lab to 
manufacturing scale and prevent failed batches.  
iv. To  determine whether a robust MSZW can be obtained at the lab scale, which 
can then be used for designing a crystallization process at pilot plant and then 
manufacturing scale to ensure a quality product. This will be achieved by 
studying how various factors including temperature, ramp rate, agitator speed, 
agitator type and scale (1 mL and 1 L) affect the MSZW using PAT tools. Also 
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the effect of system set-up (scale of vessel and agitator type) on the nucleation 
order will be investigated to determine whether crystallization models are 
system specific. 
v. To gain a deeper understanding of the crystallization of salts and to examine 
how pH and solvent affects the crystal form which nucleates from solution by 
obtaining data from PAT tools during the crystallization process and analysing 
the crystal product using a range of SSA techniques.  
 
1.3. Contributions of the thesis 
 
This thesis discusses the importance of using a QbD approach involving the use of PAT 
tools and SSA techniques to increase process understanding and knowledge, which can 
speed up the time of drug discovery to marketing by designing more robust 
crystallization processes. Information obtained from PAT tools including the FBRM 
and ATR-UV/Vis provided supporting evidence of polymorphic transformations. SSA 
techniques confirmed the formation of new undiscovered hydrates/solvates that have 
not been reported in the literature. Discovery of new polymorphic forms of a compound 
earlier on in development can prevent late stage failures. 
 
PAT tools have also been used to identify changes occurring during the crystallization 
process, which were originally thought to be polymorphic transformations but after 
further analysis using SSA techniques the change was found to be due to crusting (solid 
forming on vessel walls). A combination of PAT tools and SSA techniques increases 
process understanding, saving both time and money that would have been spent in 
researching the possible different polymorphic forms. The increase in process 
understanding obtained by a QbD approach also highlights the need for improvement in 
industrial vessel design such as vessels with variable jacket height to eliminate the 
problems of crusting (solid forming on vessel walls). Better vessel design would reduce 
the variability in product properties, increasing the likelihood of producing a quality 
product at manufacturing scale. 
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By using a QbD approach a robust meta-stable zone width (MSZW) was obtained at lab 
scale, which takes into consideration variation in ramp rate, vessel size (1 mL to 1 L), 
agitator speed and type. MSZW is defined as the difference between the solubility 
(clear) curve and nucleation (cloud) curve at any given concentration value. The robust 
MSZW was found only to apply for compounds that have a large MSZW. This robust 
MSZW can be used to design a crystallization process at larger scale (pilot and 
manufacturing scale) increasing the likelihood of producing a quality product. 
Nucleation orders were found to vary for different crystallization vessel set-up, which 
included variation to vessel size and agitator type. This research shows that 
crystallization models using nucleation orders are system specific and could result in 
failed batches if used for the design of scale up experiments.  
 
A novel method is presented in the thesis that uses a combination of five PAT tools in a 
single vessel and a range of SSA techniques to examine the best conditions to produce 
salts, for the model system para- and meta-amino benzoic acid in water and ethanol. 
The best method for crystallizing salts was found to be cooling and evaporation. 
Precipitation resulted in agglomeration forming poor quality salt crystals. Solid state 
characterisation of salt crystals showed that crystals which contain the sodium and 
potassium ions form hydrates and solvent can affect significantly the morphology of the 
salt. The QbD approach increases process understanding, which enables better design of 
the crystallization process and identifies the required stages of downstream processing 
to prevent polymorphic transformations (e.g. involving the formation of hydrates).  
 
1.4. Structure of the thesis 
 
Chapter 1 gives an introduction into the problems pharmaceutical industries face and 
focuses on the crystallization process, which is one of the final stages in the 
manufacturing of medicines. The aims of the current study, thesis contribution and 
structure of the thesis report are discussed.  
 
Chapter 2 reviews the relevant literature on pharmaceutical crystallization. The sub 
sections within this chapter consist of general concepts including definition of a crystal, 
phase diagram of a crystallization process, driving force for crystallization and different 
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methods of nucleation. Polymorphism is discussed together with the thermodynamics 
and kinetics of polymorphic systems. Various different PAT tools and solid state 
analytical (SSA) techniques are discussed. The important information that can be 
obtained about the crystallization process and crystalline product from each technique is 
mentioned.  
 
Chapter 3 focuses on experimental materials and methods. Experiments performed at 
the 1 mL scale using the Avantium Crystal 16 equipment include solubility screening, 
slurry experiments and MSZW measurements. Gravimetric method for solubility 
determination is described. Cooling crystallization expeirments at scales of 250, 750 
and 1 L are discussed for model systems sodium benzoate and the isomers of amino 
benzoic acid (ABA). Other methods of crystallization described are the antisolvent 
crystallization of sodium benzoate and precipitation and evaporative crystallization 
experiments of ABA salts. Equipment used for solid state characterisation of the 
crystals is discussed.   
 
Chapter 4 discusses the experimental results involving the use of PAT tools and SSA 
techniques for the monitoring of polymorphic transformations during the cooling 
crystallization of sodium benzoate in water. The PAT tool used for monitoring the solid 
phase within this study is the FBRM probe. These results highlight the importance of 
combining PAT tools and SSA techniques for discovering new polymorphic forms.  
 
Chapter 5 discusses the experimental results for the antisolvent crystallization of 
sodium benzoate from an IPA/water mixture. PAT tools are used for monitoring the 
crystallization process and for detecting polymorphic transformations. PAT tools within 
this study include FBRM, ATR-UV/Vis and turbidity probe. A wide range of SSA 
techniques are used for analysing the crystal product, which provides supporting data 
on the existence of new undiscovered polymorphic forms.  
 
Chapter 6 highlights the problems of crusting (solid depositing on vessel walls) 
occurring during a crystallization process which is supported with data obtained from 
PAT tools and SSA techniques. Data provided from these tools is shown to provide a 
deeper understanding of the crystallization process preventing the misinterpretation of 
results, saving both time and money.   
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Chapter 7 discusses the results obtained from meta-stable zone width (MSZW) 
experiments using the model systems of amino benzoic acid (ABA) isomers in water. A 
number of parameters were varied including ramp rate, agitator type, agitator speed and 
scale (1 mL and 1 L) to examine the effect of these on the MSZW. Combining the 
effect of all these parameters a robust MSZW region was obtained for the design of 
larger scale experiments. Calculations are presented on nucleation orders, enthalpy and 
entropy of dissolution within different crystallization set-ups to examine whether 
models using nucleation orders are system specific.  
 
Chapter 8 presents the results on solid state characterisation of salts using a range of 
SSA techniques.  The model systems used are para- and meta-amino benzoic acid 
(ABA). A range of acids and bases were used to produce the salts including 
hydrochloric acid (HCl), hydrobromic acid (HBr), sulphuric acid (H2SO4), phosphoric 
acid (H3PO4), sodium hydroxide (NaOH) and potassium hydroxide (KOH). Different 
methods are used to crystallize the salts to examine the best method of producing 
quality crystals. These methods include cooling, precipitation and evaporation. 
Structural differences between the HBr and HCl salts of para and meta-ABA are 
examined using XRPD to determine whether these are iso-structural.  
 
Chapter 9 presents the experimental results on pH controlled polymorphic 
crystallization using the zwitterionic model systems meta- and para-ABA. 
Combinations of five PAT tools were used to monitor the crystallization process 
including FBRM, ATR-UV/Vis, PVM, pH and temperature probe. pH of solution and 
solvent were varied to identify the conditions under which certain forms of the salts 
form. SSA techniques are used to characterise the crystal products and provide the 
experimental conditions for which the different polymorphic forms of meta-ABA 
crystallize.  
 
Chapter 10 gives an overall conclusion of all the results discussed within this thesis 
and a recommendation for future experiments based on the results.  
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Chapter 2. Literature review   
 
2.1 Definition and detection of a crystal 
 
Crystallization is referred to as a purification technique which involves the formation of 
a solid from a solution or vapour (Davey and Garside, 2000). A solid is classified by 
how the constituent molecules, atoms or ions are packed together. There are two solid 
forms known as crystalline and amorphous. Crystalline solids have an internal structure 
where the atoms, molecules or ions (growth units) are arranged into a specific order. 
This order continues throughout the crystal structure over many atomic lengths 
resulting in long range order. The number of molecules that make up this order can be 
as much as 10 20 , which are of specific molecular sizes. No matter how many times the 
crystallization process is repeated for the same compound, it will result in the same 
internal structure making this a very unique and powerful technique for obtaining 
purified products with specific properties (Davey and Garside, 2000). Random 
distribution of atoms, molecules or ions results in amorphous solids that only have short 
range order. The arrangement of atoms affects the internal crystal structure and hence 
the physical properties. These include growth and dissolution rates of particular crystal 
faces, habit, refractive indices, thermal and electrical conductivity. Crystalline solids are 
referred to as anisotropic as the properties vary according to the direction in which they 
are measured. The opposite is true for amorphous solids which are referred to as 
isotropic (Mullin, 2001). Typical detection of crystalline solids is carried out using 
differential scanning calorimetry (DSC) for the indication of a sharp and specific 
melting point and the use of X-ray powder diffraction (XRPD) resulting in a specific 
powder diffraction pattern (Davey and Garside, 2000).  
 
2.2 Crystal systems and lattices 
 
Crystals are highly ordered crystalline solids with specific arrangement of molecules. A 
single unit cell is the building block for a crystal (see Figure 2.1). Various lattice 
parameters including the length of axes and the angles between the axes are used to 
characterise the crystal.  
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Figure 2.1. A single unit cell. Length of axes: a, b and c. Angles between the axes: 
 ,  and   (Myerson, 2002) 
 
 
A single crystal is made up of many unit cells combined together. The internal structure 
of the crystal affects the lattice parameters, which then affect the degree of symmetry. 
Crystals are classified into specific crystal systems according to the degree of 
symmetry. The types of symmetry include symmetry about a point, line or plane (Jones, 
2002). There are seven different crystal systems, which are characterized with specific 
axes lengths and angles between the axes. These are cubic, tetragonal, orthorhombic, 
monoclinic, triclinic, trigonal, and hexagonal. Within some crystal systems the 
molecules can be arranged into different positions within the crystal lattice resulting in 
space lattices. Each molecule within the space lattice is subject to identical 
environmental conditions resulting in a homogenous structure (Mullin, 2001). Figure 
2.2 shows the four different types of space lattices known as primitive (P), end-centred 
cube (E), body-centred cube (B) and face-centred cube (F). 
 
 
                               
 
 
 
 
 
 
 
Primitive(P)       End centred cube(E)   Body-centred cube(B)    Face centred cube(F)      
 
 
Figure 2.2. Various forms of space lattices 
 
α 
β c γ 
a 
b 
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There are 14 possible Bravais lattices, which include the various different forms of 
space lattices within the 7 different crystal systems (Jones, 2002). These 14 Bravais 
lattices are shown in Table 2.1 together with crystals that resemble that specific crystal 
system. 
 
Table 2.1. 14 Bravais lattices and examples of crystals resembling particular 
crystal systems (Crystal Structure, 2010; Mineralogy Database, 2010; Minerals by 
name, 2010)   
  
Crystal system  
(Length of axes 
and angles 
between 
axis:  ,, )  
Bravais lattice Crystal example 
    (P)    (E)      (B)    (F)    
Cubic 
 
(All lengths the 
same 
: aaa  ) 
 
090 
 
 
 
 
 
 
 
 
Sodium chloride  
Tetragonal 
 
Lengths:  
aa  c  
 
Angles: 
090 
 
 
 
 
 
 
 
      Rutile 
 
          Zircon 
Orthorhombic 
 
Lengths: 
cba   
 
Angles: 
090    
 
 
 
 
   Hemimorphite 
 
       Empressite 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates  
12 Chapter 2. Literature review 
2011 
 
Monoclinic 
 
Lengths: 
 cba   
 
Angles: 
  090
 
 
 
  
 
      Kinoite 
Triclinic 
 
Lengths: 
cba   
 
Angles: 
090 
  
 
   
 
  Copper sulphate   
Trigonal 
(Rhombohedral
) 
 
Lengths:  
aaa   
 
Angles: 
090 
 
 
   
 
Ruby 
 
Quartz 
Hexagonal  
 
Lengths: ca   
 
Angles:  
 
   
 
Graphite 
 
 
2.3  Phase equilibria and crystallization methods 
 
2.3.1  Introduction 
 
A good understanding of the crystallization process is required so it can be controlled to 
produce a product, which has specific physical properties. This requires knowledge of 
under what conditions (temperature, pressure and composition) certain phases will be 
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present. Information obtained from the phase rule and diagram is important for ensuring 
the manufacturing process runs efficiently leading to the production of quality product. 
 
2.3.2 Phase rule 
The phase rule gives an indication of how many variables can be changed for the 
system to remain in the same phase (Davey and Garside, 2000). This is expressed as the 
degrees of freedom ( F ) and is shown in the following equation:  
 
2 CFP                                                                                                            (2.1) 
 
where P is the number of phases and C  is the number of components within a system. 
 
A pure system such as water contains only one component ( 1C ). There are three 
possible phases of water, which are ice, liquid water and water vapour giving a value of 
P =3. Substitution of these values into Equation (2.1) results in zero degrees of 
freedom. This indicates that in order for all three phases to coexist and be in equilibrium 
only one set of conditions of temperature and pressure can be applied. This system is 
referred to as invariant (Mullin, 2001). For a two phase system such as liquid water and 
water vapour the degrees of freedom is 1. Only one variable, either temperature or 
pressure, can be varied for the two phases to coexist in a stable state. The system is 
referred to as a univariant (Mullin, 2001). For a single phase such as liquid water the 
degrees of freedom is 2. Temperature and pressure are independent, which indicates 
that the system will remain in the liquid phase if there is a change in both variables. 
This system is referred to as bivariant (Mullin, 2001).  
 
2.3.3 Phase diagrams 
Phase diagrams show under what sets of conditions certain phases will exist and the 
equilibrium conditions for certain phases to coexist. A system that is in equilibrium is in 
a state of rest (stable state) and the chemical potential of the phases are the same 
(Smith, 1990). By changing any of the variables a new equilibrium is established. 
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An essential requirement for the crystallization process is a supersaturated solution. 
This is the driving force for crystallization (Collins et al., 1997). The supersaturation 
can be expressed in a number of ways. In thermodynamics terms the supersaturation is 
referred to as the difference in chemical potential ( )  between a molecule in a 
supersaturated state ( )ss  and a molecule in an equilibrium state ( )eq  (Davey and 
Garside, 2000): 
 
eqss   .                                                                                                       (2.2)  
 
For a pure substance the chemical potential is expressed as the free energy per mole: 
 
in
G
  ,                                                                                                                    (2.3) 
 
where G  is the Gibbs free energy and in  is the number of moles of component i . 
 
For a non-ideal system the interactions between the molecules in solution are taken into 
account and the concentration of solute in solution is replaced by an effective 
concentration known as the activity. An equation relating the chemical potential of a 
component in solution to its activity is shown in the following Equation (Smith, 1990): 
 
i
o
ii aRT ln   ,                                                                                                    (2.4) 
 
where R is the gas constant, T is the temperature and ia  is the activity of component i  
and 
0
i  is the standard chemical potential of component i  at 1atm pressure. For 
molecules in an equilibrium state and a supersaturated state the following chemical 
potential expressions are obtained:  
 
ss
o
iss aRT ln  ,                                                                                                   (2.5) 
eq
o
ieq aRT ln  .                                                                                                  (2.6) 
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Substitution of Equation (2.5) and (2.6) into Equation (2.2) results in the following 
Equation:  









eq
ss
eqss
a
a
RT ln .                                                                                  (2.7) 
 
Rearrangement of Equation (2.7) gives:  
 
 










eq
ss
a
a
RT
ln

.                                                                                                        (2.8) 
 
Effective concentration known as activity ( a ) is related to the real concentration ( c ) by 
the following Equation (Smith, 1990):  
 
iii ca  ,                                                                                                                   (2.9) 
 
where ic  is the concentration of component i  and i  is the activity coefficient.  
 
For an ideal system the interactions and hence forces between all molecules are 
assumed to be the same (Smith, 1990). In this case i  =1 and therefore ii ca  . 
Substitution of this expression into Equation (2.8) gives: 
 










eq
ss
c
c
RT
ln

,                                                                                                        (2.10) 
 
 where eqc  is the equilibrium concentration and ssc  is the supersaturated concentration. 
Rearrangement of Equation (2.10) gives (Mullin, 2001):  
 
eq
ss
c
c
RT





 
exp  = S ,                                                                                             (2.11) 
 
where S is referred to as the supersaturation ratio. 
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This equation shows how the chemical potential is related to the supersaturation ratio, 
which can be used to describe the driving force for crystallization. An alternative 
expression can be used which is shown in Equation (2.12): 
 
eqss ccc  ,                                                                                                         (2.12) 
 
where c  is the degree of supersaturation. This is known as the concentration driving 
force (Davey and Garside, 2000).                                                                                                   
 
As the temperature is lowered there is a decrease in the solubility of solute in solution. 
The equilibrium concentration eqc  decreases and the supersatuartion concentration ssc   
increases. This results in an increase in the degree of supersaturation or saturation ratio. 
The difference in chemical potential (  ) increases, as can be seen from Equation 
2.11. This concludes that the driving force for crystallization increases when the 
temperature is lowered. This is illustrated in Figure 2.3 when moving from point 1 to 2 
and as a result the system enters the metastable zone which is supersaturated. 
 
 
Figure 2.3. Phase diagram of concentration versus temperature showing the 
various regions within a crystallization process  
  
Labile zone 
Metastable 
zone 
Undersaturated zone 
C
o
n
c
e
n
tr
a
ti
o
n
, 
c
 
Temperature,T  
(a) 
(b) 
Line (a) represents the thermodynamic equilibrium saturation curve 
Line (b) represents the nucleation curve (spontaneous nucleation occurs) 
MSZW 
1 
2 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates  
17 Chapter 2. Literature review 
2011 
The phase diagram shown in Figure 2.3 is typical for a crystallization process. There are 
three key regions, referred to as undersaturated, metastable and labile, which are 
separated by two curves known as the saturation (solubility) and nucleation curves. The 
saturation curve is fixed and is based on thermodynamics. It represents the maximum 
concentration (amount) of solute that can dissolve in the solvent for the system to be in 
thermodynamic equilibrium at a specific temperature. The region below this curve is 
referred to as undersaturated. The system is in a stable state and all solute present will 
dissolve in the solvent. The nucleation curve is kinetically controlled. This curve will 
vary by alteration to a number of parameters including agitation, cooling rates, 
impurities, reactor size, which can affect the rate of nucleation. Any point on the 
nucleation curve represents a system where the degree of supersaturation is high 
resulting in spontaneous nucleation. The region above the nucleation curve is referred 
to as the labile zone. Within this region nucleation occurs but too far from the 
nucleation curve can result in excessive nucleation leading to the production of many 
small nuclei. The region in between the saturation and nucleation curve is referred to as 
the metastable region. In this region the system is supersaturated. More solute is 
dissolved in solution than that at the equilibrium saturation value resulting in a 
metastable system. The difference between the two curves is known as the metastable 
zone width (Myerson, 2002; Yu et al., 2007). Within this region crystal growth occurs 
and nucleation is negligible enabling control over the crystal size distribution (Collins et 
al., 1997). For seeded systems which contain seeds of the crystals it is desirable to 
control within these sets of conditions in order to obtain large crystals                  
(Collins et al., 1997). For unseeded systems seeds have to be generated first, which 
involves passing the metastable zone until the nucleation curve is reached. The 
determination of the MSZW region of any solute/solvent system is important for the 
successful scale up of the crystallization process from lab to manufacturing scale. The 
metastable region can be determined by using the poly-thermal technique which 
requires heating and cooling a suspended solution at a range of cooling rates to obtain 
the spontaneous primary nucleation and solubility points (Nyvlt, 1968; Barrett and 
Glennon, 2002; Kubota, 2008). The nucleation point is obtained by finding the 
temperature of nucleation at zero cooling rate using an extrapolation method. Solvent is 
added to solution to lower the concentration and then the heating/cooling cycle 
procedure is repeated (Barrett and Glennon, 2002).  
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2.3.4 Crystallization methods  
 
Within the phase diagram of concentration versus temperature the slope of the 
saturation (solubility) curve is an important indication of what the most suitable 
crystallization method is for a particular system. Solubility dependence on temperature 
for a variety number of components is shown in the Figure 2.4.       
 
 
Figure 2.4. Solubility curve for sucrose, citric acid and sodium chloride in water 
(Davey and Garaside, 2000) 
 
A flat solubility curve as that shown in Figure 2.4 for sodium chloride in water indicates 
that cooling crystallization is not a suitable method as the solubility does not change 
much with temperature. An alternative method of crystallization could be evaporative 
or  antisolvent addition.  
 
Antisolvent crystallization involves the addition of a third component to a saturated 
solution. The third component could be an impurity or a miscible non-solvent, which 
lowers the solubility of the solute in solution forming a supersaturated solution, which 
results in the crystallization of the compound (Davey and Garside, 2000; O‟Grady et 
al., 2007; Nagy et al., 2008a). This provides the driving force for crystallization 
resulting in the formation of crystals. The antisolvent crystallization process must be 
designed so as to produce the drug with the desired properties. The choice of solvent (or 
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solvent mixture), dosing rate and initial concentration are factors known to affect the 
polymorphic form of the compound that crystallizes from solution (Davey, 2003; Davey 
and Garside, 2000; Kitamura and Sugimoto, 2003).  
 
Both antisolvent and cooling crystallization methods have advantages and 
disadvantages. One advantage of the antisolvent crystallization method is that high 
degrees of supersaturation can be created within the solution (Myerson, 2002). This can 
result in the solute crystallizing out of solution, achieving high yields of the crystalline 
product that would otherwise not be possible within cooling crystallization. The 
disadvantage is that the too high supersaturation can lead to the system suddenly 
nucleating and crystallization occurs rapidly. This is known as precipitation. This can 
lead to the production of a large number of fine crystals resulting in problems in the 
downstream processing (Myerson, 2002). Another disadvantage of the antisolvent 
crystallization method is the cost of separating the two solvents at the end of the process 
for recovering/recycling and larger capital costs due to higher operating volumes than 
that required for cooling crystallization. However in same cases where the substances 
are heat sensitive antisolvent crystallization is preferred as it allows the crystallization 
process to occur at low ambient temperatures preventing decomposition of the product 
that would result in failed batches (Myerson, 2002). Recent researchers investigate new 
methods for cooling and antisolvent crystallization that will improve the quality of the 
product. Nagy et al. (2008a) developed a model-based combined technique for a 
combined cooling and antisolvent crystallization method, which simultaneously 
controls the temperature profile and antisolvent additional rate. The combined method 
improved the quality of the product by providing superior control of the crystal size 
distribution. Woo et al. (2009) investigates the use of concentration control within 
cooling and antisolvent crystallization experiments, which is proposed to increase the 
robustness of the process during scale-up. Hermanto et al. (2010) developed a modified 
method for unseeded antisolvent crystallization, which involved the use of the focused 
beam reflectance measurement to control the size of seed crystals. This method was 
shown to improve the robustness of product CSD measurements. 
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2.4 Nucleation 
 
2.4.1 Introduction 
 
Nucleation is the first stage involved in the formation of crystals. This involves the 
generation of small seed crystals (nuclei) that then grow to form crystals of detectable 
size. There are different methods involving the generation of the seed crystals including 
primary and secondary nucleation. The various different forms of nucleation are shown 
in Figure 2.5. An essential requirement for nucleation is a supersaturated solution 
(Mullin, 2001). The higher the degree of supersaturation the larger the driving force for 
nucleation and hence the rate of nucleation is greater. Nuclei exposed to a 
supersaturated solution are in an unstable state and will either grow or dissolve to 
reduce the excess Gibbs free energy in order to reach thermodynamic equilibrium. 
 
The time that elapses between forming a supersaturated solution and the appearance of 
the crystals is referred to as the induction period. This includes the time it takes to form 
clusters, which grow to the critical size and continue to grow until they are of size 
detectable by optical probes or by sight (Mullin, 2001).  
  
 
Figure 2.5. A flow chart of the different forms of nucleation 
 
 
NUCLEATION 
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(Induced by crystals) 
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2.4.2 Primary nucleation 
 
Primary nucleation is sub divided into homogeneous and heterogeneous nucleation. 
Homogeneous (spontaneous) nucleation involves the formation of a new solid phase 
from a supersaturated solution. This requires energy and is achieved through transfer of 
energy due to random collisions between molecules. During this process the molecules 
form clusters, which then grow to a critical size, which is stable in the supersaturated 
solution. The molecules arrange themselves into a specific order resulting in a specific 
crystal lattice structure. The process is shown in Figure 2.6.  
 
 
 
Figure 2.6. Two possible paths for the formation of a critical size (stable) nucleus 
 
 
In Figure 2.6 cycle 1 represents the formation of a critical size (stable) nucleus through 
a sequence known as biomolecular addition (Mullin, 2001), whereas cycle 2 represents 
the formation of critical size (stable) nucleus through the aggregation of clusters. The 
formation of a critical size nucleus is more likely to occur by cycle 2. Any further 
molecular additions will result in the formation and growth of the nucleus (crystal 
growth). 
 
+ 
+ 
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Upon collision in order for the molecules to join together they must have enough energy 
to overcome the repulsive forces that arise due to the interfacial tension between the 
different phases-solid and liquid. As the surface area of the molecular clusters increase 
the interfacial tension increases resulting in more energy required to hold the molecules 
together. Therefore a critical size nucleus is obtained within local regions of the 
solution where the degree of supersaturation is high (energy levels are high).  
 
During the formation of the stable nucleus in a homogeneous fluid there is a free energy 
change ( G ). The overall excess free energy change is a sum of the change in the 
surface excess free energy and volume excess free energy (Mullin, 2001): 
 
 
VS GGG   ,                                                                                                    (2.13)   
 
 
where SG  is the free energy change involved in developing a new surface within a 
supersaturated solution. This requires energy and is therefore a positive quantity. The 
term VG  is the free energy change involved in the formation of a solid from a 
supersaturated solution. Volume change results in a release of free energy, therefore this 
quantity is negative.  
 
During the formation of a critical size nucleus the Gibbs free energy change ( G ) 
passes through a maximum called critG . This is the amount of energy that must be 
absorbed by the system in order to form the critical size of the nucleus cr . If the radius is 
below the critical value then the newly created crystalline lattice structure will             
re-dissolve and if it is above then it will grow. Both processes will result in a decrease 
in free energy of the particle. This is represented in Figure 2.7.  
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Figure 2.7. Free energy diagram for nucleation explaining the existence of a 
‘critical nucleus’ (Mullin, 2001) 
 
Once a nucleus of critical size is reached it will grow to form crystals. The rate at which 
this occurs is referred to as the rate of nucleation ( J ). This is defined as the number of 
nuclei formed per unit time per unit volume: 
 
)/exp( kTGAJ  ,                                                                                             (2.14) 
 
where A  is the Arrhenius pre-exponential factor, k  is the Boltzmann constant and T is 
the temperature. The term critG  is the critical Gibbs free energy and is defined as:  
 
2
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  ,                                                                                             (2.15)                
 
where T  is the interfacial tension,   is the molecular volume and S  is the 
supersaturation ratio which is defined in Equation (2.11). Substitution of Equation 
(2.15) into Equation (2.14) gives (Mullin, 2001): 
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Equation (2.16) expresses the rate of nucleation for spontaneous nucleation. The three 
major factors that affect the rate of nucleation are temperature (T ), degree of 
supersaturation ( S ) and interfacial tension ( T ).  
 
An increase in the degree of supersaturation results in both a decrease in the critical size 
of the nucleus and the energy required to form it. The rate of nucleation increases. Once 
some critical value of supersaturation is exceeded this results in a rapid increase in the 
rate of nucleation as represented in Figure 2.8. From this the nucleation curve on the 
phase diagram of concentration versus temperature is obtained and hence the MSZW 
can be determined.  
                                   
Figure 2.8. Effect of the degree of supersaturation on the nucleation rate  
 
 
By changing the temperature it alters the degree of supersaturation and is therefore used 
to control the rate of the nucleation.  At lower temperatures both the critical size of the 
nucleus and the energy required to form this is lower as shown in Figure 2.9. Lower 
energy processes are favoured resulting in an increase in the rate at nucleation when the 
system has been cooled down to a lower temperature.   
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Figure 2.9. Effect of the temperature on the critical size nucleus and the Gibbs free 
energy change of formation (Mullin, 2001) 
 
Heterogeneous nucleation is the other form of primary nucleation. Nucleation is 
induced by the presence of impurities. The formation of a solid nucleus from solution   
takes place on a solid surface. The presence of impurities can either enhance or inhibit 
the nucleation process. Enhancing the nucleation process results in nucleation occurring 
at lower degrees of supersaturation and a lower Gibbs free energy change compared 
with spontaneous nucleation. The nucleation curve is closer to the saturation curve and 
hence the MSZW is narrower.  
 
2.4.3 Secondary nucleation 
 
Nucleation that occurs within a solution that contains seed crystals that are the same as 
the crystals that will crystallize out of solution is referred to as secondary nucleation. 
Nucleation will occur at lower degrees of supersaturation compared to primary 
nucleation and hence the MSZW will be narrower. Seeded crystallization is widely used 
in industry at large scale production. It is used to control the crystal size, size 
distribution and polymorphic form (stable or meta-stable form), which affect the quality 
of the product (Zencirci et al., 2009; Doki et al., 2004; Beckmann, 2000; Hojjati and 
Rohani, 2005; Lung-Somarriba et al., 2004). Properties of seeds including seed surface 
F
re
e
 e
n
e
rg
y
, 
 Δ
G
 
Size of nucleus, r 
1T  2T  
1cr  
2cr
2c  
21 TT   
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates  
26 Chapter 2. Literature review 
2011 
area, mean size and seed loading are important to consider when designing a 
crystallization process as optimisation of these parameters can increase the likelihood of 
producing a quality product (Hojjati and Rohani, 2005; Lung-Somarriba et al., 2004). 
 
There are many different mechanisms by which secondary nuclei are produced. These 
include „initial‟ breeding, „polycrystalline‟ breeding, „needle‟ breeding (shear 
nucleation) and „collision‟ breeding (contact nucleation). Dry seed crystals may contain 
dust particles at the surface. Once introduced into a solution, these particles can be 
swept off from the surface leading to secondary nuclei. Crystals with needle 
morphology have a weak structure. Agitation can lead to breakage and fragmentation of 
the needles resulting in polycrystalline breeding. Any weak outgrows from the crystal 
surface can be removed due to fluid shearing across the crystal surface. This occurs 
within an agitated vessel and the weak outgrows act as secondary nuclei. This is known 
as needle breeding. Contact nucleation is one of the most important mechanisms for the 
production of secondary nuclei (Garside et al., 2002). 
 
For contact nucleation, crystal fragments are produced due to the collisions between 
crystals, crystal-agitator and crystals and vessel wall. Upon collision there is a transfer 
of energy resulting in fragments that may contain many dislocations. These fragments 
tend to grow slower than larger nuclei. Fragments of all different sizes will be 
produced. The smaller fragments may be unstable in the supersaturated solution and 
will only become stable if swept into a region where the degree of supersaturation ( c ) 
is high.  
 
The rate of secondary nucleation ( B ) is affected by three main factors. These include 
the degree of supersaturation ( c ), the concentration of seed crystals present in the 
supersaturated solution (M T ) and the interactions between the crystals and solution 
expressed as either stirrer speed ( N ) or power input into the solution ( ) (Davey and 
Garside, 2000): 
 
bkj
Tb cNMkB   ,                                                                                                (2.17) 
   
where bk  is the rate constant for secondary nucleation. 
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Previous researchers involve the use of population balance modelling to developed 
correlations relating secondary nucleation to a number of different parameters to those 
expressed in Equation (2.17). Chianese et al. (1993) and Matthews et al. (1996) 
expressed secondary nucleation rate as a function of nucleation rate constant, 
supersaturation ratio, moment of the crystal size distribution, and minimum size of 
crystals for collisions to produce secondary nuclei. However these expressions did not 
include stirrer speed or concentration of crystals in suspension.  Van Der Heijden et al. 
(1994) includes a new parameter in the expression for secondary nucleation that is not 
included by the researchers mentioned previously, which is the number of parent 
crystals per unit volume. The parameters mentioned in these expressions affect the 
secondary nucleation rate by a number of different ways.            
                                                                                 
As the stirrer speed increases the thickness of the fluid boundary layer around the blade 
of the agitator decreases resulting in an increase in the number of agitator and crystal 
collisions. More fragments are produced leading to higher nucleation rates. As the 
number of crystals in suspension increases this increases the frequency of collisions 
leading to more crystal fragments and hence higher nucleation rates. The size of the 
seed crystals may have an influence on the nucleation rate. Larger seeds have higher 
contact probabilities and collision energies resulting in higher nucleation rates. Small 
seeds may circulate in fluid eddies which are created in an agitated system. These act as 
a stagnant fluid resulting in no collisions (Mullin, 2001).  
 
Contact nucleation is not the only mechanism by which crystal fragments are produced. 
Adsorption of impurities onto the crystal surface can lead to an increase in internal 
stress as the crystal grows. This can lead to breakage and the formation of fragments 
(secondary nuclei) (Mullin, 2001).     
 
2.5 Polymorphism 
2.5.1 Introduction 
 
Polymorphism has been a key area of research related to the pharmaceuticals over the 
last 40 years (Pudipeddi and Serajuddin, 2005). Polymorphs are defined as crystals with 
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the same chemical composition but have different arrangement of molecules. This 
affects the structure of the crystal and hence the types of bonds formed between the 
molecules resulting in different physico-chemical properties. These include melting 
point, density, electrical and thermal conductivity, stability, solubility, dissolution rates 
and bioavailability (Cote et al., 2009; Beckmann 2000; Hilfiker 2006; Bernstein 2002, 
Yu et al., 2004). Compounds are often crystallized as salts to overcome problems with 
solubility, dissolution rate, stability and hygroscopicity (Forbes et al., 1992, Haynes et 
al., 2005). Reports state that 50% of pharmaceutical drug products are crystallized as 
salts (Kumar et al., 2009). Structural differences between the different polymorphic 
forms affect the morphology of the crystals. This can affect the downstream processing 
involving filtration and washing (Davey and Garside, 2000). Many compounds are 
known to have different polymorphic forms that can transform during the crystallization 
process, downstream processing (filtration, washing and drying) or during storage in the 
solid state. Polymorphic transformations that occur in solution are referred to as solvent 
mediated. These types of transformations are more common than solid state 
transformations. To prevent polymorphic transformations it is essential to know all the 
possible polymorphic forms of an active pharmaceutical ingredient (API) and under 
which conditions different polymorphic forms are favoured. This is required so the 
process can be controlled to produce the desired polymorph with specific physical 
properties.  
 
A poor understanding of the crystallization process can lead to the production of 
undesired polymorphs, which would result in an increase in economical costs (Davey, 
2003). This is a key area for further research as it is estimated that for the production of 
about 80% of all pharmaceutical products, a crystallization step will be required 
(Reutzel-Edens, 2006). Model based approaches have also been proposed, which 
describe the polymorphic transformation using population balance approaches and 
introduce innovative control methods for better consistency in polymorphic purity (Ono 
et al., 2004; Hermanto et al., 2007; Hermanto et al., 2009).  
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2.5.2 Classification of polymorphs 
 
A large proportion of pharmaceutical products contain the API in the crystalline form. 
There are three different classes known as anhydrates, hydrates and solvates 
(Vippagunta et al., 2001). To distinguish hydrates and solvates from the anhydrate 
forms of a crystalline compound the term pseudo-polymorphs is used (Vippagumta et 
al., 2001). These contain additional molecules within the crystal structure compared to 
the anhydrate forms, which are known as polymorphs. If these molecules are water then 
the crystalline form is referred to as a hydrate and if it contains the solvent molecules 
other than water it is referred to as a solvate (Khankari and Grant, 1995). The presence 
of pseudo-polymorphs within organic compounds is of very high importance within the 
pharmaceutical industry as these have different physical properties which will affect the 
quality of the product (Bechtloff et al., 2001). 
 
Anhydrate forms are referred to as polymorphs, which can consist of ions, atoms 
(elements) or molecules. Crystallization of a compound into different forms, which 
contains only one element, is referred to as allotropy (Mullin, 2001). A common 
example of this is diamond and graphite where the chemical element is carbon.  
                                        
Each carbon atom in diamond is covalently bonded to four other carbon atoms resulting 
in a regular crystal lattice structure. Each carbon atom in graphite is bonded to three 
other carbon atoms resulting in a hexagonal crystal lattice structure with a free electron 
that can move between the layers. This affects the physical properties resulting in 
diamond having a high tensile strength and hard, while graphite is weak and brittle 
(Fontana, 1987). Structural differences between allotropes/polymorphs affect the 
morphology and appearance of the crystals. This is clearly seen in the case of diamond 
and graphite, where diamond has a shiny appearance and in a pure state is transparent 
while graphite can appear dull and black in colour. Structural differences between 
polymorphs also affect the stability of the different forms. Graphite is the more 
thermodynamic stable form at conditions at the earth surface but the rate of 
transformation from diamond to graphite is very slow (Bernstein et al., 1999). 
                                               
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates  
30 Chapter 2. Literature review 
2011 
Hydrates are classified into different groups according to the arrangement of water 
molecules within the crystal lattice structure and the bonding between the molecules. 
Due to the presence of water this will result in hydrogen bonds forming and these bonds 
are maximised within a hydrate (Gillon et al., 2003). Reports state that 33.3% of 
pharmaceutical compounds are known to form hydrates (Gillon et al., 2003).  The types 
of hydrate formation are classified into three groups including isolate, channel and 
metal-ion coordinated hydrates (Gillon et al., 2003; Lester et al., 2006; Brittain, 1999). 
A schematic of the channel and isolate hydrates are shown in Figure (2.10).  Isolated 
hydrates contain water molecules which are isolated from each other within the crystal 
lattice structure (Gillon et al., 2003). Hydrogen bonds occur between the water and 
solute molecules within isolate hydrates (Brittain, 1999). Channel hydrates contain 
channels of water molecules within the crystal lattice structure occupying specific sites 
(Kennedy et al., 2003; Brittain et al., 1999). These water molecules can be easily lost 
from the structure resulting in dehydration occurring at low temperature of below      
100 ºC and the crystal lattice structure can remain intact (Redman-Furey et al., 2005; 
Lester  et al., 2006). These hydrates are also known as non-stoichoimetric hydrates in 
which the ratio of water to drug molecule is not an integer value and generally is less 
than 1 (Hilfiker, 2006). At high relative humidities expanded hydrates may form if 
additional water molecules are taken up in the channels within the lattice (Brittain, 
1999). Ion-coordinated hydrates contain water molecules, which form bonds with the 
metal ion. These bonds are very strong resulting in a high temperature required for 
dehydration (Redman-Furey et al., 2005).   
 
 
 
 
 
 
 
 
 
 
Figure 2.10. Schematic of (a) channel hydrate and (b) isolate hydrate 
(a) (b)  water 
channels pocket of 
water 
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2.5.3 Thermodynamics of polymorphism 
 
Thermodynamics is an important factor to consider in determining the stability of 
polymorphs within a given system as this will have an influence on which polymorph 
crystallizes out of solution.  The polymorph that has the lower Gibbs free energy is the 
more thermodynamically stable form. An expression for the Gibbs free energy at 
constant pressure is shown in Equation (2.18) (Smith, 1990): 
 
  STHG  ,                                                                                                  (2.18)   
 
where T  is the temperature, H is the enthalpy change and S  is the entropy change. 
 
Polymorphic transformations will involve enthalpy and entropy changes, which will 
either be positive or negative quantities. Positive enthalpy changes indicate heat has 
been absorbed and a negative enthalpy change indicates heat has been released. Entropy 
measures the change in disorder of the system. A polymorphic transformation that 
results in an increase in disorder has a positive entropy value. These are known as 
order-disorder transformations (Davey and Garside, 2000). A useful set of 
thermodynamic rules, which involve measurements of enthalpy and entropy, can be 
applied to a polymorphic system that enables the nature (monotropic or enantiotropic) 
and stability order of the polymorphs to be determined (Burger and Ramberger, 1979). 
These thermodynamic rules include heat of transition, heat of fusion, density and the 
infrared rule. Burger and Ramberger (1979) reports that for the heat of transition rule an 
endothermic transition indicates the two polymorphs are enantiotropic related and an 
exothermic transition indicates the two forms are monotropic related. The heat of fusion 
rule states that if the higher melting form has a higher heat of fusion then the two forms 
are usually monotropic related, otherwise they are enantiotropic. The density rule states 
that if one polymorphic form has a higher density than the other, it can be assumed to 
be more stable at absolute zero.  
    
A system containing two polymorphs is referred to as dimorphic. As mentioned 
previously the nature of the system can be classified as either monotropic or 
enantiotropic, which depends on how the stability of the polymorphs changes with 
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temperature (Lin et al., 2007). For a monotropic system the order of stability of the 
polymorphs does not change with temperature. Polymorphic transformations are 
irreversible (Bernstein et al., 1999). For an enantiotropic system a change in 
temperature can result in a change in stability of the polymorphs. Polymorphic 
transformations are reversible (Reutzel-Edens, 2006). Figure 2.11 illustrates a 
monotropic and enantiotropic system for a compound containing two polymorphs ( A  
and B ).  
 
 
Figure 2.11. Phase diagrams for a compound containing two polymorphic forms 
(dimorphic) showing a monotropic and enantiotropic system  
 
 
For the monotropic system polymorph B is the stable polymorph at all temperatures. 
For the enantiotropic system at low temperatures below the transition point polymorph 
B is the more thermodynamic stable form. For temperatures above the transition point 
polymorph A is the more thermodynamic stable form. At the transition point the 
stability of the two polymorphs is the same and the system is in thermodynamic 
equilibrium (Bechtloff et al., 2001). 
 
Phase diagrams provide the link between solubility and stability of different 
polymorphs of a given system. The solubility of the polymorphs is an important 
parameter to consider as this affects the dissolution rate and bioavailability, which 
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affects the quality of the product. The polymorph with the lower solubility is the more 
stable form (Bechtloff et al., 2001).  
 
The polymorph with the lower Gibbs free energy is the more stable form and hence its 
chemical potential is lower. The relationship between the chemical potential of each 
polymorph in its solid state is shown in Equation (2.19) (Smith, 1990):  
 
)()( AB ss   ,                                                                                                      (2.19) 
 
where s  refers to the chemical potential of a particular polymorph in its solid state. 
Equation (2.19) indicates that polymorph ( B ) is more stable due to its lower chemical 
potential. 
 
The chemical potential of the solute of a particular polymorph in a saturated solution is 
shown in Equations (2.20 and 2.21), for ideal systems: 
 
)(ln)( BcRTB eq
o
eq   ,                                                                                   (2.20) 
)(ln)( AcRTA eq
o
eq   ,                                                                                   (2.21) 
 
where eq  is the chemical potential of  a polymorph in a saturated equilibrium state 
within a solution, R  is the gas constant, T is the temperature, 0  is the standard 
chemical potential at 1 atm pressure and eqc  is the equilibrium concentration. 
 
For a solid of polymorph B  to coexist and be in equilibrium with a saturated solution of 
polymorph B , the two phases must have the same chemical potential. This also applies 
for polymorph A :  
 
 
)()( BB seq   ,                                                                                                     (2.22) 
)()( AA seq   .                                                                                                     (2.23) 
 
Substitution of these expressions into Equations (2.20) and (2.21) gives the following: 
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)(ln)()( BcRTBB eq
o
eqs   ,                                                                     (2.24) 
)(ln)()( AcRTAA eq
o
eqs   .                                                                     (2.25) 
 
Substitution of these expressions into Equation (2.19) gives the following:   
 
)()( AcBc eqeq  .                                                                                                      (2.26) 
 
By comparing Equations (2.19) and (2.26) it shows that the polymorph, which has a 
lower Gibbs free energy also has a lower saturation concentration. This results in the 
less soluble polymorph being the more stable form.  
 
The phase diagrams provide important information on the solubility difference between 
the polymorphs, which is the driving force for phase transformations (Brittain, 1999). 
These also provide the required operating conditions of the crystallization process in 
order to produce the desired polymorph. Solubility studies on a range of compounds 
containing polymorphs were carried out by Pudipeddi and Serajuddin, (2005). The 
results obtained in most cases showed a solubility ratio between the polymorphs of a 
value of 2 or lower indicating a small solubility difference between the polymorphs. For 
these cases it indicates that the presence of different polymorphs will not have any 
significant effect on the dissolution rate and hence bioavailability. However the 
importance of control within the crystallization process is essential to ensure a robust 
manufacturing process that will produce a pure product (Reutzel-Edens, 2006). Within 
industry the stable polymorph is usually the common choice for the large scale 
manufacturing of the API as this reduces the likelihood of polymorphic transformation 
during storage (Gu et al., 2001). A robust crystallization process was designed for the 
production of the desired stable polymorph within an enantiotropic system by Muller et 
al. (2006). A compound produced from Novartis was used as the model compound. 
This was achieved through the use of solubility tests in various solvents. Information 
obtained from the studies included solubility data, possible polymorphic forms and 
transition temperature between the two polymorphic forms. This provided the 
information for the conditions required to operate the crystallization process so as to 
prevent the system from being supersaturated with respect to the undesired polymorph. 
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A combined method of seeding at low supersaturated solution following by moderate 
cooling was used to produce the stable desired polymorph (Muller et al., 2006).  
 
There are some cases where the metastable polymorphic form of an API may be 
desirable as these may have faster dissolution rates and properties resulting in the 
manufacturing process being more efficient. This was found be the case for the API of 
Ritonavir. The metastable form I had faster dissolution rates compared to the stable 
from II, shorter processing time and a more effective separation of impurities in the 
crystallization step (Muller et al., 2006).   
 
Within each system, monotropic and enantiotropic, there is a different method that can 
be used for the formation of the metastable polymorph. Rapid cooling within the 
monotropic system will lead to the system being supersaturated with respect to both 
polymorphs and if the energy barrier required for formation of metastable polymorph is 
lower then this will form. A change in temperature within an enantiotropic system will 
result in a change in the stability of the polymorph resulting in the formation of a 
metastable polymorph. Once obtained the metastable polymorph the problem arises of 
how to prevent conversion into the stable form. Davey et al. (1997) used additives to 
inhibit the nucleation and growth of the stable polymorph (  ) of L-glutamic acid. This 
resulted in the metastable polymorph ( ) of L-glutamic acid becoming stabilised.   
2.5.4 Polymorphic transformation and kinetics 
 
Transformation between different polymorphs is explained in thermodynamic terms by 
Ostwald (1897). The polymorph that crystallizes out of solution can be of the 
metastable form. This will then transfer to the more stable form, which has a lower 
Gibbs free energy. However this is assumed not to be a direct process but to occur in 
stages. The transformation that has the lowest energy barrier is favoured leading to a 
metastable polymorph, which has a lower Gibbs free energy than the previous form. 
This procedure will continue until the stable polymorph forms, which has the lowest 
Gibbs free energy. This is known as Ostwalds rule of stages (Bernstein et al., 1999). 
However there is no theoretical proof of this rule.  Investigations were carried out 
involving the use of kinetics to explain the rule (Bernstein et al., 1999). This involved 
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investigating the effect of the degree of supersaturation of the rate of nucleation of the 
different polymorphic forms of a dimorphic system. At certain values of supersaturation 
the rate of nucleation of the two polymorphs is the same leading to polymorphs 
crystallizing concomitantly (Bernstein et al., 1999). This indicated that kinetics of 
nucleation and growth are important factors in determining which polymorph will 
crystallize out of solution. This concludes that both thermodynamics and kinetics have 
an effect on which polymorph crystallizes out of solution with kinetics being the more 
important factor.  
 
The crystallization process involves the formation of solid crystals from solution. This 
change in phase requires energy. The energy barriers required to overcome for the 
formation of the metastable and stable polymorph for a dimorphic system is shown in 
Figure 2.12. 
 
Figure 2.12. Activation energy barriers required to overcome for the formation of 
the two polymorphs (I and II) within a dimorphic system, where  0G  is the Gibbs 
free energy of the solute in a supersaturated solution, IG  is the Gibbs free energy 
of polymorph (I), IIG is the Gibbs free energy of polymorph (II),
*
IG  is the energy 
required to form polymorph (I) and 
*
IIG is the energy required to form polymorph 
(II). 
 
The energy barriers show the energy required in order to form a critical size nucleus for 
each polymorph. The height of the energy barrier is affected by the size of the critical 
nucleus. The polymorph that has a smaller critical size nucleus will have a lower energy 
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barrier and hence this process will be kinetically favoured. Polymorph I is the 
kinetically favoured form (see Figure 2.12). Thermodynamics predicts that polymorph 
(II) will crystallize out of solution as it has  the lower Gibbs free energy and is therefore 
the more stable polymorph. Considering the effects of both thermodynamics and 
kinetics this can lead to the formation of the unstable polymorph (I). Transformation 
from the unstable (metastable) to stable form will occur over time. The time required 
for transformation will depend on kinetics.  
 
Transformation between different polymorphic forms can occur by two different 
processes. These are known as reconstructive (solvent-mediated) or displasive (solid 
state) transformations (Davey and Garside, 2000). The type of transformation that will 
take place will depend on the structural change involved. A large structural change will 
result in reconstructive transformations taking place which involves dissolving the 
metastable (less stable) polymorph and reconstruction of the stable polymorph 
involving nucleation and growth. These transformations occur within solution and are 
referred to as solvent mediated transformations (Gu et al., 2001). There are three factors 
that affect the rate of polymorphic transformation within solutions; these are the choice 
of solvent, temperature and rate of agitation. The effect of these parameters on the 
compound sulfamerazine (SME) was carried out by (Gu et al., 2001). The results 
showed that the rate of transformation from the metastable to stable form depends 
largely on the kinetics of nucleation. Slower rates of transformation were found to occur 
at lower rates of agitation, lower degrees of supersaturation (solubility difference 
between the two polymorphs is smaller) and a choice of solvent where the solubility of 
the metastable form was lower. These are empirical findings and there is no theory for 
example on how the agitation rate is directly related to the polymorph that crystallizes. 
Solvent choice not only affects the rate of transformation but it can also affect the 
stability of the polymorphs, which can lead to the production on an undesired 
polymorph. 
 
The other parameters that affect the stability of the polymorph include relative humidity 
(RH), temperature and pressure (Bechtloff et al., 2001). A change in conditions will 
affect the stability and hence which polymorphic form crystallizes out of solution. 
Relative humidity is referred is as the water vapour pressure within the air. The amount 
of water present will determine the activity of water, which will affect the stability of 
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the hydrate. If the compound under investigation forms hydrates then a high RH, where 
the water activity is high, may lead to the formation of a hydrate as this is the stable 
form under these conditions. An increase in the RH can lead to the formation of higher 
hydration states that have lower solubilities (Brittain, 1999). This will affect the 
dissolution rates, bioavailability and hence dosage form performance (Aaltonen et al., 
2006). Temperature is known to affect the stability of the different forms. Hydrates are 
more stable at lower temperature and anhydrates are more stable at higher temperatures 
(Bechtloff et al., 2001). This suggests dehydration will take place at high temperatures. 
It has been reported for some cases that dehydration can lead to the formation of the 
amorphous solid (Brittain, 1999). The rate of dehydration depends on the hydration 
form. This process is slow and continuous for channel hydrates and rapid for isolate 
hydrates once the dehydration temperature is reached (Brittain, 1999). Phase 
transformations were observed after suspension of a monohydrate (sodium -2-keto-L-
gulonate monohydrate) in an organic solvent (methanol) leading to a change in 
appearance of solution and morphology (Bechtloff et al., 2001). Another possibility 
where phase transformations can occur in solution is during dissolution testing. This is 
required to ensure the API is in the correct polymorphic form before scale up from lab 
to pilot plant. Experiments were performed using in-situ probes (Raman and UV/Vis) to 
monitor phase transformations during dissolution testing (Aaltonen et al., (2006)). The 
phase transformation of one model system resulted in a clear decrease in dissolution 
rates. Information obtained by monitoring the solid phase using the Raman probe 
provided molecular level information resulting in a deeper understanding of the phase 
transformation during dissolution testing and the consequent effect on dissolution rates 
(Aaltonen et al., 2006). A deeper understanding of the solvent mediated phase 
transformations is required in order to prevent undesired phase transformations.  
 
The other type of transformation, known as displacive (solid state) transformation, 
involves changes in the interactions between neighbouring molecules without affecting 
the solid state form of the crystal (Davey and Garside, 2000).  This occurs when the 
structural change between the polymorphs is small. Solid state transformations can 
occur during processing of the drug (tablet compression and milling) and during storage 
(Gu et al., 2001; Vippagunta et al., 2001).  Possible causes for transformations include 
a change in storage conditions (temperature) affecting the stability of the polymorphs 
for an enantiotropic system or if the desired state of API is in a metastable form. 
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Formation of a hydrate due to absorption of water from the air at high RH or from 
transfer of water from the drug carrier can also result in a solid state transformation. 
Studies on the dehydration and hydration of solid state aspartame were carried out at 
25°C by Leung et al. (1998). The results showed that once a RH of 58% is reached it 
lead to the formation of a higher hydration state forming a 2.5-hydrate from a hemi-
hydrate. The rate of these transformations, which depends on kinetics, will determine 
the shelf life of the drug (Gracin and Rasmuson, 2004). Overall, solution mediated 
transformations tend to have lower energy barriers than solid state transformations 
(Davey and Garside, 2000). Lower energy barriers processes are kinetically favoured 
and the transformation will occur over a shorter period of time. 
2.5.6 Conclusion on polymorphism 
 
Crystallization is a major stage involved in the manufacturing of pharmaceutical drugs. 
For the production of about 80% of all drugs a crystallization step will be required. 
During this stage the compound can crystallize into different polymorphic forms 
leading to the production of an undesired polymorph. Transformations can occur during 
downstream processing involving filtration, washing, drying, wet granulation, tablet 
compression, milling and also during storage. Production of the undesired polymorph 
can lead to increases in economical costs. It is therefore essential to control the 
polymorphic form that crystallizes out of solution and to ensure that it remains in that 
state.  
 
2.6 Analytical methods for crystallization 
2.6.1 Introduction 
 
Process analytical technology (PAT) tools are probe based techniques that can be 
placed within the process stream providing real-time data resulting in an increase in 
process understanding, which can be used to design a robust crystallization process 
during scale up (Wu and Khan, 2010; Nagy, 2009; Kail et al., 2009; Read et al., 2010; 
David et al., 2004; Birch et al., 2005; Cote et al., 2009). These tools are also used to 
monitor changes occurring during the crystallization process, which are thought to be 
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due to polymorphic transformations (David et al., 2004; Birch et al., 2005; Yang et al., 
2009; Ferrari et al., 2003; O‟Sullivan and Glennon, 2005; Scholl et al., 2006; Gillon et 
al., 2006; Kobayashi et al., 2006; O‟Sullivan et al., 2003). Data obtained from these 
tools enable the system to be designed ensuring a quality product (quality by design) 
rather than to achieve a target quality by trial and error (quality by testing). The Food 
and Drug Administration (FDA) agency encourages pharmaceutical industries to use 
PAT tools to ensure quality by design (Yu et al., 2004; Abu Bakar et al., 2009a; Wang 
et al., 2007; David et al., 2004; Yu et al., 2007). This enables the system to be more 
flexible in terms of changes to the operational procedure so long as the quality of the 
product is maintained. There are a number of different PAT tools which include 
turbidity probe, focused beam reflectance measurement (FBRM), particle vision and 
measurement (PVM), pH probe and a range of spectroscopic techniques. These include 
nuclear magnetic resonance (NMR), attenuated total reflectance (ATR)-UV/Vis, 
attenuated total reflection (ATR)-Fourier transform infrared (FTIR) and Raman 
spectroscopy. These techniques are used to monitor the crystallization processes as it 
proceeds and are therefore referred to as in situ techniques.  
 
Crystal samples are taken during and at the end of the crystallization process for 
characterising the polymorphic form using a range of solid state analytical techniques. 
As the samples are removed and analysed far from the process stream this type of 
analysis is referred to as off-line. Thermal techniques include differential scanning 
calorimetry (DSC), thermal gravimetric analysis (TGA), and hot stage microscopy 
(HSM). Other techniques also include optical microscope, dynamic vapour sorption 
(DVS), X-ray powder diffraction (XRPD), solid state nuclear magnetic resonance 
(NMR), infra-red (IR) and Raman spectroscopy. Combinations of the above techniques 
are used for the monitoring, design and control of a particular crystal system ensuring a 
quality product. Not all of the above techniques are used within this research work. This 
section discusses each of the techniques used within this research work, giving a 
description of how they work, the information that can be obtained from the techniques 
together with the advantages and disadvantages of some techniques.  
          
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates  
41 Chapter 2. Literature review 
2011 
2.6.2 FBRM and its use with other PAT tools  
 
Focused beam reflectance measurement (FBRM) is an in situ probe based technique, 
which operates by the use of a laser beam that passes through the centre of the probe. 
The beam is focused on a particular point and is rotated in a circular path at a high 
speed of 2 m/s to cope with changes in solution velocity (Tadayyon and Rohani, 1998). 
A schematic representation of the FRBM probe combined with the laser beam is shown 
in Figure 2.13.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. FRBM probe tip with laser beam (adapted from Greaves et al., 2008) 
 
The FBRM probe measures the chord length distribution of a crystal population. As the 
focal beam crosses two edges of a particle it measures the chord length. There is a back 
scattering of light into the probe. The velocity of this focal beam and the time required 
for detection of the backscattering of light gives a measure of the chord length. The 
device is able to measure 1000‟s of chord lengths per second and can detect many chord 
lengths for a single particle as shown in Figure 2.14.  
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Figure 2.14. Laser beam detection of many chord lengths for a single particle  
 
 
The size range of the chords that can be detected by this technique is between 0.8/1 -
1000 m , which is distributed into 38 or 91 channels depending on the model of FBRM 
probe (Barrett and Glennon, 1999). This enables the detection of nucleation by an 
increase in the number of fine counts (0-20 m ) and crystal growth or agglomeration by 
an increase in the number of coarse counts (50-250 m ) (Barrett and Glennon, 2002). 
Through a change in the number of counts it is able to detect breakage of crystals, and 
even polymorphic transformations. Selecting certain statistics (e.g. unweighted,    
square-weighted, cube-weighted mean chord length, etc.) to monitor changes during the 
crystallization process provides a deeper understanding of the process and minimises 
the time of process operation resulting in a more efficient process (Yu et al., 2007). 
Many researchers have used this tool for the detection of polymorphic transformations 
that can result in a change in crystal size or morphology (O‟Sullivan and Glennon, 
2005; Scholl et al., 2006; Kobayashi et al, 2006; Gillon et al., 2006; Abu Bakar et al., 
2009; Woo et al., 2009; Kail et al., 2009; Howard et al., 2009a; Howard et al., 2009b). 
Many studies have also used the FBRM for measuring MSZW values for compounds. 
An alternative in situ probe used for measuring MSZW values is the turbidity meter. 
This technique measures the liquid turbidity (cloudiness). It operates by transmitting 
near-infrared light into the solution and any particles present will scatter light back into 
the probe (Parsons et al., 2003). This technique requires a threshold concentration 
before any particles are detected. Lasentec FBRM has an advantage over the turbidity 
probe as it is able to detect the presence of a single particle as long as it is within a 
certain size range. 
 
High velocity 
laser scanning 
beam 
Chord length is proportional to the 
duration of reflection measured 
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Chord length distribution (CLD) data obtained from the FBRM can be converted to 
particle size distribution (PSD). However the conversion of CLD to PSD is relatively 
complex and requires the assumption of a particular shape for all crystals, which has 
prevented the use of measurements obtained from the FBRM from being used in a 
feedback loop for the direct quantitative control of the CSD (Yu et al., 2007). Feedback 
control provides a more robust process than the traditionally open-loop control (Yu et 
al., 2007). However recent developments have been made involving the use of FBRM 
measurements combined with a feedback control loop of temperature, for the control of 
the PSD within batch crystallization processes (Abu Bakar et al., 2009a; Chew et al., 
2007; Doki et al., 2004; Woo et al., 2009).   
 
The position of the probe and the operating conditions can have an effect on the 
accuracy of the results. In order to ensure the FRBM readings are a good sample 
representation of the whole system the probe should be positioned so that the probe 
window faces the direction of flow within the vessel. Barrett and Glennon (1999) 
investigated the effect of different probe positions relative to the agitator within a 
crystallization vessel. The results of the studies showed that more accurate results were 
obtained when the probe is positioned at an angle to the agitator ensuring good flow 
towards the probe window. The agitator speed has to be chosen properly, to achieve 
proper suspension of solids but avoid air entrainment since bubbles affect the FBRM 
readings (Tadayyon and Rohani, 1998).   
 
As mentioned before the PSD is an important parameter to control in the crystallization 
process to ensure a quality product. There are many techniques that can be used to 
measure the PSD, as well as the FBRM probe, including sieve analysis, coulter counter 
and forward light scattering. The FBRM probe is able to operate at high solid 
concentrations eliminating the need for sample dilution. Another advantage of this 
technique is that the probe can be placed within the crystallization vessel and can 
therefore measure changes within the system in real-time, giving more direct 
information related to CSD than the other methods which require a sample to be 
removed from the system for analysis (Tadayyon and Rohani, 1998).  
 
FBRM is often used in combination with other PAT tools in order to gain a better 
understanding of the crystallization process. A combination of FBRM and Raman 
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spectroscopy was used to determine the kinetics of nucleation, growth and form 
conversion of a proprietary  pharmaceutical compound in a solvent mixture of  methyl 
ethyl ketone (MEK)/water (Birch et al., 2005). The FBRM readings showed a decrease 
in particle size during dehydration indicating a partial collapse of the crystal structure. 
This showed that the solvent system was not suitable for the crystallization of the 
proprietary pharmaceutical compound as the particle size distribution could not be 
controlled. Gillon et al., (2006) used a combination of FBRM, PVM and ATR-UV/Vis 
spectroscopy to study crystallization of caffeine. The affect of cooling rate on the 
MSZW and the effect of agitation and temperature on the kinetics of hydration were 
studied. FBRM was used in automated MSZW determination, and it was shown that it 
can detect polymorphic transformation of the anhydrous caffeine into the hydrated 
form. 
2.6.3 Particle vision measurement (PVM) probe 
 
PVM is a probe based tool which is placed within the process stream. This device 
consists of a high resolution video microscope allowing the images of the crystals 
morphology to be obtained (Barrett and Glennon, 2002; Braatz et al., 2002). A change 
in morphology due to a polymorphic transformation can be detected with the use of 
PVM (Gillon et al., 2006). The in situ images which are recorded in real-time can 
confirm whether an increase in number of coarse counts, as detected by the FBRM 
probe, is due to crystal growth or agglomeration (Barrett and Glennon, 2002). FBRM 
can provide such information related to dynamic changes in the crystallization 
processes however the results must be interpreted carefully since a particular change in 
an FBRM signal can have various causes. Often FBRM results must be confirmed with 
other PAT tools or solid state analytical techniques (Howard et al., 2009a; Howard et 
al., 2009b).   
 
2.6.4 ATR-UV/Vis spectroscopy 
 
Attenuated total reflectance (ATR)-UV/Vis spectroscopy is used to monitor changes in 
properties of the liquid phase during the crystallization process such as solute 
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concentration (Thompson et al., 2005; Billot et al., 2010; Doyle and Tran, 1999; Abu 
Bakar et al., 2009; Aamir et al., 2010). This technique operates by using an 
electromagnetic radiation beam which interacts with the solute molecules. The radiation 
beam is directed towards the interface of two surfaces (crystal and solvent) at an angle 
(θ1) greater than that of the critical angle (θc) resulting in the deep penetration (dp) of an 
evanescent wave into solution. The critical angle is the smallest angle for complete 
reflection of the radiation beam. The solute interacts with the evanescent wave resulting 
in absorption of a particular wavelength and the radiation beam is reflected as shown in 
Figure 2.15. Absorption results in the attenuation of the reflected beam.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.15. Total internal reflection occurring within the ATR-UV/Vis probe        
(adapted from Billot et al., 2010) 
 
 
Absorbance of the radiation beam is expressed in terms of the intensities of incident and 
reflected beam by the following mathematical expression (Billot et al., 2010):  
                                     
                                                                                         (2.27)                                            
                                                                                       
where bA  is the absorbance, I0 is intensity of incident light beam and I  is intensity of 
reflective light beam. 
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The concentration of the species is determined from the absorbance using the following 
Beer-Lambert law (Billot et al., 2010):  
       
    (2.28)                                          
                                                                                                                                                                                                                                              
 where bA  is the absorbance, λ is wavelength, a  is absorption coefficient, C is the 
concentration of the absorbing species and is the optical path length, which is equal 
to the number of reflections (z) multiplied by the depth of penetration of the evanescent 
wave (dp).  
 
The UV/Vis wavelength range is between 200-800 nm for which compounds will only 
absorb if they contain a chromophore (a multiple bond) group (Rao, 1961). Fibre optics 
used within the probe limit the wavelength range for absorption between 220 and 600 
nm (Thompson et al., 2005). A typical UV-Vis spectrum is shown in Figure 2.16. This 
technique is useful within the pharmaceutical industry as many compounds contain the 
chromophore group (Billot et al., 2010). For this technique to be successful the crystal 
and solvent must have significantly different refractive indices with a high refractive 
index for the crystal (solute) and a low refractive index for the solvent. Also the solvent 
must not interfere with the absorbance of the solute (Thompson et al., 2005).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16. UV/Vis spectrum for sodium benzoate in water 
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One of the advantages of ATR-UV/Vis spectroscopy is that it is able to measure high 
concentrations and it is not affected by the presence of solid particles or bubbles in 
solution (Thompson et al., 2005). This technique has also been used for a wide range of 
other applications including monitoring of polymorphic transformations (Howard et al., 
2009b), controlling the crystallization process to produce the desired polymorph and 
crystal size distribution (Abu Bakar et al., 2009b), solubility curve determination, 
MSZW and monitoring supersaturation levels (Nagy, 2009; Aamir et al., 2010). ATR-
UV/Vis spectroscopy is easy to set up in the laboratory and inexpensive compared to 
other PAT tools such as ATR-FTIR, which is also used to measure concentration 
values, giving this technique an additional advantage (Billot et al., 2010).  
 
2.6.5 Introduction to solid state analysis (SSA) 
 
There are many different solid state analytical techniques used to analyse the crystals at 
any stage during the crystallization process and during formulation. Combinations of 
SSA techniques are used to characterise the crystal product, for example for identifying 
the different polymorphic forms of a compound (Braum et al., 2008; Abu Bakar et al., 
2010; Howard et al., 2009a; Howard et al., 2009b; Brittain, 1999; Giron, 2003; Giron, 
1995; David et al., 2004). These techniques provide additional information to 
understanding the crystallization process and identify the conditions required to produce 
the desired form (Yu et al., 2004; Yang et al., 2009; Desikan et al., 2005). The 
techniques that will be discussed in this section include microscopy (optical, SEM and 
HSM), DSC, TGA, DVS and XRPD. 
 
2.6.6 Microscopy 
 
There are three types of microscopy that will be mentioned within this report including 
polarized light, scanning electron and hot stage microscopy. These techniques are used 
to determine the solid state properties of the drugs, which are useful for the early stages 
in drug development (Brittain, 1999). The properties that it can measure include 
refractive index, colour, particle size and particle shape (habit). It can also detect the 
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presence of inclusions, twinning between crystals and crystallinity within samples. 
Polymorphic conversions can be detected by the change in habit.  SEM can achieve 
higher magnifications than optical microscopy enabling a more detailed structure 
analysis of the crystal particles. SEM also gives better 3D information. The difference 
of hot stage microscopy compared to the other microscopy techniques is that is requires 
heating and cooling a sample material. This technique requires a small amount of 
material and provides rapid data (Brittain, 1999) about the thermal behaviour of a solid 
(e.g. polymorphic transformation, melting point, etc.). This microscopy technique is the 
most widely used within industry for determining solid state properties and for the 
detection of polymorphs (Hilfiker, 2006). There are other thermal techniques for the 
solid state analysis of the crystals including DSC and TGA. 
 
2.6.7 Differential scanning calorimetry (DSC) 
 
Differential scanning calorimetry is a thermal analysis technique used for solid state 
analysis of the crystalline drug compound. DSC was developed in the 1960‟s through 
modifications to an existing technique known as differential thermal analysis (DTA) 
(Hilfiker, 2006). The DSC technique is simple to operate resulting in it being the most 
common thermal method used for polymorphic screening within the pharmaceutical 
industry (Abu Bakar et al., 2010).  
 
DSC measures the melting point and enthalpy of melting of the different polymorphic 
forms of a given compound. This technique is also used for detecting the presence of 
hydrates as represented by a broad peak at low temperatures below 100 ºC. The 
operation of this technique involves the heating of two cells, one containing the 
reference material and the other containing the sample material. The two cells are kept 
at the same temperature by a constant heating rate.  This must be controlled in order to 
ensure accurate results and a clear understanding of the thermal events. A slow heating 
rate is required to ensure all the thermal events are detected. The importance of this was 
clearly indicated by Giron (1995), which showed that once the hydrate form had 
dissolved, re-crystallization into the anhydrate form was only detected at slow heating 
rates. Any changes within the system that occur during the heating process, such as a 
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polymorphic transition from a meta-stable to stable polymorph, will result in a change 
in the heat flow rate to the sample. The relationship between melting point and enthalpy 
of melting enables the nature of the polymorphic system to be classified. As discussed 
by Burger and Ramberger (1979), two polymorphs are monotropic related if the higher 
melting polymorphic form has a higher enthalpy of melting and the reverse is true for 
enantiotropic related polymorphs. 
 
The type of polymorphic transformation, solid state or re-crystallization from the melt, 
can be detected through the use of DSC. The difference in DSC plots for the two types 
of transformations are shown in Figures 2.17 and 2.18. 
 
As shown in Figure 2.17, the solid-solid transition occurs before the melting point of 
the high melting point form. A positive enthalpy change (endothermic peak) in the solid 
state transition indicates the polymorphs are enantiotropic related and a negative 
enthalpy change (exothermic peak) indicates a monotropic system. DSC can monitor 
polymorphic transformation by melt crystallization, which is shown in Figure 2.18. This 
is achieved in three stages, which include melting of the meta-sable polymorph, re-
crystallization of the stable polymorph followed by melting of the stable polymorph.  
 
 
   
 
Figure 2.17. Typical DSC plot of a polymorphic transition occurring within the 
solid state  
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Figure 2.18. Typical DSC plot of a polymorphic transition occurring from re-
crystallization of the melt  
 
Preparation of the crystals and the operating conditions of the equipment can have a 
profound effect on the accuracy of the data obtained from the DSC. During running of 
the DSC a flow of nitrogen must be on to prevent degradation of the material before the 
melting point is reached. Gentle grinding of the crystal sample is required to enable 
even heat flow throughout the crystal sample. This factor, sample mass and the 
presence of contaminants can broaden the melting peak leading to inaccurate results. A 
small sample mass gives better resolution of the thermal events  as it prevents thermal 
lags  occurring within the sample material, which would lead to a wider temperature 
range over which the melting point occurs.  
 
An advantage of DSC is that it is simple to use and provides rapid data (Hilfiker, 2006), 
related to melting points, purity, polymorphic transformation etc. Each experiment 
requires a small amount of sample material in the range of a few milligrams, which is a 
major advantage when there is limited amount of drug available in the development 
stage. It also provides direct quantitative information on the thermodynamic parameters 
associated with polymorphic transitions that enable the stability relationship between 
the polymorphs and the temperature of transition to be determined. This data is useful 
for the design and control of the crystallization process. However this technique does 
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have disadvantages, which include its inability to detect the presence of different 
polymorphic forms that have close melting points. Polymorphs with a melting point 
difference of 10 °C could not be distinguished in a study by Hilfiker (2006). Only one 
polymorphic form of mannitol was detected through the use of DSC, which is known to 
have 4 different polymorphic forms (Giron, 1995). The presence of additional peaks can 
appear in the DSC plot due to a noise factor that can lead to confusion in results (Giron, 
1995). Another limitation of this technique is that it does not provide any structural data 
and therefore cannot be used alone for the quantitative analysis of the polymorphic 
systems. DSC results are generally supported with XRPD data, which provides the 
structural information of the different polymorphic forms. David et al. (2004) reported 
the use of DSC combined with optical microscopy to confirm the presence of different 
polymorphic forms by the appearance of different habits as shown by the microscope 
images. Giron (1995) mentioned the use of TGA combined with DSC results for the 
detection of pseudo-polymorphs. Abu Bakar et al. (2010) used DSC in combination 
with HSM and images analysis to study the polymorphic transformation of sulfathiazole 
crystals.  
 
2.6.8 Thermal gravimetric analysis (TGA)  
 
TGA is a thermal technique used for identification and characterisation of solvent 
species. TGA is operated by supplying heat to the sample material, which results in a 
temperature rise. Over the operating temperature range if there is a decrease in mass 
then this indicates that solvent is present. Solvent can be either on the surface of the 
crystal or in the internal structure of the crystal. If a solvate or hydrate is present the 
type of bonds between the molecules can be estimated by the temperature at which 
solvent is lost from the sample (Hilfiker, 2006). TGA can also determine the 
stoichiometry of solvates and hydrates. A case study was carried out on a disodium salt 
by applying different relative humidity‟s (RH) of values 33, 52, 60 and 75% to a 
sample, which resulted in the formation of different hydrate states. TGA was then 
applied to show the different types of hydration states by a different percentage 
decrease of mass loss over the operating temperature range (Brittain, 1999).  
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TGA does have the disadvantage that it is unable to determine the nature of the solvent 
lost (Hilfiker, 2006). The weight loss can be due to either solvent on the surface of the 
particles indicating the presence of an anhydrate form or from the internal structure of 
the crystal indicating the presence of a hydrate. An estimation can be made on the 
nature of the solvent based on the extent of weight loss and the temperature range over 
which this occurs. A weight loss at high temperatures usually indicates the loss of 
solvent from the internal structure of the crystal as energy must be supplied to break the 
bonds. However this is just an estimation, which does not provide any proof and 
therefore further analysis must be carried out with the use of other techniques such as 
mass spectroscopy. This technique is used to identify the nature (solvent, hydrate or 
anhydrate) and chemical structure of the compound (Hilfiker, 2006), to identify 
potential bonds between the solvent and compound in solid state.   
 
2.6.9 Dynamic vapour sorption (DVS) 
 
Dynamic vapour sorption is used within the pharmaceutical industry to determine the 
hygroscopicity of solids (Hilfiker, 2006). This is referred to as the extent of moisture 
taken up by the solid. This method is also used for the detection of different hydrate 
forms and from the isotherms the kinetic stability of the different hydrates can be 
determined (Hilfiker, 2006). DVS works by measuring the change in mass as the 
relative humidity (RH) is increased or decreased while keeping the system at a constant 
temperature. Different isotherms can be obtained for stoichiometric, non-stoichiometric, 
amorphous and crystalline solids. The presence of impurities, crystal defects and 
amorphous compounds can affect are generally combined with other techniques such as 
XRPD in order to identify the different hydrate forms (Hilfiker, 2006).   
 
2.6.10 X-ray powder diffraction (XRPD) 
  
There are two different types of X-ray diffraction techniques. One is used to determine 
the structure of single crystals and the other method known as X-ray powder diffraction 
(XRPD) is used to determine the presence of different polymorphs within a given 
system. Solid state analysis of crystals will require the use of XRPD, which may be 
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supported with other techniques to provide back up evidence for the existence of 
polymorphs (Brittain, 1999).  
 
The determination of the crystal structure through the use of X-rays involves a beam of 
electromagnetic wavelengths of size less than 1 nm (Breithaupt, 1990). This beam is 
directed onto a sample material and then diffracted from the sample at certain angles 
depending on the arrangements of atoms within the crystal lattice. A representation of 
the set up of the X-ray diffractometer is shown in Figure 2.19. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.19.  Schematic view of an X-ray diffractometer 
 
 
The measured angles of diffraction are used to determine the arrangement and spacing 
between the atoms within a crystal lattice by the use of Braggs law (Brittain, 1999): 
 
 sin2dno  ,                                                                                                         (2.29) 
  
where    is the angle of beam diffraction from the sample, d is the distance between 
the planes in the crystal,   is the wavelength of the incident beam and on  is the order 
of the diffraction pattern. 
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The different angles of diffraction are measured and are presented on an X-ray pattern 
by the presence of different peaks. A polymorph containing a different structure will 
result in a different set of diffraction angles and hence a different X-ray pattern. The 
detection of crystalline or amorphous solids can be detected by the use of X-ray patterns 
(Stephenson et al., 2001). In order to ensure accurate results the sample material must 
be prepared so as to reduce the extent of preferred orientation of the crystals. Roberts et 
al., (2002) studied the effects of preferred orientation of mannitol particles, which 
contain 3 different polymorphic forms. XRPD showed preferred orientation of the 
crystals, which lead to difficulties in the quantitative analysis of the different 
polymorphic forms. The effects of preferred orientation were minimised by reducing 
the size of the particles and by rotating the samples. This enabled two similar 
polymorphs to be distinguished. However the grinding of organic samples can lead to 
polymorphic transformations. An alternative way to prevent preferred orientation is to 
mix the sample material with an inert amorphous compound (Stephenson et al., 2001).  
 
The identification of the presence of polymorphs within a pharmaceutical tablet is 
essential as these contain different physicochemical properties. Different techniques 
involving XRPD, Raman and IR spectroscopy were used in order to identify the 
presence of a Risperidone polymorph within film coated tablets, which contained other 
crystal phases and excipients (Karabas et al., 2007). XRPD was the only technique that 
was able to identify the polymorph showing the importance of XRPD in the detection of 
different polymorphic forms. XRPD also has the advantage of being able to detect the 
percentage of different polymorphs within a given sample. Lu et al., (2005) used XRPD 
for the quantitative analysis of a sample material containing two chlorothalonil 
polymorphs (A and B). The areas under the peaks of the X-ray patterns were used to 
determine the percentage of each polymorph present within the sample material. For 
example for polymorph A has a characteristic peak at 14.5º 2θ and polymorph B has a 
characteristic peak at 15.5º 2θ. For a mixed sample the percentage of form A can be 
obtained by Equation 2.30.  
 
   
    (2.30) 
                                                                                                                                
 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates  
55 Chapter 2. Literature review 
2011 
2.6.11 Solid state spectroscopy techniques 
 
Spectroscopy techniques including infra-red (IR) and nuclear magnetic resonance 
(NMR) are widely used within in the pharmaceutical industry for the characterisation of 
polymorphs, hydrates and solvates (Bugay, 2001; Threlfall and Chalmers, 2007; Harris, 
2006; Harris, 2007). 
 
IR spectroscopy measures the vibrational modes of the molecules in a compound and is 
therefore referred to vibrational spectroscopy. There are three different types of 
vibrations, including symmetric stretching, asymmetric stretching and bending 
vibrations (Atkinson and Hibbert, 2001). As the covalent bonds vibrate within a 
compound they absorb infra-red radiation. The wavelength range of the IR spectrum is 
400 to 4000 cm
-1
. Each covalent bond within a molecule absorbs infra-red radiation of a 
particular frequency producing a specific peak in the IR spectrum (Atkinson and 
Hibbert, 2001). This technique enables the different functional groups within the 
compound to be detected, which can provide supportive information in the 
identification of hydrates and solvates. Within each IR spectrum there is a fingerprint 
region in the wavelength range 400 to 1500 cm
-1
 (Atkinson and Hibbert, 2001). This 
region is useful for the identification of different polymorphic forms of a compound as 
each polymorph will have a different pattern in the fingerprint region. The advantages 
of this technique are that very little sample preparation is required and the 
spectrophotometers are relatively inexpensive compared to NMR (Bugay, 2001).      
 
NMR spectroscopy is used to determine the structural differences between compounds 
by studying the different electronic environment of nuclei within the molecule. This 
technique only applies for atoms with odd numbers of neutrons and protons in the 
nucleus resulting in an overall charge. Once the nucleus spins it creates a magnetic field 
and when this is placed within an external magnetic field then the nucleus aligns itself 
up with the lower energy level. Radio waves of specific frequency will cause the 
nucleus to resonate between a low and high energy level resulting in a peak in the NMR 
spectrum. Nuclei of the same atom (e.g. hydrogen) that is within a different chemical 
environment will resonate between two different energy levels, resulting in a different 
peak in the NMR spectrum. Chapter 5 of this thesis highlights the importance of proton 
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NMR for the detecting of a new undiscovered solvate. Hydrogen atoms bonded to a     
(-CH3), (-CH2) and (-OH) group were detected with the latter group indicating the 
presence of a solvate as this does not appear in the compound studied. One of the 
strengths of the NMR spectroscopy is that it overcomes problems that arise in 
diffraction studies and can detect differences in spectrum for different forms of a 
compound that are not detectable by IR spectroscopy of XRPD (Harris, 2006). Another 
advantage of this technique is that it can achieve a high degree of spectral resolution 
compared with the other spectroscopy techniques leading to clear and accurate results 
(Stephenson et al., 2001).   
2.6.12 Conclusions  
 
PAT tools are probe based techniques, which can be placed within the process stream 
enabling properties of the crystallization process to be measured in real-time. A 
commonly used tool for monitoring properties of the solid phase is the FBRM probe. 
This tool measures the chord length distribution of a crystal population, which can be 
used to detect nucleation, attrition, agglomeration, polymorphic transformations and 
MSZW values. PVM provides images of the crystals in real time. Changes in 
morphology of the crystals can be detected indicating possible polymorphic 
transformations, attrition or agglomeration. ATR-UV/Vis is a useful tool to use in 
combination with FBRM and PVM as this tool measures properties of the liquid phase. 
Changes in concentration values of the solute can be used for detecting polymorphic 
transformations, obtaining MSZW values and monitoring supersaturation levels. 
Combining all the information obtained from the PAT tools provides a deeper 
understanding of the crystallization process.  
 
For successful analysis of a drug compound a range of solid state techniques can be 
carried out to determine the solid state properties of different polymorphic and pseudo-
polymorphic forms (hydrates and solvates). Thermal techniques including DSC and 
HSM determine the melting point of different forms of a substance and can monitor 
polymorphic or pseudo-polymorphic conversions while TGA and DVS are used for the 
analysis of different solvate or hydrate forms. However the above techniques do not 
include information on the crystal structure. Therefore these techniques are used in 
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combination with XRPD, IR and NMR spectroscopy, which are used to determine the 
crystal structure of different polymorphic and pseudo-polymorphic forms. The use of 
these techniques combined with the PAT tools enables the system to be designed and 
controlled at a certain set of conditions increasing the likelihood of producing a quality 
product.  
 
2.4 Conclusions on literature survey 
 
The aim of this literature review was to gain a deeper knowledge of the research that 
has been carried out related to pharmaceutical crystallization within batch systems. 
Phase rule and diagrams have been briefly mentioned and previous research has shown 
the importance of operating within the MSZW of the phase diagram in order to obtain 
crystals of quality standard. The various factors that could affect the MSZW have been 
mentioned. Following on from this research studies will be carried out using PAT tools 
within batch crystallization processes to see how various process parameters including 
temperature, ramp rate, size of vessel, agitator type and speed affect the MSZW. These 
parameters will be combined to determine whether a robust MSZW region can be 
obtained, which can then be used in designing crystallization experiments at the larger 
scale involving feedback loops and the use of PAT tools. 
 
A literature search on polymorphism, salts and PAT has been included, which showed 
the importance of being able to distinguish the differences between crystal forms of a 
single compound. The use of PAT tools has been used for monitoring and controlling 
the crystallization process. The range of SSA techniques available for characterising the 
crystal product and the information that can be obtained from each technique are 
mentioned. The work within this thesis aims to progress this field of research in which 
PAT tools are combined with SSA techniques for monitoring the crystallization process 
and for the discovery of new polymorphic forms. The literature review highlights the 
importance of crystallizing salts in order to overcome problems with solubility, 
dissolution rate, stability and hygroscopicity (Forbes et al., 1992, Haynes et al., 2005). 
Research within this thesis uses a combination of PAT tools and SSA techniques to 
investigate the best conditions required to produce salts. Various parameters that will be 
varied include method of crystallization, strength of acid, solvent and pH of solution.
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Chapter 3. Materials, experimental set-up and 
methodology  
 
3.1 Introduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
 
This Chapter shall present a detailed description of materials, model systems used and 
methodology of experiments performed. The process analytical technology (PAT) tools 
used to monitor the crystallization process and the range of solid state analytical (SSA) 
techniques used for characterising the crystal products will be discussed. Detailed 
methodology of small scale (1 mL to 20 mL) solubility and slurry experiments, salt 
precipitation and evaporation experiments are discussed. The larger scale crystallization 
experiments of size 250 mL to 1 L were performed in similar jacketed glass vessels 
with slightly different combinations of PAT tools. Cooling, pH controlled and 
antisolvent crystallization rig set-ups are shown in separate Figures highlighting the 
differences in the PAT arrangements.  
 
3.2 Materials 
 
Sodium benzoate was one of the compounds used as the model system for experiments 
(see Chapters 4 and 5). The raw material (sodium benzoate) is the anhydrous form and 
was obtained from two different sources. These included Sigma Aldrich and Fisher 
Scientific, both which had of purity greater than 99.0%. Solubility studies were carried 
out using a range of solvents including water, methanol, ethanol, propan-2-ol (IPA), 
butan-2-ol, acetone, acetonitrile, methyl ethyl ketone (MEK) and tretrahydrofuran (see 
Chapters 4 and 5). Ultra-pure Millipore water generated from a MilliQ reverse osmosis 
unit was used and all other solvents were of analytical reagent grade, which were 
obtained from Fisher Scientific. Para-amino benzoic (PABA) acid, meta-amino benzoic 
acid (MABA) and ortho-amino benzoic (OABA) acid were three other model 
compounds used in the crystallization studies (described in Chapters 6, 7, 8 and 9). 
PABA and MABA were obtained from Sigma Aldrich with purity of 99%. OABA was 
also obtained from Sigma Aldrich with purity of 98%. There are two known 
polymorphic forms of PABA (Gracin and Rasmuson, 2004), two polymorphic forms of 
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MABA (Svard et al., 2010) and three polymorphic forms of OABA (Jiang et al., 2008; 
Rajeshwar and Secco, 1976; Ojala and Etter, 1992). Solvents used include water, 
ethanol and ethyl acetate. The latter two solvents were of analytical reagent grade and 
obtained from Fisher Scientific. A range of acids and bases were used in the pH/salt 
crystallization experiments (described in Chapters 8 and 9) including hydrochloric acid 
(molarity of 0.5M for pH swing and 5M for cooling crystallization experiments), 
hydrobromic acid (3M), sulphuric acid (2M), phosphoric  (3M), sodium hydroxide 
(5M) and potassium hydroxide (5M). 
 
3.3 Avantium Crystal 16 experiments and solubility 
measurements  
 
Solubility screening, slurry and meta-stable zone width (MSZW) measurement 
experiments were performed at 1 mL scale using the Avantium Crystal 16 equipment. A 
picture of the Crystal 16 equipment can be found in Appendix A. This contains reactor 
blocks of 4 by 4 of 1 mL HPLC vials agitated by magnetic fleas which were set at a 
rotation speed of 700 rpm. Each vial contained a turbidity sensor which was used to 
detect the clear (all crystals dissolved) and cloud points (apparent nucleation). A 
turbidity value of zero% represents a cloudy solution and 100% represents a clear 
solution. The temperature was controlled by a Huber ministat which was connected to a 
PC.  
 
Solubility screening experiments involved suspending sodium benzoate in a range of 
solvents and heating using a ramp rate of 0.3 °C/min. Solvents used include water, 
alcohols (methanol, ethanol, propan-2-ol and butan-2-ol) and 4 other organic solvents 
(acetone, acetonitrile, MEK and tetrahydrofuran). Results are discussed in Section 4.3 
of Chapter 4. Solubility determination for sodium benzoate in water, IPA and volume 
ratios of IPA/water 2:1, 4:1 and 5:1 were carried out using a gravimetric method. This 
method involved suspending sodium benzoate in the required solvent using 20 mL vials 
which were shaken in a water bath at the desired temperature for 22-24 hours to allow 
the system to reach equilibrium.  Three samples of 1-2 mL for each solvent system were 
placed in petri dishes and left in the oven at 25 °C for 24 hours for solvent evaporation. 
Results are discussed in Section 4.3 of Chapter 4 and Section 5.3 of Chapter 5.  
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Slurry experiments were performed in order to determine the stability order of the 
different crystal forms of sodium benzoate within different solvent mixtures of 
IPA/water. Vials of 1 mL were used to suspend sodium benzoate in the solvent mixture 
for 4 days at 25 °C. Results are discussed in Section 5.3 of Chapter 5.  
MSZW measurements involved suspending PABA in water using 1 mL vials. The 
range of concentrations used is 10 to 35 mg/mL. A ramp rate of 0.5, 0.3 and 0.1 °C/min 
is used for each concentration value to obtain the clear (solubility) points and cloud 
(nucleation) points. The process is repeated using the isomer MABA using the 
concentration range of 12 to 28 mg/mL. Results are discussed within Chapter 7.  
3.4 Cooling crystallization experiments at scales of 250 mL, 
750 mL and 1 L 
 
Cooling crystallization experiments were performed in a range of jacketed glass vessel 
sizes, including 250 mL, 750 mL and 1 L, using a linear cooling rate of 0.1, 0.2, 0.3 and 
0.5 ºC/min. Each experiment consisted of a different combination of PAT tools for 
monitoring the crystallization process. The PAT tools used within these studies include 
the FBRM, turbidity, PVM, ATR-UV/Vis, pH and temperature probe. The FBRM 
probe is used for monitoring changes in the solid phase. This PAT tool is used for 
detecting changes in the number of counts with chord lengths within size range of 1-20 
microns (fine counts), 50-250 microns (coarse counts) and 1-1000 microns (total 
counts).  A 90 logarithmic channel mode was used to collect data into specific bins. 
This PAT tool can be used to detect nucleation, growth, agglomeration, attrition and 
polymorphic transformations. Turbidity probe is used to detect changes in the 
cloudiness of the solution. For experiments performed at the 1 L scale a turbidity of 
zero % indicates a clear solution and a turbidity value of 100% represents a cloudy 
solution. This PAT tool can be used to detect the point of nucleation and dissolution, 
which is required for MSZW determination of a crystallization system. An ATR-
UV/Vis probe is used for monitoring changes in the liquid phase. Any changes in 
concentration are detected by a change in absorbance of the peak wavelength at which 
the compound absorbs. The wavelength range for measuring absorbance is 242 to 614 
nm. The ATR-UV/Vis was used for qualitative monitoring of the changes in the 
crystallization process, hence calibration was not performed. PVM is an in-line video 
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camera detecting any changes in morphology of the crystals during the crystallization 
process.  
3.4.1 Cooling crystallization of sodium benzoate in water 
 
Cooling crystallization experiments were performed in a 250 mL and 1 L vessel using 
the model system sodium benzoate in water. Results are discussed within Chapter 4. 
The 250 mL scale experiments performed at AstraZeneca (AZ) were carried out using a 
3-blade glass retreat curve agitator and using a D600l-HC-K FBRM Lasentec probe. 
The 1 L scale experiments performed at Loughborough University (LU) were 
conducted using a stainless steel 3-blade marine agitator and an A100 Lasentec FBRM 
probe. In all experiments a stirrer speed of 300 rpm was used whereas the ramp rates 
and initial concentrations varied. Ramp rates of 0.1, 0.3 and 0.5 °C/min were used at 
initial concentrations of 466, 566 and 633 mg/mL solvent. The temperature was 
controlled using a Huber Ministat unit. For the 250 mL scale this was connected to a 
computer package known as Labworldsoft, which controlled the temperature at a 
desired set-point. For the 1 L scale experiments both FBRM and temperature are 
recorded using a software tool (Crystallization Process Informatics System, Cry 
PRINS) developed in Labview. Figure 3.1 shows both the schematic of the set-up and 
picture of the crystallization rig.  
 
  
 
                                                                  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1. (a) Schematic of the set-up and (b) picture of the crystallization rig at 
LU for the cooling crystallization of sodium benzoate from water experiments 
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3.4.2 Cooling crystallization of PABA in ethyl acetate  
 
Cooling crystallization experiments using the model system PABA in ethyl acetate 
were performed within two different setups using a jacketed glass vessel of 1 L. Results 
are discussed within Chapter 6. A solution of initial concentration 133 mg/mL was 
heated up from 25 to 70 
o
C using a ramp rate of 5 
o
C/min and kept at 70 
o
C until all the 
crystals dissolved (clear solution). The method of cooling to crystallize the compound 
was used by cooling from 70 to 45 
o
C at a ramp rate of 0.5 
o
C/min and then the system 
was kept at 45 
o
C for durations of 6.8-17.5 hours. The system was further cooled from 
45 to 5 
o
C using a ramp rate of 0.5 
o
C/min and then kept at 5 
o
C for durations of 14-22 
hours. PAT tools were used to monitor the cooling crystallization experiments. The 
crystallization rig set-up at AZ consisted of a Mettler Toledo FSC402 turbidity meter 
and Lasentec (D6001-HC-K) FBRM probe. The type of agitator used is a 3-blade glass 
retreat curve at a rotation speed of 300 rpm.  The crystallization rig set-up at LU 
consisted of the same model of FBRM probe and a MSC 621 ATR-UV/Vis probe (Carl 
Zeiss, Inc). A 4-(PTFE coated) pitched blade turbine was used at a rotation speed of 
315 rpm.  Figure 3.2 shows the schematic representation of the set-ups of both rigs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Schematic set up of the crystallization rig using (a) 4-pitched blade 
turbine with FBRM and ATR-UV/Vis (LU rig) and (b) 3-blade glass retreat curve 
agitator with FBRM and turbidity probes (AZ rig) 
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3.4.3 Cooling crystallization of PABA/MABA in water for MSZW 
determination 
 
Cooling crystallization experiments were performed within two different vessels of size 
1 L using a Mettler Toledo FSC402 turbidity meter and Lasentec (D6001-HC-K) 
FBRM probe to obtain MSZW measurements for the model systems PABA, MABA 
and OABA in water. Results are discussed within Chapter 7. One of the rig set-ups used 
a 3-blade glass retreat curve agitator and another set-up used a 4-(PTFE coated) pitched 
blade turbine. Stirrer speeds of 250, 300 and 400 rpm were used to create a well 
suspended solution. Ramp rates of 0.5, 0.3 and 0.1 °C/min were used to obtain 
solubility and nucleation points at concentrations in the range 10 to 35 mg/mL. The set-
up of the crystallization rig is the same as that shown in Figure 3.1. 
3.4.4 pH controlled cooling crystallization experiments of 
PABA/MABA in ethanol  
 
Crystallization of acidic salts and pH controlled polymorphic crystallization 
experiments are performed using a linear cooling crystallization method within a       
750 mL vessel.  Results are discussed within Chapter 8 and 9. The type of agitator used 
is a 3-blade glass retreat curve agitator at a rotation speed of 300 rpm. Experiments 
were performed within a crystallization rig at AZ.  Model system used in these 
experiments is PABA and MABA in solvents of pure ethanol and water. PAT tools 
were used to monitor the crystallization process including a Lasentec (D6001-HC-K) 
FBRM, MSC 621 ATR-UV/Vis (Carl Zeiss, Inc), Lasentec PVM (supplied by Mettler 
Toledo) and pH probe. A schematic of the crystallization rig is shown in Figure 3.3. 
 
The method of cooling crystallization involved heating the system to 40 °C to achieve a 
well suspended solution of raw material in solvent. The next stage involved starting the 
pH control at the desired set-point and heating to 70 °C using a ramp rate of 0.3 °C. 
During this stage acid and base is added in steps and at the end of the stage all the 
crystals dissolve. The system is then cooled to 5 °C using a ramp rate of 0.3 °C/min 
resulting in nucleation. For the crystallization of PABA in ethanol at pH=2.5 and 
MABA in ethanol at pH=4.1 the temperature increase from 40 to 70 °C does not start 
until all the acid is added. A slight modification is made to the method for crystallizing 
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the hydrobromic (HBr) salts. This involved adding acid to a well suspended solution at 
40 °C to achieve the desired pH set-point resulting in complete dissolution. The system 
was then cooled to 5 °C using a ramp rate of 0.3 °C/min, resulting in nucleation. For the 
crystallization of MABA in water after cooling the system to 5 °C base (NaOH) is 
added to achieve the desired pH and the system is left overnight for 13 hours before 
nucleation occurs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.  Schematic of the crystallization rig for the pH controlled cooling 
crystallization experiments (AZ rig) 
 
3.5 Antisolvent crystallization experiments 
 
 
Antisolvent crystallization experiments were performed using sodium benzoate in pure 
water with an initial concentration of 545 mg/mL. Results are discussed within Chapter 
5. The system was heated up from 20 to 25 °C and kept at 25 °C until all the crystals 
dissolved resulting in a clear solution. IPA (antisolvent) was then added using a dosing 
rate within the range 0.3-2 g/min, reaching a final volume ratio of IPA/water of 5:1. The 
temperature of the system was maintained constant at 25 °C using a Huber ministat 
unit. Experiments were performed using two different rigs within a 1 L jacketed glass 
vessel. The crystallization rig set-up at AZ consisted of an automated lab reactor 
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(Mettler-Toledo Lab Max system) using a 3-blade glass retreat curve and a stirrer speed 
of 300 rpm. PAT tools used to monitor the solid phase include a Lasentec (D6001-HC-
K) FBRM probe and Mettler Toledo FSC402 turbidity meter. The crystallization rig 
set-up at LU consisted of a 1 L crystallization vessel and a peristaltic pump for the 
addition of the antisolvent to the vessel. The type of agitator used was a 4-pitched blade 
turbine (coated with PTFE) with a rotation speed in the range of 255-300 rpm. The 
same model of FBRM probe was used and a MCS 621 ATR-UV/Vis probe (Carl Zeiss, 
Inc). The wavelength range used for measuring absorbance is 242-614 nm in which 
sodium benzoate has a peak absorbance at 270 nm. A schematic representation of the 
set-ups of both antisolvent crystallization systems are shown in Figure 3.4 and a picture 
of the crystallization rig set-up for experiments performed at LU using the peristaltic 
pump is shown in Figure 3.5. 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 3.4. Schematic set-up of the crystallization rig for (a) automated LabMax 
system with a 3-blade glass retreat curve agitator (AZ rig) and (b) laboratory rig 
with a 4-pitched blade turbine agitator (LU rig) 
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Figure 3.5. Picture of the antisolvent crystallization rig set-up performed with a 
peristaltic pump (Loughborough University) 
 
3.6 Salt precipitation and evaporation experiments 
 
Acidic salts including sulphate and phosphate salts of PABA were produced by the 
method of precipitation. Results are discussed within Section 8.4 of Chapter 8. Vessel 
size of 750 mL is used with a 3-blade glass retreat curve agitator at a rotation speed of 
300 rpm. A well suspended solution is heated to 40 °C and then acid is added with the 
use of a pump. The moment acid is added to solution crystals precipitate from solution. 
The experiment is repeated in a 100 mL beaker using a magnetic flea and hot plate to 
heat the well suspended solution until all the crystals dissolve. Acid is added and 
crystals precipitate from solution.   
 
Alkali salts of PABA were produced by a method of evaporation using a 100 mL 
beaker. Results are discussed in Section 8.5 of Chapter 8. The raw material was well 
suspended in an ethanol solution at room temperature (25 °C) using a magnetic stirrer. 
Alkali (NaOH) was then added to achieve a high pH of solution. During this stage the 
crystals dissolved until complete dissolution occurred. The solution was then left in a 
fume cupboard at room temperature for approximately 48 hours resulting in nucleation. 
The procedure was repeated using KOH resulting in the crystallization of the potassium 
salt of PABA.  
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3.7 Summary of experiments performed within each Chapter  
 
A range of experiments were performed in which process analytical technology (PAT) 
tools were used to investigate the crystallization of pharmaceutical polymorphs, salts 
and hydrates. The details of each experiment including crystallization method, model 
compound, solvent and acids/ bases used are shown in Table 3.1. The details of each 
experimental set-up and parameters used include vessel size, impeller type, agitator 
speed, ramp (cooling) rate or dosing rate, PAT tools used and where the vessel is based 
(AZ or Uni) is shown in Table 3.2.  
 
Table 3.1. Summary of experiments performed including method and materials 
Experiment 
number 
Chapter 
number 
Crystallization 
method 
 Model 
(AI) 
compound 
Solvent Acids/bases 
1 and 2 4 Cooling  Sodium 
benzoate 
(SB) 
water - 
3 4 Cooling 
(solubility 
determination) 
SB Organic 
solvents and 
water 
- 
4 4 and 5 Gravimetric  
method 
(solubility 
determination) 
SB Water and 
water/IPA 
ratios 
- 
5 and 6 5 Anti-solvent SB Water 
(solvent) 
and IPA 
(anti-
solvent) 
- 
7 5 Slurry 
experiment at 
 25 ˚C 
SB Water/IPA 
(different 
ratios) 
 
8 and 9 6 Cooling PABA Ethyl 
acetate 
- 
10 and 11 7 Cooling (MSZW 
determination) 
PABA, 
MABA 
water - 
12 7 Cooling (MSZW 
determination) 
PABA, 
MABA, 
OABA 
water - 
13 8 Precipitation PABA ethanol H2SO4 
H3PO4 
14 8 Evaporation PABA ethanol NaOH, 
KOH 
15 8 and 9 Cooling (pH 
control) 
PABA, 
MABA 
Ethanol and 
water 
HCl, 
HBr, 
NaOH 
16 9 pH swing  PABA water HCl,     
NaOH 
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Table 3.2. Summary of experiments performed including experimental set-up and 
parameters 
 
Exp.  
no.  
Chapter 
number 
Vessel 
size  
Impeller 
type 
Agitator 
speed 
(rpm) 
Ramp 
(cooling) 
rate 
(˚C/min) 
Vessel 
at AZ 
or Uni 
PAT 
tools 
1 4 250 mL 3-blade glass 
retreat curve 
(GRC) 
300 0.1, 0.3, 
and 0.5 
AZ FBRM  
2 4 1 mL Stainless steel 
3-blade marine 
300 0.3 Uni  FBRM  
3 4 1 L Magnetic flea 700 0.3 AZ Turbidity 
4 4 and 5 20 mL Shaker/ water 
bath for 
stirring 
- - Uni - 
5 5 1 L 3-blade GRC 300 Dosing 
rate: 
0.33g/min 
AZ FBRM, 
Turbidity 
6 5 1 L 4-pitched 
blade turbine 
(PBT) (coated 
with PTFE) 
255, 300 Dosing 
rate: 1 and 
2g/min 
Uni FBRM, 
ATR-
UV/Vis 
7 5 1 mL Magnetic flea 700 - AZ - 
8 6 1 L 3-blade GRC 300 0.5 AZ FBRM, 
Turbidity 
9 6 1 L 4-PBT  315 0.5 Uni FBRM, 
ATR-
UV/Vis 
10 7  1 mL Magnetic flea 700 0.1, 0.3, 0.5 AZ Turbidity 
11 7 1 L 3-blade GRC 250, 300, 
400 
0.1, 0.2, 
0.3, 0.5 
AZ Turbidity 
12 7 1 L 4-PBT  255, 300 0.3, 0.5 Uni FBRM 
13 8 100 mL 
beaker 
and  
750 mL 
Magnetic flea/ 
3-blade GRC 
300 - AZ pH probe 
14 8 100 mL 
beaker 
- - - AZ pH probe 
15 8 and 9 750 mL 3-blade GRC 300 0.3 AZ FBRM, 
ATR-
UV/vis, 
PVM, pH 
probe 
16 9 750 mL 3-blade GRC 300 - AZ FBRM, 
pH probe 
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3.8 Solid state analysis of crystals 
 
Solid samples of the crystals were analysed using a range of SSA techniques. Visual 
images of the crystals are obtained with the use of two types of optical microscopes 
including an Olympus BX51 microscope using image Pro Plus software and a Leica 
DMLM microscope. Crystal samples were placed on a cover slide with a cover slip on 
top and viewed under the microscope. Crystal samples are viewed using a scanning 
electron microscope providing 3D images with higher magnification. Samples are gold 
plated to provide clear images. Two types of hot stage microscopy (HSM) units were 
used to determine the melting point of polymorphs and for detecting higher melting 
point polymorphic forms. One of the HSMs consisted of an Olympus BX51 microscope 
with a Linkam heating stage attachment connected to a 3-CCD colour video camera 
(JVC model KY-F55B). Another HSM unit consisted of a Leica DMLM microscope 
with a Mettler Toledo FP90 HS attachment connected to a JVC colour video camera. 
 
Thermal techniques used include differential scanning calorimetry (DSC) and thermal 
gravimetric analysis (TGA) units which provide data on the melting point of 
polymorphs, identify polymorphs transitions and the presence of hydrates/solvates. 
Three types of DSC machines are used to analysis samples including a Perkin Elmer 
(Pyris 1), Mettler Toledo and TA instrument Q10. The ramp (heating) rate used 
includes 1 and 10 °C/min. Samples were analysed using a Perkin Elmer TGA unit with 
a heating rate of 10 °C/min. Dynamic vapour sorption (DVS) is a useful technique for 
identifying the likelihood of compounds forming hydrates and to determine whether the 
material is amorphous or highly crystalline. The manufacturer of the DVS unit is 
Surface Measurements Systems Ltd and the model used is Dynamic Vapour Sorption 
Analyser, DVS-1. Samples are placed inside a chamber and the relative humidity (RH) 
is increased from 40 to 90% resulting in a change in mass. 
 
An X-ray powder diffraction unit of model Rigaku Miniflex is used to determine 
structural differences between the different polymorphic forms of the compound 
sodium benzoate. All XRPD samples except the samples obtained from the sodium 
benzoate anti-solvent crystallization experiments at volume ratio IPA/water of 3:1 and 
5:1 were gently grinded before being placed onto a shallow aluminium plate. Gently 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates  2011 
70 Chapter 3. Materials, experimental set-up and methodology 
grinding of the crystals is required to prevent preferred orientation. The aluminium 
plates are spinning while the XRPD machine is operating, therefore, a thin layer of 
crystals is placed onto the shallow aluminium plate to prevent the loss of sample from 
the plate which would contaminate the XRPD chamber and can result in 
misinterpretation of the results. A scan speed of 1 °/min was used and the start and stop 
angles were 3 and 35 respectively. Solid state NMR spectra were obtained using a 
Bruker Avance III NMR spectrometer. Samples were packed into 4 mm OD rotors and 
spun at 12 kHz. Carbon spectra were recorded at a frequency of 125.64 MHz using the 
cross polarisation method with a 1 ms contact time and 100 kHz of proton decoupling. 
Sodium (
23
Na) spectra were recorded at 132.17 MHz using a one pulse acquire 
sequence. Proton spectra were recorded at a frequency of 499.66 MHz using a one pulse 
acquire sequence. IR data were obtained using a Perkin Elmer instrument (FT-IR 
system) of model spectrum GX. Crystal samples were placed onto a small glass hole in 
the centre of a plate in which a laser beam is directed towards. The crystals were kept in 
position with the use of a metal probe and the sample was covered with a lid for 
containment before analysis.    
 
3.9 Conclusions 
 
A description of the materials used and a detailed methodology of all experiments are 
discussed within this chapter. The model systems used include sodium benzoate and 
isomers (ortho, meta and para) of amino benzoic acid (ABA). Small scale experiments 
were performed at the 1 mL scale using the Avantium Crystal 16. These experiments 
provide data on solubility measurements, stability determination in various solvents and 
MSZW values. An alternative method used for solubility determination is the 
gravimetric method. The methodology of beaker experiments at the 100 mL scale 
involving salt precipitation and evaporation are mentioned. Larger scale crystallization 
experiments were performed at the 250 mL to 1 L scale. Methods used include cooling, 
antisolvent and pH controlled. PAT tools used for monitoring the process include 
FBRM, turbidity probe, ATR-UV/Vis, PVM and pH probe. A schematic set-up of each 
experiment is shown in a range of Figures highlighting the differences in PAT 
arrangements. SSA techniques used in this research work for characterising the crystal 
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product include optical microscope and SEM, XRPD, DSC, TGA, DVS, NMR and IR 
spectroscopy. The detailed operating conditions of these techniques are discussed in this 
Chapter.
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Chapter 4. PAT based investigation of the cooling 
crystallization of sodium benzoate hydrate 
 
4.1 Introduction 
 
Traditionally the cooling crystallization method of an active pharmaceutical ingredient 
is by trial and error in which an under-saturated solution is cooled down at a constant 
ramp rate resulting in a supersaturated solution. The process often leads to failed 
batches due to the crystallization of different polymorphic forms, which may result in 
an increase in economical costs (Davey, 2003). Recent advances in the pharmaceutical 
industry have involved the use of process analytical technology (PAT). These tools 
enable the systematic design and control of the crystallisation systems to produce high 
quality crystalline products with reduced variability in the properties (Braatz, 2002; 
Fujiwara et al., 2002; Zhou et al., 2006; Nagy et al., 2008b). Process analytical tools 
can be used to indicate a potential polymorphic transformation, however a range of 
solid state analytical (SSA) techniques usually must also be used to confirm the 
formation of polymorphs. 
 
This chapter presents the advantages of using PAT tools combined with SSA techniques 
for the monitoring and detection of different polymorphic/pseudo-polymorphic forms of 
a model system, sodium benzoate. As there is limited literature data on the solubility of 
sodium benzoate the first stage of experiments involved solubility screening using the 
Avantium Crystal 16 unit on a 1 mL scale.  Scale up experiments were performed from 
the 1 mL to vessel sizes of 250 mL and 1 L for the cooling crystallization of sodium 
benzoate from water. The main PAT tool used within these studies was the FBRM 
probe, which detected the formation of an unknown hydrate. A series of solid state 
analyses were carried out on the crystals using a range of techniques including DSC, 
TGA, DVS, XRPD, HSM, optical microscopy, SEM, solid state NMR and IR 
spectroscopy. The results provide evidence of the existence of a new channel hydrate of 
sodium benzoate that has not yet been reported in the literature.  
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4.2 Experiments performed  
 
Solubility experiments were performed using the Avantium Crystal 16 and a 
gravimetric method. A picture of the Crystal 16 equipment can be found on Appendix 
A. The materials and solvents used are mentioned in Section 3.2 of Chapter 3. A 
detailed description of the method can be found in Section 3.3 of Chapter 3. Cooling 
crystallization experiments were performed in jacketed glass vessels at the 250 mL and 
1 L scale using an FBRM probe to monitoring the process. The model of FBRM probe 
and parameters used in each experiment including type of agitator, stirrer speed, ramp 
rates and initial concentrations of sodium benzoate in water are discussed in Section 
3.4.1 of Chapter 3. A schematic and picture of the crystallization rig is shown in Figure 
3.1 of Chapter 3.  
 
4.3 Solubility measurements  
 
The main aims of the experiments were to use PAT tools combined with solid state 
techniques to identify the different polymorphic forms of sodium benzoate. The first 
stage of the experiments involved solubility screening in order to find a suitable solvent 
for which sodium benzoate can be re-crystallized using cooling. For the screening 
experiments Avantium Crystal 16 equipment was used. This detects the cloud and clear 
points using turbidity probes. A turbidity of 100 represents a clear solution which 
indicates that all the crystals have dissolved and a turbidity value of zero indicates a 
cloudy solution with crystals present. Turbidity values for organic solvents remained at 
0% for the concentration range 20-40 mg/mL, indicating that sodium benzoate has a 
very low solubility in organic solvents. The solubility results for sodium benzoate in 
organic solvents can be found in Appendix C. Figure 4.1a shows the turbidity results for 
the cooling crystallization experiments using water as a solvent. A concentration of 
sodium benzoate in water of 649.8 mg/mL results in a clear point of 85 °C indicating 
that sodium benzoate has a high solubility in water. The solubility obtained using 
gravimetric analysis is slightly lower when compared with literature data, as shown in 
Figure 4.1b, however both these results show a similar solubility curve over the 
temperature range 30-70 °C. For the gravimetric method a syringe and filter was used to 
uptake the fluid sample from the slurry mixture. In some cases the uptake of fluid was 
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slow, which was due to blockage of the filter head. This indicated that crystals from the 
fluid were crystallizing on the filter head, which would lower the solubility value and 
would explain why the gravimetric results are slightly lower than literature data.  To 
improve the accuracy of the gravimetric results a fresh filter head would be used for 
each sample vial. Also the time taken to remove the fluid from the syringe to the 
crystallizing dish would be kept to a minimum to prevent solid crystallizing inside the 
syringe due to a drop in temperature (high temperature in water batch to room 
temperature). Literature solubility data shows that for the operating temperature range 
of water between 15 and 97 °C the solubility of sodium benzoate is between 628 and 
733 mg/mL, indicating a high solubility but small temperature sensitivity of the 
solubility (flat solubility curve). In the interval 10-50 °C, there is practically no change 
in solubility and even in the range of 50-90 °C, the change is only about 10%. Due to 
the high solubility, water was chosen as the solvent for the cooling crystallization 
experiments, and initial concentrations and operating temperature were carefully 
selected to be able to crystallize the compound via cooling. 
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Figure 4.1. Solubility results for sodium benzoate in water obtained from (a) 
Crystal 16 unit (turbidity points) and (b) literature data (Stephen and Stephen, 
1963) and gravimetric method  
 
 
4.4 Monitoring of sodium benzoate hydrate formation using 
PAT tools 
 
Experiments were performed at 250 mL and 1 L scales with the use of the FBRM probe 
to monitor the cooling crystallization of sodium benzoate from water. Figure 4.2 shows 
(a) (b) 
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the FBRM results for the 1 L scale and 3 repeated experiments using a   250 mL vessel 
with variations in the initial concentration of sodium benzoate in water of 466, 566 and 
633 mg/mL solvent. The agitator types were varied within the different size vessels to 
examine the effect of mixing conditions on the behaviour of the system. In all cases as 
the system was heated the crystals dissolve as indicated by a decrease in the FBRM 
counts. The larger baseline in the case of the 1 L vessel (Figure 4.2a) is due to the use 
of an older FBRM probe (model A100) with small defects on the window. At 
temperatures above 65 °C there is a fluctuation in the number of counts, which is 
thought to be due to either attrition, agglomeration or a morphology change as the 
crystals dissolve and grow or a polymorphic transformation. The fluctuation in FBRM 
counts is repeatable within the same vessel using different concentrations. For a 
concentration of 566 mg/mL, the fluctuations occurred at all ramp rates of 0.1, 0.3 and 
0.5 °C/min. The repeatability of the results using different mixing conditions, within the 
different vessel sizes, indicates that this factor does not affect the behaviour of the 
system.  
 
The use of a combination of FBRM statistics including fine (1-20 microns), coarse (50-
250 microns) and total (1-1000 microns) counts show that the FBRM signal is not due 
to attrition or agglomeration as all counts show a similar behaviour during the 
fluctuation, providing further evidence of a possible morphology change resulting from 
a polymorphic transformation. Similar results for other model systems were reported in 
the literature, which involved the use of FBRM statistics to indicate a polymorphic 
transformation from a meta-stable to a stable form (O‟Sullivan and Glennon, 2005; 
Nagy et al., 2007; O‟Sullivan et al., 2003). However, it has to be mentioned that the 
FBRM signal is very difficult to interpret since various events during the crystallisation 
may lead to similar changes in the FBRM signal (Yu et al., 2008). Nevertheless FBRM 
can provide a very useful tool to signal that an event happens in a particular stage of the 
crystallisation process, which generally requires additional solid-state analytical 
methods to elucidate.  
 
As hydrates tend to be stable at lower temperatures and anhydrates tend to stable at 
higher temperatures (Bechtloff et al., 2001) the hypothesis is that there is a possible 
polymorphic transformation from a hydrate to the anhydrate form of sodium benzoate at 
a temperature above 65 °C. This transformation occurs without complete dissolution of 
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the anhydrous form (FBRM counts do not decrease to zero as shown in Figure 4.2(d)). 
An additional FBRM statistic including the mean chord length is plotted in Figure 
4.2(d). This graph shows that at a temperature of above 65 ºC there is an increase in fine 
counts and a decrease in coarse counts and mean chord length suggesting the formation 
of fine particles. As the temperature is decreased below 65 ºC the coarse counts and 
mean chord length increase and the fine counts decrease and then increase suggesting 
the formation of a possible needle like morphology.   
 
 
 
      
 
 
 
 
Figure 4.2. FBRM results for the cooling crystallization of sodium benzoate in 
water at different initial concentrations (C0): (a) 1 L vessel and C0 = 466 mg/mL; 
(b) 250 mL vessel and C0 = 466 mg/mL; (c) 250 mL vessel and C0 = 566 mg/mL (d) 
250 mL vessel and C0 = 633 mg/mL 
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4.5 Evaluation of the formation of the new sodium benzoate 
hydrate using solid state analytical methods 
 
 
To investigate whether a hydrate forms when sodium benzoate re-crystallizes from 
water, samples were taken from the cooling crystallization experiments and analysed 
using a range of SSA techniques, such as optical and SEM, HSM, XRPD, DSC, TGA, 
DVS, NMR and IR spectroscopy.  
 
Figure 4.3 shows the optical and SEM images of the anhydrous form of sodium 
benzoate and samples re-crystallized from water. The optical microscope image of the 
anhydrous form shows large agglomerates made up of many fine particles of size less 
than 10 μm. The SEM image shows the particles have a rough surface. SEM images of 
the sample re-crystallized from water show the formation of a solid clump which has a 
fibrous surface structure. This is in correlation with the optical microscope images, 
which show long fibrous needles with longest dimension of approximately 200 μm. 
Any differences in these images is due to the fact that the optical microscope image was 
obtained from a mobile slurry and the SEM images were obtained after the crystals had 
been filtered under vacuum resulting in the formation of the solid clump. Comparing 
the SEM‟s of the raw material (anhydrous) and sodium benzoate re-crystallized from 
water, shows a clear difference between the surface characteristics. The change in 
morphology from fines to needles indicates the possibility of a different form (hydrate). 
These results fit with the FBRM results shown in Figure 4.2(d) suggesting a 
polymorphic transformation from anhydrate (fines) to hydrate (needle morphology) 
form once the temperature is below 65 ºC. Nagy et al., (2007) reported similar results 
for the detection of a polymorphic transformation of caffeine from anhydrous form to a 
channel hydrate that resulted in a change in morphology from fines to needles. During 
the cooling crystallization of sodium benzoate from water a solid clump formed, which 
is immobile due to the result that sodium benzoate uses up water during the formation 
of the hydrate.  
                   (a) 
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Figure 4.3. (a) Optical microscope image of sodium benzoate re-crystallized from 
water, (b, c) SEM images of sodium benzoate re-crystallized from water, (d) 
optical microscope image of raw material (anhydrous) form of sodium benzoate 
and (e) SEM image of raw material  (anhydrous) form of sodium benzoate 
 
Figure 4.4 shows the HSM results for the anhydrous form of sodium benzoate. The 
HSM images show that the crystals start to melt between 436 and 440 °C which is 
considered very high for organic compounds even if sodium benzoate is an organic 
ionic compound (salt). HSM images also show that sodium benzoate re-crystallizes 
from the melt showing a birefringent crystal behaviour with an anisotropic structure, 
also illustrated in Figure 4.5. These compounds are known to exhibit a tendency to form 
polymorphs. HSM was performed on the sample of sodium benzoate re-crystallized 
from water (hydrate). Brittian, (1999) reported hot stage microscopy as a useful 
technique in classifying the type of hydrate. For channel hydrates, de-hydration is 
observed as a progressive darkening of the ends of the crystal towards the centre as the 
crystals are heated. However, these results showed no change in the appearance of the 
crystals during the temperature range 25-440 °C (melting point of anhydrous form). 
20 μm 200 μm 
100 μm 100 μm 50 μm 
      (a)       (b)       (c) 
   (e)    (d) 
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This could be due to the fact that the crystals appeared as dark solid agglomerates made 
up of very fine fibres as shown by the SEM images in Figure 4.3 (b, c).   
 
       
          
      
         
     
                                     
 
Figure 4.4. Hot stage microscopy (HSM) images of sodium benzoate. Images (a-d) 
are during the heating phase and (e- l) are during the cooling of the melt 
 
 
 
 
                              
 
Figure 4.5. Birefringent crystal of the anhydrous sodium benzoate crystal re-
crystallised from melt 
 
  
  (a) 400°C   (b) 436°C   (c) 440°C   (d) 448°C 
(e) 433.9°C (f) 433.6°C    (g) 433.2°C ( h) 432.9°C 
(i) 432.6°C  (j) 432.2°C (k) 431.9°C (l) 431.5°C 
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Further analysis was carried out using XRPD. This technique is used for the 
identification of different polymorphic forms of a given compound as each polymorph 
is represented by a particular X-ray diffraction pattern (Lu et al., 2005; Yu et al., 2004). 
Figure 4.6 shows the XRPD patterns for the raw material, anhydrous form of sodium 
benzoate and the sodium benzoate re-crystallized from water. The anhydrous sodium 
benzoate for these tests was produced by heating the crystals obtained from the 
crystallisation in water above the dehydration temperature, using TGA. These XRPD 
results show similar patterns for the raw material and the anhydrous form, indicating 
that the raw material is anhydrous however the pattern for sodium benzoate re-
crystallized from water shows additional and missing peaks indicating a different 
internal structure compared to the anhydrate form. This provides evidence that a 
different polymorphic form exists. 
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Figure 4.6. XRPD results for (a) raw material and sodium benzoate (air-dried and 
TGA applied) and (b) raw material and sodium benzoate re-crystallized from 
water 
 
NMR spectroscopy is a powerful technique for identifying different forms of a 
compound including (non-stoichiometric and stoichiometric) hydrates and anhydrates 
(Harris and Jackson, 1987; Harris, 2007). This technique is used with XRPD to provide 
supporting evidence on the presence of different forms of a compound as related to 
geometry and compositional differences. The different chemical environments exposed 
to the carbon and hydrogen atoms within the molecule are represented by specific peaks 
in the NMR spectrum. Figure 4.7 shows the solid state NMR data of 
13
C, 
1
H and 
23
Na 
for the anhydrous form of sodium benzoate and the form re-crystallized from water. 
13
C 
data for both forms is very similar showing 4 peaks representing 4 different chemical 
 (a)  (b) 
crystallized from water 
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environments. The peak at 177 ppm is due to the carboxylate carbon (COO
-
) and the 3 
peaks within the range 120-140 ppm are due to the carbon atoms in the aromatic ring of 
sodium benzoate (Harris, 2006).  
23
Na spectra shows a broad peak for the anhydrous 
form of sodium benzoate representing immobile sodium ions while the spectra for the 
sample re-crystallized from water shows an additional sharp peak at 1 ppm. The sharp 
peak represents mobile sodium ions providing supporting evidence of the presence of 
water molecules within the internal structure of the crystal. 
1
H data for the anhydrous 
form show a broad peak in the range 0-10 ppm while the spectra for the sample re-
crystallized from water shows 2 sharp peaks in the range 4-6 ppm which has been 
reported due to the –OH group of a molecule indicating the presence of a hydrate 
(Atkinson and Hibbert, 2001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
Figure 4.7. NMR data of 
13
C, 
23
Na and 
1
H spectra for the anhydrate and hydrate 
form of sodium benzoate 
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An additional spectroscopy technique involving infra-red (IR) is applied to the 
anhydrous and a sample of sodium benzoate re-crystallized from water. The IR data is 
shown in Figure 4.8. There are two additional peaks in the IR spectrum at wavenumbers 
of 3440 and 3600 cm
-1
 for the sample of sodium benzoate re-crystallized from water.   
IR data on a hydrated form of a compound showed peaks at wavenumbers within the 
region of 3400-3700 cm
-1
 and a sharp peak at 3600 cm
-1
 which is due to the hydroxyl 
group (-OH) of water molecules (Rocco et al., 1995). These data provide supporting 
evidence that the peaks at wavenumbers 3440 and  3600 cm
-1
 in the IR spectra for 
sodium benzoate re-crystallized from water are due to the presence of water molecules 
within the crystal lattice structure signifying the formation of a hydrate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. IR spectra for the anhydrous form and re-crystallized from water 
sample of sodium benzoate 
 
Further solid state analysis was performed using DSC. Figure 4.9 shows the DSC 
results for the raw material (anhydrate) form of sodium benzoate and sodium benzoate 
re-crystallized from water. The type of pan used is a sealed pan with a pin hole to 
prevent the build up of pressure. DSC results for the raw material (anhydrous) show a 
sharp peak at 440 °C which confirms the results obtained from HSM, of a high melting 
point for the organic compound sodium benzoate. The enthalpy of melting for the raw 
material is 164 J/g. Figure 4.9(b) shows the DSC results for the sample of sodium 
benzoate re-crystallized from water, showing two peaks. The first peak occurs at a 
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sample under analysis has not been completely air dried indicating that this is due to 
water on the surface of the crystals. The second peak occurs at a temperature of 125 °C, 
which could be due to the dehydration of a hydrate. Giron (1995) reported DSC results 
for a hydrated form of a compound which showed the dehydration process as a single 
endothermic peak occurring within the temperature range 70-130 °C. This also suggests 
that the second peak at a temperature  of 125 °C in the DSC results for sodium benzoate 
re-crystallized from water is possible due to the dehydration of a hydrate. The enthalpy 
of dehydration is 10 J/g. The low enthalpy change signifies the formation of a channel 
hydrate as not much energy is required for removal of water from the crystal lattice 
structure due to the loosely bonded water molecules throughout the crystal lattice 
structure. For channel hydrates once dehydration has occurred this forms a crystal 
structure of low density with empty voids resulting in an unstable structure (Brittain, 
1999). The crystal lattice parameters may then alter to obtain a stable structure. From 
DSC analysis this confirms that the anhydrous form is stable above the dehydration 
temperature of 125°C. 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. DSC results for (a) raw material form of sodium benzoate and (b) 
sample of sodium benzoate re-crystallized from water 
 
To support the prediction that a channel hydrate forms, TGA analysis is performed on 
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temperature range of 60-80 °C. The decrease in mass represents a loss in water from the 
internal structure of the crystals. Based on the weight% decrease the stoichiometry of 
sodium benzoate to water is calculated. The mean molecular ratio of sodium benzoate 
to water is 1:0.28 with standard deviation of   0.02. The individual steps for this 
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calculation is shown in Appendix E. The non-stoichiometric ratio and the relatively low 
temperature at which the dehydration occurred indicate that the hydrate formed is a 
channel hydrate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. TGA results for the raw material form of sodium benzoate and 
sodium benzoate re-crystallized from water at the 1 mL and 250 mL scale 
 
 
DVS studies are very useful for classifying hydrates and to determine whether the 
material is amorphous or highly crystalline. Amorphous or deliquescent material absorb 
large amount of water at high relative humidity whereas highly ordered crystalline 
materials can absorb very small amount of water of up to 0.1% weight increase 
(Hilfiker, 2006). Stoichiometric hydrates show sudden increases in water uptake 
whereas non-stoichiometric hydrates (channel hydrates) show a small and gradual 
increase in water uptake as the relative humidity is increased from 0 to 90% (Hilfiker, 
2006). DVS was applied to a sample of anhydrous sodium benzoate to see how this 
behaves when subject to different amounts of water. This is achieved by changing the 
relative humidity (RH) between 0 and 90% while keeping the temperature constant at a 
value of 24.7 °C. As the RH increases any uptake in water results in an increase in mass 
and the reverse is true for when the RH is lowered. The results for two repeated 
experiments are shown in Figure 4.11.  
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DVS results show a large increase in the mass% as the RH is increased from 80 to 90% 
which suggests that during this phase sodium benzoate deliquesces (Hilfiker, 2006). For 
cycle 2 during the sorption stage as the relative humidity increases from 40% to 60% 
there is a small and gradual increase in the mass of sodium benzoate. Both desorption 
cycles also show a small but significant decrease in mass% as the RH is decreased from 
30 to 10%. This change is significant enough to suggest the formation of a hydrate. The 
type of hydrate is assumed to be a non-stoichiometric (channel) hydrate as the weight% 
change is small and gradual, which is a common behaviour for channel hydrates 
(Hilfiker, 2006). These observations reinforce the results obtained from TGA which 
also indicated the formation of a channel hydrate when sodium benzoate re-crystallizes 
from water. From the small and gradual change in mass during each step in the DVS 
results the molecular ratio of sodium benzoate to water is calculated and a summary of 
the results are shown in Table 4.1. A sample calculation can be found in Appendix E.  
The results show a mean molecular ratio of sodium benzoate to water of 1:0.27 with 
standard deviation of  0.02. These results are very similar to those obtained from TGA 
analysis which gave a mean value of 1:0.28 and standard deviation of  0.02.  Studies 
carried out on the hydration of caffeine showed similar findings involving the formation 
of a non-stoichiometric hydrate with a molecular ratio of caffeine to water of 1:0.8 
(Pirttimaki and Laine, 1994).  The above results from both TGA and DVS confirm that 
a hydrate forms from the re-crystallization of sodium benzoate from water, which has a 
molecular ratio of sodium benzoate to water of 1:0.28, leading to the conclusion that a 
channel hydrate forms which has not been reported before. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. DVS results for sodium benzoate showing how the sample mass and 
relative humidity change with time 
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Table 4.1. Summary of the DVS results for the molecular ratio of sodium benzoate 
to water 
 
Step Change in 
humidity (%) 
Change in mass 
(%) 
Molecular ratio of 
sodium benzoate to 
water 
Sorption (cycle 2) 40-60 2.89 1 : 0.24 
Desorption (cycle 1) 30-10 3.47 1 : 0.29 
Desorption (cycle 2) 30-10 3.53 1 : 0.29 
 
 
4.6 Conclusions 
 
Cooling crystallization experiments were performed with the use of the FBRM probe 
which detected an unexpected fluctuation in the total number of counts above 65°C. 
Repeated cooling crystallization experiments under different conditions showed very 
similar behaviour. The fluctuation indicated that probably a polymorphic transformation 
occurred during that stage of the crystallisation process. The use of PAT combined with 
SSA techniques provided evidence of the formation of a new hydrate when sodium 
benzoate re-crystallizes from water. TGA and DVS confirmed that the molecular ratio 
of sodium benzoate to water in the new hydrate is 1:0.28 indicating the existence of a 
previously not reported channel hydrate. 
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Chapter 5. A PAT based investigation of the 
polymorphic transformations during the antisolvent 
crystallization of sodium benzoate from IPA/water 
mixture 
 
5.1 Introduction 
 
There are many different crystallization methods including cooling, anti-solvent, pH-
controlled and evaporation of solvent. The preferred method of crystallization for heat 
sensitive compounds and for compounds, in which there are insignificant changes in 
solubility with temperature, is antisolvent crystallization (O‟Grady et al, 2007). 
Extensive studies have been carried out which demonstrate the importance of PAT 
tools for the detection or control of polymorphic transformations during the 
crystallization process (Simon et al., 2009; Howard et al., 2009a; David et al., 2004; 
O‟Sullivan and Glennon, 2005; Dharmayat et al., 2006; Caillet et al., 2008; Fevotte, 
2002; Nagy et al., 2007). 
 
This chapter presents the importance of using process analytical technology (PAT) 
tools combined with solid state analytical (SSA) techniques for the monitoring and 
detection of polymorphic transformations during the antisolvent crystallization 
process and for the discovery of new forms of the crystalline compound, sodium 
benzoate. The model system used is sodium benzoate in a propan-2-ol (IPA)/water 
mixture. Sodium benzoate is extensively used in preservatives of food and medicines. 
It was used as a model system since it exhibits difficult crystallization behaviour, such 
as very thin needle like crystal structure, low temperature sensitivity of the solubility 
(making cooling difficult to use for the control of the crystallization process), features 
which are often characteristic to pharmaceutical compounds. Additionally, despite the 
widespread use of sodium benzoate very little has been reported in the literature about 
its crystallization behaviour. Recent studies by the authors on the cooling 
crystallization of sodium benzoate in water have lead to the discovery of a new 
channel hydrate (Howard et al., 2009a). In this research work, the antisolvent 
crystallization of sodium benzoate is corroborated and the formation of a new          
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meta-stable IPA solvate and a new polymorphic form (stable at higher temperatures) 
are reported for the first time.  
 
The use of PAT is demonstrated for monitoring the polymorphic transformation of the 
channel solvate into the channel hydrate as the amount of IPA increases in the system. 
The solubility of sodium benzoate in water is very high and in IPA is very low, 
therefore, water is chosen as the solvent and IPA as the antisolvent. The PAT tools 
used within this study are the focused beam reflectance measurement (FBRM) probe, 
turbidity meter and attenuated total reflectance (ATR) ultraviolet/visible (UV/Vis) 
spectroscopy. Solid samples of  filtered and air dried crystals are analysed using a 
range of SSA techniques including optical microscopy, scanning electron microscopy 
(SEM), X-ray powder diffraction (XRPD), high temperature X-ray powder diffraction 
(HT-XRPD) solid and solution state nuclear magnetic resonance (SSNMR), solid 
state infrared (IR) spectroscopy, thermal gravimetric analysis (TGA), differential 
scanning calorimetry (DSC) and hot stage microscopy (HSM). A combination of 
these techniques provides the conditions under which a new unreported channel 
solvate of sodium benzoate forms, as well as provide evidence of the existence of a 
new higher melting polymorphic form of the anhydrous form.  
 
5.2 Experiments performed  
 
Solubility experiments involving a gravimetric method were performed to determine 
the solubility of sodium benzoate in a range of solvents and mixed solvents. A 
detailed methodology can be found in Section 3.3 of Chapter 3. Antisolvent 
crystallization experiments were performed for sodium benzoate in an IPA/water 
mixture. PAT tools were used for monitoring the crystallization process and detecting 
polymorphic transformations. The methodology and PAT tools are described in 
Section 3.5 of Chapter 3.  Figure 3.4 in Chapter 3 shows the schematic set-up of the 
crystallization rig. SSA techniques are used to characterise the crystals. The 
equipment used and the operating conditions are highlighted within Section 3.7 of 
Chapter 3.   
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5.3 PAT tools for the monitoring and detection of solvent 
mediated polymorphic transformation of sodium benzoate in 
water/IPA mixture 
 
As there is limited literature data on the solubility of sodium benzoate, gravimetric 
tests were carried out using water and IPA as the solvents. Figure 5.1 shows the 
solubility results for sodium benzoate in water (including literature data), IPA and 
solvent mixtures of IPA/water of volume ratio 2:1, 4:1 and 5:1. Solubility curves for 
all solvent systems are flat indicating that the solubility does not change much with 
temperature. From the solubility results the method of antisolvent crystallization was 
chosen to crystallize sodium benzoate using a solvent system of water and IPA. 
Figure 5.1c shows how the solubility changes with the solvent system at constant 
temperature. As the extent of IPA present in the solvent mixture increases the 
solubility decreases. Water is used as the solvent and IPA as the antisolvent, for the 
antisolvent crystallization experiments, due to the high and low solubilities 
respectively, as shown in Figure 5.1.  
    
Antisolvent crystallization experiments were performed within two different 
experimental rigs of vessel sizes of 1 L both, but with different agitator types, to 
investigate whether the mixing conditions influenced the crystallization behaviour. 
The temperature was kept constant at 25 ºC. Figure 5.2 shows the FBRM and 
turbidity results for the experiments performed within the different vessels. 
Experimental results using an automated lab reactor with a 3-blade glass retreat curve 
at a rotation speed of 300 rpm are shown in Figure 5.2a.  The initial concentration of 
sodium benzoate in water was 545 mg/mL and IPA (antisolvent) was added using a 
dosing rate of 0.33 g/min. The FBRM results show a peak in the number of counts (1-
1000 microns) at the start of the experiment. The high counts are due to the probe not 
being fully immersed within the solution and the creation of a vortex. The turbidity 
results show a value of 0% at the start indicating a clear solution. As IPA is added to 
the solution this reduces the solubility of the solute in solution, forming a 
supersaturated solution. Spontaneous nucleation occurs once the volume ratio of 
IPA/water reaches a value between (1.74-1.8):1 which is shown in the FBRM results 
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by a sudden increase in the total number of counts. As more IPA is added both the 
FRBM and turbidity probes detected a second nucleation event resulting in a 
fluctuation in the FBRM counts and an increase in turbidity. The second nucleation 
event occurred at a volume ratio of IPA/water within the range of (3.9-4.3):1.  Similar 
results, with the use of FBRM statistics, showed that the change in the FBRM 
readings is due to the different morphologies of the polymorphic forms indicating a 
polymorphic transformation (Nagy et al., 2007; Hermanto et al., 2009; Scholl et al., 
2006).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Solubility data for sodium benzoate in (a) IPA/water (w) volume 
ratios and pure IPA, (b) water, (c) different solvent systems at temperatures 32 
and 70 °C 
 
Additional antisolvent crystallization experiments were carried out within different 
mixing conditions using a 4-pitched blade turbine (coated with PTFE) at a rotation 
speed of 255 rpm. The previous method was slightly altered in which the same 
amount of sodium benzoate was dissolved in a starting solution of volume ratio 
IPA/water of 1:1 and IPA was added using a dosing rate of 1 g/min. The FBRM 
results are shown in Figure 5.2b.  
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Similar behaviour is observed showing the first nucleation event which occurs at 
volume ratio of IPA/water of 2.26:1 and a second nucleation event at volume ratio of 
IPA/water of 4.2:1. At this volume ratio of IPA/water the FBRM statistics show an 
increase in the coarse counts and mean chord length and an initial decrease in fine 
counts, which would suggest agglomeration. However there is a fluctuation in fine 
counts resulting in a final increase in fine counts suggesting a possible morphology 
change to needles due to a polymorphic transformation.  
 
Figure 5.3 shows images of the crystallization vessel in which a transformation from 
mobile slurry to the formation of a solid clump occurred after the second nucleation 
event. These images support the FBRM results as shown in Figure 5.2(b) in which an 
initial decrease in fine counts (1-20 microns) and increase in coarse counts (50-250 
microns) occurs during the second nucleation event, indicating agglomeration of the 
crystals. The formation of a solid gel clump results in insufficient mixing yielding a 
„spiky‟ signal as shown in the FBRM results in Figure 5.2. The crystals may stick to 
the probe resulting in an increase in the FBRM signal as shown in Figure 5.2(a) or 
there may be a mobile fluid around the impeller and probe and the rest is a solid 
clump resulting in a decrease in the FBRM signal as shown in Figure 5.2(b). The 
sudden change in the FBRM signal indicates a possible polymorphic transformation. 
A change in morphology of the crystals from fines to needles after the second 
nucleation event is observed from the optical microscope images in Figure 5.4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. FBRM results for the antisolvent crystallization of sodium benzoate 
from an IPA/water mixture performed within a 1 L vessel using a (a) 3-blade 
glass retreat curve and (b) 4-pitched blade turbine (coated with PTFE)  
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Figure 5.3. Visual images of the crystallization vessel using a 4-pitched blade 
turbine showing (a) a mobile cloudy solution after the first nucleation event and 
(b) formation of solid clump after the second nucleation event  
 
             
 
Figure 5.4. Optical microscope images of the crystals obtained from the 
antisolvent crystallization experiments after (a) the first nucleation event and (b) 
second nucleation event (fluctuation in FBRM counts) 
 
 
The change in morphology and appearance of solution combined with repeatability of 
the results within different crystallization vessels supports the hypothesis that the 
second nucleation event detected by the FRBM and turbidity probes is due to a 
polymorphic transformation. Repeats of the experiment were performed with a 
modified method in order to determine the cause of the transformation. This involved 
stopping the IPA addition after the first nucleation event reaching a volume ratio of 
IPA/water of 3:1. The system is kept at this volume ratio and held at 25 °C over night. 
IPA is then added in small amounts to increase the volume ratio of IPA/water by 0.5:1 
and held at 25 °C for 2 hours before the next IPA addition. This is required in order to 
determine whether kinetics (system exposed to the water/IPA mixture for a longer 
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period of time) or the extent of IPA present within the solution is the cause of the 
transformation. A dosing rate of 2 g/min and stirrer speed of 300 rpm were used. 
ATR-UV/Vis spectrometer is used to measure absorbance in the wavelength range 
242-614 nm in which sodium benzoate has peak absorbance at 270 nm. Figure 5.5 
shows the UV/Vis spectrum of sodium benzoate in water between 190 and 340 nm. 
To protect against solarisation the fibre optic connecting the ATR probe to the 
UV/Vis spectrophotometer, for the monitoring experiments which required longer 
durations, spectra above 242 nm was only collected, hence the peak value at 270 nm 
was used to monitor changes in concentration. The FBRM and UV/Vis results are 
shown in Figure 5.6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5. UV/Vis spectrum for sodium benzoate in water 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6. FBRM and UV/Vis results for the anti-solvent crystallization 
experiment with the step additions of IPA 
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The FBRM results show a second nucleation event as represented by a change in the 
counts (1-1000 microns), indicating a polymorphic transformation. This event occurs 
after the system is held at volume ratio of IPA/water of 4.5:1 for approximately 2 
hours, showing that both the extent of IPA present within solution and kinetics has an 
influence on the second nucleation event. The temperature was maintained constant at 
25 °C throughout the experiment indicating that this factor has no contribution 
towards the change occurring within the system which is thought to be due to a 
polymorphic transformation. The UV/Vis data show a decrease in absorbance at 
wavelength 270 nm during the second nucleation event. As crystals nucleate from 
solution this lowers the concentration of solute in solution resulting in a decrease in 
absorbance. The UV/Vis data correlates with the FBRM results indicating that the 
second nucleation event is due to a polymorphic transformation and not caused by 
problems with crystals sticking to the vessel/probe walls or sedimentation of crystals 
due to insufficient mixing. The increase in the absorbance during the first nucleation 
event is due to the tendency of sodium benzoate to nucleate from water on the surface 
of the probe yielding to increase in the absorbance. As the amount of IPA increases in 
the system the tendency is lower and the second nucleation is already indicated by a 
decrease in the absorbance as expected. 
 
A summary of the results for all antisolvent crystallization experiments performed 
within different crystallization vessels using different mixing conditions and dosing 
rates of IPA is shown in Table 5.1. These results show that the variation in mixing 
conditions and dosing rate had no effect on the crystallization behaviour but the extent 
of IPA present in solution has a significant effect, resulting in a polymorphic 
transformation.  
 
 
To identify the possible crystal form that nucleates at volume ratio IPA/water 2:1 and 
4:1, slurry experiments were performed using the Avantium Crystal 16 equipment. 
Sodium benzoate was suspended in 1 mL vials using different volume ratios of 
IPA/water to vary the water content in the solvent mixture which will alter the water 
activity and hence the stability of the crystal forms (Variankaval et al., 2007; Li et al., 
2008; Zhu et al., 1996). Previously performed experiments showed that the hydrate 
form of a compound or a higher hydrated form is likely to form as the water activity 
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increases (Variankaval et al., 2007).
 
Figure 5.7 shows the XRPD patterns for each 
sample obtained from the slurry experiments in which the water activity varies from 0 
to 1. XRPD results show that for samples obtained from solutions in which the water 
activity varies from 0 to 0.66, the anhydrous form of sodium benzoate forms (see 
Figure 5.7b). For slurry solutions in which the water activity is in the range 0.77 to 1, 
the hydrate forms (see Figure 5.7c). These results confirm that for water activities 
above 0.77 the hydrate form of sodium benzoate is more stable. Water activities for 
solutions of volume ratio IPA/water of 2:1 and 4:1, in which the two nucleation 
events occur in the anti-solvent crystallization experiment, are calculated from 
polynomial equations obtained from the literature (Zhu et al., 1996). For volume ratio 
IPA/water of 2:1 and 4:1 the water activity is 0.86 and 0.83 respectively. For these 
volume ratios the water activity is above 0.77 in which the hydrate form is stable 
indicating the likelihood of the formation of the sodium benzoate hydrate. To 
investigate the type of transformation during the two nucleation events as shown in 
the FBRM results in Figure 5.2, solid state analyses were carried out on a sample of 
crystals obtained after the
 
first and second nucleation events.  
 
 
Table 5.1. Summary of the different conditions and volume ratios of IPA/water 
for the first and second nucleation events, for all sodium benzoate antisolvent 
crystallization experiments  
 
 
 
Experiment Type of 
agitator 
Stirrer 
speed 
(rpm) 
Dosing 
rate 
(g/min) 
Volume ratio of 
IPA/water for 
first nucleation 
event 
Volume ratio of 
IPA/water for 
second nucleation 
event 
I 3-blade glass 
retreat curve 
(3GRC) 
300 0.3 1.8:1 4.3:1 
II (Repeat) (3GRC) 300 0.33 1.74:1 3.9:1 
I 4-pitched 
blade turbine 
(4PBT) 
255 1 2.26:1 4.2:1 
II  
(Modified 
method) 
(4PBT) 300 2 2.26:1 4.5:1 
 (hold at this ratio for 
2 hours) 
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Figure 5.7. X-ray powder diffraction patterns for (a) anhydrous and hydrated 
form of sodium benzoate, (b and c) sodium benzoate samples obtained from the 
Crystal 16 slurry experiment with different water activities (wa). In figures (b) 
and (c) intensities are shifted for clearer plotting 
 
5.4 SSA for the detection of new forms of crystalline 
compound 
 
The solid state techniques used for analysing the crystal samples include scanning 
electron microscope (SEM), hot stage microscopy (HSM), X-ray powder diffraction 
(XRPD), high temperature XRPD, differential scanning calorimetry (DSC), infra-red 
(IR) spectroscopy, solid and solution state nuclear magnetic resonance (NMR) 
spectroscopy, and thermal gravimetric analysis (TGA).  
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5.4.1 Discovery of a new solvate form of sodium benzoate 
 
Figure 5.8 shows the XRPD patterns of the raw material form of sodium benzoate and                                                                                                                            
samples obtained from the antisolvent crystallization experiment after the first 
nucleation (volume ratio of IPA/water of 3:1) and second nucleation event (volume 
ratio of IPA/water of 5:1). XRPD results for the hydrated form of the sodium 
benzoate were obtained from samples re-crystallized from pure water. Wet and air 
dried samples were analysed using XRPD. Figure 5.8a compares the XRPD patterns 
for the raw material and anhydrous form of sodium benzoate showing very similar 
patterns indicating that the raw material is the anhydrous form. Figure 5.8b shows 
very similar XRPD patterns for the sample of crystals obtained at volume ratio of 
IPA/water of 5:1 and the hydrated form of sodium benzoate. This indicates that the 
form that nucleates out at the second nucleation event in the antisolvent crystallization 
experiment is a hydrate. Figures 5.8 (c) and (d) show that the sample of crystals 
obtained after the first nucleation event (volume ratio of IPA/water of 3:1) is neither 
the hydrated form, as there are additional peaks at high angles, nor the anhydrous 
form similar to the raw material since it has a different XRPD pattern. These XRPD 
results suggest that either a different polymorphic form or a solvate forms from the 
first nucleation event in the antisolvent crystallization experiments. XRPD results 
obtained from the slurry experiments as shown in Figure 5.7 indicated that the hydrate 
form of sodium benzoate is more stable at volume ratio of IPA/water of 3:1 which 
suggests that a meta-stable form nucleates from the first nucleation event as shown in 
the FBRM results of Figure 5.2. Further solid state analysis is performed with the use 
SEM and DSC, which provides data on the melting point and enthalpy of melting of 
different forms of a compound. 
 
SEM images of the sample of sodium benzoate crystals obtained after the first 
nucleation event and a previously reported hydrate form of sodium benzoate are 
shown in Figure 5.9. Crystal samples have been vacuum filtered resulting in the 
formation of agglomerates as shown in images (a) and (b) in Figure 5.9. A higher 
magnification is used to examine the surface characteristics of the two crystal 
samples, which are shown in images (c) and (d) in Figure 5.9. The surface of the 
sample at a volume ratio IPA/water of 3:1 is rough, while the hydrate form of sodium 
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benzoate shows a fibrous surface structure. The clear differences between the two 
SEMs support the results obtained from XRPD, which suggest that a different 
polymorphic form or solvate nucleates from the first nucleation event in the 
antisolvent crystallization experiments.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8. X-ray powder diffraction patterns for (a) raw material form of 
sodium benzoate, (b) sodium benzoate re-crystallized from volume ratio of 
IPA/water of 5:1 and (c and d) sodium benzoate re-crystallized from volume 
ratio of IPA/water of 3:1 
 
 
Figure 5.10 shows the DSC results of the raw material and samples of crystals 
obtained after the first (volume ratio IPA/water 3:1) and second nucleation event 
(volume ratio IPA/water of 4.4-5:1) using sealed pans and pans with pin holes. Figure 
5.10a shows a peak at temperature of 442 °C which is the melting point of the raw 
material form of sodium benzoate (anhydrous). The enthalpy of melting is 177 J/g.  
Figure 5.10b obtained from a sample of crystals after the first nucleation event shows 
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a peak at temperature of 126 °C with an enthalpy of 7.4 J/g and a second peak at 
temperature 432 °C. The peak at 126 °C is thought to be due to either a solid state 
polymorphic transformation or removal of solvent from a solvate. This stable form 
(raw material) then melts at 432 °C.   
 
         
 
       
 
Figure 5.9. SEM images of (a, c) sample of sodium benzoate re-crystallized from 
volume ratio of IPA/water 3:1 and (b, d) hydrated form of sodium benzoate 
 
Figures 5.10 (c) and (d) show the DSC results for a sample of crystals obtained after 
the second nucleation event using a sealed pan and a pan with a pin hole. DSC results 
using a sealed pan show a peak at 132 °C and the melting of the anhydrous form of 
sodium benzoate at 434 °C. The results obtained using a pan with a pin hole show a 
peak at temperature of 74.5 °C. Giron (1995) reported DSC results for a dehydrate, 
which showed dehydration at a peak at approximately 72 °C when using a pan with a 
pin hole and the melting of the dihydrate at a peak of approximately 125 °C when 
using a sealed pan. These results suggest that the peaks at 74.5 and 132 °C are due to 
the dehydration of the hydrate which has an enthalpy of 63.2-64.7 J/g. Dehydration 
occurs at a higher temperature when using a sealed pan due to the build up of pressure 
within the pan. DSC and XRPD results provide supporting evidence that a hydrate 
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forms after the second nucleation event, which is in correlation with results presented 
in Chapter 4 obtained during cooling crystallisation experiments of sodium benzoate 
in water (Howard et al., 2009a). However it was uncertain at this stage whether a 
different polymorphic form or a solvate nucleates from the first nucleation event. 
Additional solid state analysis involving the use of HT-XRPD is performed on the 
sample of crystals obtained after the first nucleation event to identify the crystal form.  
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10.  DSC results for (a) raw material form of sodium benzoate, (b) 
sodium benzoate re-crystallized from a volume ratio of IPA/water of 3:1 and (c, 
d) sodium benzoate re-crystallized after the second nucleation event at volume 
ratio of IPA/water of 4.4:1 and 5:1 
 
 
HT-XRPD provides data on how the X-ray powder diffraction pattern of a crystal 
sample changes with temperature. Figure 5.11 shows the HT-XRPD results for the 
sample of crystals obtained after the first nucleation event (volume ratio IPA/water of 
3:1). XRPD patterns show no change within the temperature range 25-175 °C, which 
suggests no polymorphic transformation between different forms. However, solvent 
-2.5
-2
-1.5
-1
-0.5
0
0 100 200 300 400 500
Temperature (
o
C)
H
e
a
t 
fl
o
w
 E
n
d
o
 U
p
 (
 W
/g
 )
 Sodium benzoate sample at volume ratio of
IPA/water of 3:1 (sealed pan)
-3.5
-3
-2.5
-2
-1.5
-1
-0.5
0
0 100 200 300 400 500
Temperature (
o
C)
H
e
a
t 
fl
o
w
 E
n
d
o
 U
p
 (
 W
/g
 )
Raw material-Sodium benzoate (anhydrous) 
d
o
w
n
 (
 W
/g
 )
 
d
o
w
n
 (
 W
/g
) 
H
e
a
t 
fl
o
w
 E
n
d
o
 d
o
w
n
 (
 W
/g
 )
 
H
e
a
t 
fl
o
w
 E
n
d
o
 d
o
w
n
 (
 W
/g
 )
 
Temperature (°C) Temperature (°C) 
(a) (b) 
442°C 
 ΔH: 177 J/g 
432°C 
126°C 
ΔH: 7.4 J/g 
-3
-2.5
-2
-1.5
-1
-0.5
0
0 100 200 300 400 500
Temperature (
o
C)
H
e
a
t 
fl
o
w
 E
n
d
o
 d
o
w
n
 (
 W
/g
 )
Sodium benzoate sample at volume ratio
of IPA/water of 4.4:1 (sealed pan)
   360    295    230    165    100    35 
          -1.57 
      -1.26 
      -0.63 
0 
      -0.31 
- Sodium benzoate sample at volume 
ratio of IPA/water of 5:1 (pan with pin 
hole) 
      -0.94 
74.5°C 
     
ΔH: 63.2 J/g 
H
e
a
t 
fl
o
w
 E
n
d
o
 d
o
w
n
 (
 m
W
 )
 
              Temperature (°C) 
H
e
a
t 
fl
o
w
 E
n
d
o
 d
o
w
n
 (
 W
/g
 )
 
Temperature (°C) 
(d) (c) 
434°C 
132°C 
    ΔH: 64.7 J/g 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates 
 
101 Chapter 5. Antisolvent crystallization of SB from IPA/water 
2011 
molecules can be removed from a channel (non-stoichiometric) solvate crystal 
without affecting the structure (Hilfiker, 2006), which suggests that possibly a 
channel solvate forms from the first nucleation event. The XRPD patterns identify 
geometric changes within a compound. When the cavities within the crystal structure 
are small due to the elimination of loosely bounded small amount of solvate (which is 
often the case for channel solvates) the crystal structure will not necessarily rearrange 
to the form of the anhydrous compound. Since XRPD results may be influenced by 
sample preparation this technique is useful to be combined with spectroscopy 
techniques such as NMR and IR, which highlight composition differences between 
different forms of a compound.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11. HT-XRPD results of sodium benzoate re-crystallized from volume 
ratio IPA/water of 3:1 at temperatures within the range 25 to 175 °C. Intensities 
are shifted for clearer plotting 
 
NMR analysis including solid and solution state was preformed on the anhydrous 
form of sodium benzoate and a sample of sodium benzoate re-crystallized from 
volume ratio IPA/water of 3:1. The NMR results are shown in Figure 5.12. 
13
C 
spectra for the two samples are very similar with a slight shift in the peak at 177 ppm, 
which is due to the carboxylate carbon (COO
-
). 
23
Na spectra for the sample re-
crystallized at volume ratio IPA/water of 3:1 shows an additional sharp peak at           
1 ppm, which is thought to be due to free mobile sodium ions caused by the presence 
of solvent molecules in the crystal lattice structure and confirms the existence of 
channel solvate. 
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crystallized sample at volume ratio IPA/water of 3:1. 
1
H solid state spectra shows a 
peak at 4 ppm, which is due to the (-OH) group and an additional peak compared with 
the hydrate spectra at 0 ppm which is due to the (-CH3) group from the IPA, 
indicating the presence of a solvate (Fox and Whitesell, 1997). Solution state 
1
H 
NMR data shows peaks at 7-8 ppm, which is due to the hydrogen atoms in the 
benzene ring and the peak at 1 ppm which represents hydrogen atoms in the (-CH3) 
and (-CH2-) groups of the alcohol (IPA), indicating the presence of a solvate (Fox and 
Whitesell, 1997).   NMR results provide supporting evidence that a meta-stable 
solvate forms from the antisolvent crystallization experiments at volume ratio 
IPA/water of 3:1, which then transforms into the hydrate at higher IPA/water ratio. 
 
 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12. Solid state NMR data of (a) 
13
C, (b) 
23
Na, (c) 
1
H and (d) solution 
state 
1
H data for anhydrous form of sodium benzoate and sample re-crystallized 
from volume ratio IPA/water of 3:1  
 
 
IR data on the anhydrous form of sodium benzoate and sample of sodium benzoate   
re-crystallized from volume ratio of IPA/water of 3:1 is shown in Figure 5.13. The 
full spectrum for the sample at volume ratio IPA/water of 3:1, as shown in Figure 
5.13a, shows an additional broad peak at wavenumber 3403 cm
-1
, which is due to the 
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hydroxyl group (-OH) of the alcohol indicating the formation of a solvate (Atkinson 
and Hibbert, 2001). Figure 5.13b shows that the IR spectra of the fingerprint region 
(1500-400 cm
-1
) of the two samples are different, indicating different forms of the 
compound sodium benzoate. For the sample obtained at volume ratio of IPA/water of 
3:1, there are additional peaks at 1165 and 1271 cm
-1
 that are due to the (C-O) bond of 
an alcohol. The peak at 1484 cm
-1
 is thought to be due to plane blending in the        
(C-O-H) of an alcohol. Additional peaks are also observed at 1584 and 760 cm
-1
 in 
which the latter peak is due to (C-H) bending vibrations in aromatic rings (Stuart et 
al., 1998). These additional peaks in the fingerprint region indicate the presence of a 
solvate. Both IR and NMR data provide supporting evidence that a solvate forms 
when sodium benzoate re-crystallizes from volume ratio of IPA/water of 3:1, which 
has not yet been reported in the literature. Moreover, the apparently paradoxical 
transformation of the solvate into hydrate with increasing IPA ratio is reported for the 
first time, but it is strongly supported by the detailed SSA results. 
          
 
 
 
 
 
 
 
 
 
 
Figure 5.13. IR data for the anhydrous form of sodium benzoate and sample re-
crystallized from volume ratio IPA/water of 3:1 showing (a) the full spectrum 
and (b) the fingerprint region   
 
 
To identify the formation of hydrates or solvates TGA is also carried out on samples 
of crystals obtained after the first and second nucleation events from the anti-solvent 
crystallization experiments and the results are shown in Figure 5.14. 
 
TGA results for the raw material (anhydrous) show a flat line indicating no change in 
weight%. For the crystals obtained at volume ratio of IPA/water of 3:1 there is a 
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temperature range this would suggest that a channel solvate forms. This prediction is 
supported with DSC results shown in Figure 5.10(b), which shows a low enthalpy of    
7.4 J/g for solvent removal as not much energy is required to remove the loosely 
bonded solvent molecules in the crystal lattice structure. HT-XRPD results also 
support the hypothesis of the formation of a channel solvate.   
 
TGA results for sample of crystals obtained after the second nucleation event (volume 
ratio of IPA/water of 5:1) for two repeated runs show a small weight decrease of 2.7-
3.2%.  XRPD results as shown in Figure 5.8(b) and DSC results as shown in Figure 
5.10(c) and (d), provide supporting evidence that a hydrate forms. From the weight% 
decrease the stoichiometry of sodium benzoate to water is shown to be within the 
range of 1: 0.24-0.27. A sample calculation of the individual steps can be found in 
Appendix E. These values are very similar to those obtained for the channel hydrate 
which forms when sodium benzoate is re-crystallized from pure water (Howard et al., 
2009a). The non-stoichiometry ratio also indicates the presence of a channel hydrate 
in which the water molecules form a loosely bonded channel throughout the crystal 
lattice structure. This supports the TGA results as the weight% decrease occurs over a 
low temperature range. Previous studies of the cooling crystallisation of sodium 
benzoate from water also indicated the formation of channel hydrate with very similar 
stoichiometry (1:0.28) confirmed by TGA and dynamic vapour sorption (DVS) 
experiments (Howard et al., 2009a).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14. TGA results of (a) anhydrous form of sodium benzoate and crystals 
obtained from volume ratio IPA/water of 3:1 and (b) anhydrous form of sodium 
benzoate and crystals obtained from volume ratio of IPA/water of  5:1 
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A combination of SSA techniques provides supporting evidence that a polymorphic 
transformation occurs from meta-stable solvate to a hydrate during the antisolvent 
crystallization experiments. SSA techniques provided the evidence for the formation 
of a new, previously unreported, channel solvate form of sodium benzoate.  
5.4.2 Combined DSC and HSM for the detection of higher melting 
polymorphic forms of sodium benzoate 
 
Combining DSC and HSM for the study of different forms of a compound is useful as 
both techniques provide supplementary data apart from the melting point, which is an 
important physical property used to identify the different forms. DSC provides 
additional data such as enthalpy of melting and re-crystallization allowing the stability 
of the polymorphs to be identified. HSM is a useful technique for identifying different 
polymorphic forms of a compound by changes in habit, size and reflectance properties 
resulting in changes in colour (Hilfiker, 2006; Bernstein, 2002; Abu Bakar, et al., 
2009a). DSC results for the anhydrous form of sodium benzoate are shown in Figure 
5.15. The first endothermic peak at 437 °C is due to the melting of the anhydrous 
form of sodium benzoate which then re-crystallizes into a higher melting polymorphic 
form as shown by the small exothermic peak at temperatures within the range 445-
447 °C, with an enthalpy of 4.2-5 J/g. This higher polymorphic form then melts 
within the temperature range of 452-454 °C, as shown by the second endothermic 
peak. This form has an enthalpy of melting between 18 and 29 J/g. Similar findings 
were obtained from DSC results reported from Giron (1995), which supports the 
above prediction of the formation of a higher melting polymorphic form of sodium 
benzoate as the system is heated above 437 °C (melting point of anhydrous form).  
 
HSM is applied to the hydrated form of sodium benzoate during the heating stage 
from 199 to 500 °C and cooling to 402 °C, as shown in Figure 5.16. The hydrate 
transforms into the anhydrous form at lower temperatures without any noticeable 
modification in the crystal structure or other properties detectable with HSM. Melting 
of the anhydrous form occurs at a temperature of 444 °C.  A phase transformation is 
observed by a change in colour of crystals as shown in images c and d in Figure 5.16. 
This is thought to be due to the crystallization of a higher polymorphic form, which 
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then melts as shown in Figure 5.16f and completely dissolves at temperature 493 °C.   
Similar observations were reported from the HSM of sulphathiazole in which two 
melting stages were observed due to the re-crystallization of a higher polymorphic 
form which then melts as temperature is increased (Bernstein, 2002). Both DSC and 
HSM provide supporting evidence of a new higher-melting polymorphic form of 
sodium benzoate at temperatures above the melting point (437 °C) of the anhydrous 
form 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15. DSC results for 2 repeated runs of anhydrous form of sodium 
benzoate showing the re-crystallization and melting of a higher melting 
polymorphic form  
 
       
 
        
 
 
Figure 5.16. Hot stage microscopy (HSM) of hydrated form of sodium benzoate 
crystals during (a-g) heating phase and (h) re-crystallization from cooling  
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5.5. Conclusions 
 
The use of PAT tools including the FBRM probe, turbidity meter and ATR-UV/Vis 
spectrometer showed evidence of a polymorphic transformation during the anti-
solvent crystallization of sodium benzoate in propan-2-ol (IPA)/water system. The 
PAT tools clearly indicate the occurrence of two distinct events during the addition of 
IPA in a solution of sodium benzoate in water. First a new channel solvate form 
nucleates at IPA/water volume ratio of approximately 2:1, which transforms into a 
hydrate as the IPA/water volume ratio increases to a value of about 4:1, evidenced 
also by change in morphology and mixing properties of the slurry. Solid state analysis 
including XRPD, solid and solution state NMR, and IR spectroscopy with TGA and 
DSC provided evidence that the type of transformation is from a meta-stable channel 
solvate form to a channel hydrate. A combination of these tools identified the 
conditions under which different forms of the compound sodium benzoate exist and 
has led to the discovery of a new channel solvate form of sodium benzoate, which has 
not yet been reported in the literature. Additionally, the combination of DSC and 
HSM provided supporting evidence of the formation of a higher melting polymorphic 
form of sodium benzoate at temperatures above 437 °C (melting of anhydrous form) 
reported for the first time in this contribution.   
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Chapter 6. Application of PAT tools for the 
identification of crusting problems within 
crystallization processes 
 
6.1 Introduction  
 
Understanding of the crystallization process is required to design a robust process 
with consistence in product quality and purity (desired polymorphic form with no 
impurities). A narrow crystal size distribution (CSD) and large crystals are often 
desirable to obtain a quality product (Abu Bakar et al., 2009a), which can be achieved 
by operating at experimental conditions within the meta-stable zone width (MSZW) 
region of the phase diagram (Lu and Ching, 2006 and Beckmann, 2000). Monitoring 
of the crystallization process can be achieved with the use of process analytical 
technology (PAT). These tools provide real time data, which can be used to gain a 
better understanding of the crystallization process.  Data provided from PAT tools can   
be used to minimise error during scale up from laboratory to manufacturing scale 
increasing robustness of the crystallization process and product consistency (Sistare et 
al., 2009; David et al., 2004; Birch et al., 2005).  
 
The novelty of this research presents the importance of using PAT tools for the 
identification of common problems such as crusting (solid depositing on vessel walls) 
occurring during the crystallization process. This would lead to errors in the estimated 
and actual concentration values resulting in inaccurate MSZW measurements. Scaling 
up of the crystallization process would then lead to the possibility of product failure 
and increasing economical costs. This research highlights the need for improvement 
within vessel design to eliminate the problems of crusting. The model system used is 
para-amino benzoic acid (PABA) in ethyl acetate. PAT tools are used to monitor the 
cooling crystallization experiments including the focused beam reflectance 
measurement (FBRM) probe, turbidity meter and ATR-UV/Vis spectrometer. A range 
of solid state analytical (SSA) techniques were used to characterise the crystal product 
including the optical microscope, differential scanning calorimetry (DSC), hot stage 
microscopy (HSM) and X-ray powder diffraction (XRPD) analysis. Combining PAT 
tools with SSA techniques provides further evidence of changes that occur during the 
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crystallization process which are initially thought to be due to polymorphic 
transformations, are due to common problems such as crusting forming on vessel 
walls. Combining these tools saves both time and money that would be spent in 
researching the possible different polymorphic forms of the compound.   
 
6.2 Experiments performed 
 
Cooling crystallization experiments were performed in a jacketed glass vessel of size 
1 L. The initial volume of solvent used in the experiments was varied to investigate 
the problem of crusting forming on vessel walls. The initial volume of solvent varied 
from 0.5 L to 1 L in which all walls of vessel were covered with solvent (ethyl 
acetate). A detailed methodology and PAT tools used to monitor the crystallization 
process can be found in Section 3.4.2 of Chapter 3. SSA techniques used to 
characterise the crystal product and the operating conditions used are mentioned 
within Section 3.7 of Chapter 3. A schematic of crystallization rig is shown in Figure 
3.2 of Chapter 3.  
 
6.3 Monitoring the cooling crystallization process of para-
amino benzoic acid (PABA) from ethyl acetate using PAT 
tools     
 
The aims of this research are to identify common problems such as crusting forming 
on the walls of crystallization vessels, highlighting the need for improvement for 
vessel design. The model system used in these experiments is para-amino benzoic 
acid in ethyl acetate.  PABA contains different polymorphic forms known as the alpha 
and beta forms with the possibility of new undiscovered polymorphs/solvates due to 
the hydrogen bond acceptors and donors within the crystal structure (Gracin and 
Rasmuson, 2004). The alpha form has needle morphology and a melting point of    
189 °C. The beta form has a prismatic morphology and a melting point of 145 °C. The 
two polymorphs are enantiotropic related with a transition temperature of 25 °C. 
Above this temperature the alpha form is stable and below this temperature the beta 
form is stable (Gracin and Rasmuson, 2004). XRPD patterns for the raw material 
PABA and the simulated pattern for the alpha form are very similar as shown in 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates 
 
110                                       Chapter 6. PAT tools for identifying crusting within vessels 
2011 
Figure 6.1, indicating that the raw material is the alpha form (Cambridge Structural 
Database (Version 5.30; Allen, 2002)).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. XRPD patterns for the raw material form of PABA and alpha-PABA 
(simulated) 
 
Cooling crystallization experiments were performed within two set-ups using a 1 L 
jacketed glass vessel with different agitator types to examine if the mixing conditions 
had any influence on the behaviour of the system. The maximum working volume 
within the vessels is 0.5 L exposing the top part of the vessel walls to no solution. 
Figure 6.2 shows the FBRM, turbidity and UV/Vis results for two repeated 
experiments in which crusting formed on vessel walls. Cooling crystallization 
experiments using a 3-blade glass retreat curve are shown in Figure 6.2b. As the 
system is heated up the crystals dissolved, as represented by a decrease in FBRM 
counts and turbidity. A turbidity value of 0% represents a clear solution. Cooling over 
the temperature range 70 to 5 °C, results in two nucleation events as shown by an 
increase in FBRM counts and turbidity. The first nucleation event occurs at a 
temperature of 51 °C. Complete dissolution of all the crystals (solubility point) 
occurred at a temperature of 64 ºC as indicated by both the FBRM and turbidity 
probe. A 1 ºC temperature difference is detected for the nucleation point during the 
first nucleation event by both FBRM and turbidity probe. These results show that 
there is not much difference between the FBRM and turbidity values for solubility or 
nucleation points.  
 
After cooling the system down to a temperature 45 ºC, the system is then kept at a 
constant temperature of 45 °C in which there is a continuous decrease in FBRM 
counts and turbidity until the values reach 0 indicating a clear solution. The 
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continuous decrease in counts could be due to a polymorphic transformation, which 
would occur due to Ostwald‟s rule of stages from a meta-stable to a more stable form 
(Threlfall, 2003). In order for Ostwald‟s rule to apply the „meta-stable‟ form would 
have a lower solubility than the stable form (alpha) and this stable form then dissolves 
due to higher dissolution kinetics. An alternative explanation to this continuous 
decrease could be due to decomposition of the PABA crystals as it is reported that 
after 4-5 days PABA reacts with ethyl acetate (Gracin and Rasmuson, 2004), or 
alternatively the effect of crusting could be considered. As solid deposits on the side 
of the vessel wall the concentration in the liquid reduces, causing additional solid 
crystals to dissolve. Through this process the solution can reach concentrations below 
the saturation concentration at the particular temperature. As the temperature is 
decreased to 5 
o
C, nucleation corresponding to the lower concentration is observed.  
 
The cooling crystallization experiment was repeated in a different 1 L vessel using a 
4-pitched blade turbine. PAT tools used include FBRM probe and ATR-UV/Vis 
spectrometer and very similar results were observed as shown in Figure 6.2a. Two 
nucleation events occur at temperatures of 46 °C and 9 °C. As the system is kept 
constant at 45 and 5°C there is a continuous decrease in FBRM counts. The UV/Vis 
spectrum for PABA in ethyl acetate shows a peak absorbance at 300 nm, as shown in 
Figure 6.3, which is monitored throughout the cooling crystallization experiment. 
During the first nucleation event at 46°C there is a decrease in the absorbance and as 
the system is kept at 45°C the absorbance remains constant (see Figure 6.2a and 6.3). 
Once all the crystals have dissolved and the system is kept at 45 °C there is a slight 
decrease in absorbance. UV/Vis results do not support the prediction that the 
continuous decrease in FBRM counts is due to decomposition of crystals or 
polymorphic transformations but favour the prediction of crusting. Decomposition 
would result in less PABA dissolved in solution and therefore the concentration and 
absorbance would decrease. The solubility of different polymorphic forms varies in 
the same solvent system resulting in a change in concentration and absorbance. Solid 
deposits on the vessel walls during each stage of the crystallization process resulting 
in an increase in crusting height. As the system is kept at a constant temperature of   
45 °C there is a reflux of solvent and solid forms of vessel walls. Solvent evaporates 
from the slurry and condenses back in the condenser. The solvent falls back into the 
solution, lowering the concentration and solubility. Any solid crystals present in 
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solution will then dissolve to reach a saturated equilibrium state and the absorbance 
would remain constant. Once all the crystals have dissolved the solution becomes 
undersaturated and crusting continues to form on vessel walls resulting in a decrease 
in concentration and absorbance. The system is cooled from 45 to 5 °C forming a 
supersaturated solution resulting in the 2
nd
 nucleation event at temperature of 9 °C and 
a decrease in absorbance. To reach an equilibrium state once nucleation has occurred 
crystals will either grow or the system will continue to nucleate. As the system is kept 
constant at 5 °C the absorbance decreases slightly and then remains constant. The 
slight decrease in absorbance is due to nucleation. As the system is kept constant at    
5 °C crusting continues to form on vessel walls and solid in solution dissolves to 
maintain an equilibrium saturated state shown by a decrease in FBRM counts and 
constant absorbance. The decrease in the number of counts/sec at 5 ºC is slower than 
at 40 ºC since the evaporation at lower temperatures is significantly slower than at the 
higher temperatures, yielding slower crust formation.  
 
Figure 6.4 shows photos of the crystallization vessel during the cooling crystallization 
process. The system starts off as a mobile slurry as shown in Figure 6.4 (a). As the 
system is heated up crystals dissolve forming a clear solution and crusting forms on 
vessel walls (see Figure 6.4 (b, c and d)). Figure 6.4 (e, f and g) show that the crusting 
height increases as the system is cooled down and kept at a constant temperature of  
45 ºC. Further cooling to 5 ºC and holding at this temperature results in the crust 
height increasing to greater than 8cm as shown in Figure 6.4 (h and i). 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. FBRM, turbidity and UV/Vis results for the cooling crystallization of 
PABA from ethyl acetate using (a) 4-pitched blade turbine and (b) 3-blade glass 
retreat curve  
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Figure 6.3. UV/Vis spectrum for PABA in ethyl acetate at 45 
o
C during 2-6 hours 
of crusting experiment, showing a peak absorbance of 300 nm 
 
   
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 6.4. Photos of the crystallization vessel during the cooling crystallization 
of PABA in ethyl acetate showing an increase in crusting on vessel walls as the 
system is kept at a constant temperature of 45 and 5 
o
C 
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6.4 Identifying a common problem of crusting in 
crystallization vessels through the use of solid state analysis 
 
 
Crystal samples obtained after the first and second nucleation events were analysed 
using a range of solid state analytical techniques including optical microscope, 
differential scanning calorimetry and X-ray powder diffraction. Samples were taken at 
the point of nucleation and 2-4 hours after nucleation. Figure 6.5 shows the optical 
microscope images of PABA crystals after both nucleation events showing a needle 
morphology which is characteristic to the alpha form. However different polymorphic 
forms of the compound may have the same morphology so further solid state analysis 
is required to identify the crystal forms.  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Optical microscope images of PABA samples obtained during the 
cooling crystallization experiment at (a) point of first nucleation 2 hours (45 °C), 
(b) 4 hours from start (45 °C), (c) point of second nucleation 10 hours  (5 °C) and 
(d) 14 hours from start (5 °C) 
 
 
DSC is performed on the crystal samples obtained after the first and second 
nucleation events and the results are shown in Figure 6.6. All samples show a single 
sharp peak at 191 °C which is the melting point of the alpha form of PABA. The 
alpha form of PABA nucleates from the first nucleation event at temperatures in the 
range 46-51 °C as this is the more stable form at temperatures above 25 °C. Kinetics 
favours the formation of the alpha form of PABA during the second nucleation event. 
Physical properties of crystals such as melting point vary for the different 
polymorphic forms. As no additional peaks are observed in the DSC patterns for the 
samples obtained while the system was kept at a constant temperature of 45 °C (4 
hours from start of experiment) and 5 °C (14 hours from start of experiment), this 
supports the prediction that the decrease in FBRM counts and turbidity as the system 
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is kept at a constant temperature is not due to a polymorphic transformation but due to 
crusting. As solid deposits on vessel wall some of the alpha PABA crystals dissolve 
and the rest remain suspended in solution (i.e. no change occurring within the 
solution), which corresponds to the constant melting point of 191 °C in the DSC 
results for all samples.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6. DSC plots for PABA samples obtained from the first and second 
nucleation events during the cooling crystallization experiment in which crusting 
formed on vessel walls. Heat flows for each plot are shifted by -1 W/g for clearer 
plotting 
 
 
Further SSA involving the use of XRPD is applied to the crystal samples. This is a 
key SSA technique for the identification of different polymorphic forms of a 
compound as the structural differences between the forms are shown by different 
XRPD patterns. Figure 6.7 shows the XRPD results for crystal samples obtained after 
the first and second nucleation events. Patterns are very similar to the alpha form of 
PABA, which supports the DSC results and the prediction that the continuous 
decrease in FBRM counts and turbidity as the system is kept at a constant temperature 
is due to crusting and not a polymorphic transformation or decomposition.   
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Figure 6.7. XRPD patterns for raw material PABA (alpha form) and crystal 
samples obtained after the first and second nucleation events during the 
experiment in which crusting formed on vessel walls. Intensities for each pattern 
are shifted by 3000 for clearer plotting 
 
 
Repeats of the cooling crystallization experiment are performed in a 1 L vessel with 
the solution filled up to the top of the vessel to prevent the formation of crusting on 
vessel walls. The same 4-pitched blade turbine as in the previous experiment is used 
for homogeneous mixing. Figure 6.8 shows the FBRM and UV/Vis results for the 
cooling crystallization experiment. As the system is cooled from 70 to 45 °C both 
PAT tools detect a single nucleation event at 52 °C shown by an increase in counts 
and decrease in absorbance. The system is then kept at 45 °C overnight and both the 
FBRM counts and absorbance remains constant. The vessel walls were covered in 
solution so no crusting formed, which provides further evidence that the decrease in 
FBRM counts and turbidity as shown in Figure 6.2, in which crusting formed on 
vessel walls, is due to crusting increasing with time. SSA including hot-stage 
microscopy, DSC and XRPD is performed on the crystal samples at the point of 
nucleation (2 hours and 25min from start of experiment) and at the end (20 hours).  
 
Figure 6.9 shows the HSM images of crystal samples obtained from the single 
nucleation event as shown in Figure 6.8. The crystal sample was heated from 25 °C to 
200 °C. Melting of the crystals is observed at 189 °C, which is the melting point of 
alpha form of PABA. No other changes are observed in the images during the heating 
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stage providing evidence that the pure alpha form of PABA nucleates from the 
experiment in which no crusting formed on vessel walls. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8. FBRM and UV/Vis results for the cooling crystallization of PABA 
from ethyl acetate in which no crusting formed on vessel walls (full vessel) 
 
 
             
 
             
  
                    
Figure 6.9. HSM images of PABA from the cooling crystallization experiments in 
which no crusting formed on vessel walls. Images 1-5 are during the heating 
phase and image 6 is cooling from the melt 
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Figure 6.10 shows the DSC results for crystal samples obtained at the point of 
nucleation and after PABA is exposed to ethyl acetate for 18 hours during the 
experiment in which no crusting formed on vessel walls. A single sharp peak at       
191 °C is observed in the DSC results for both samples indicating the formation of the 
alpha-PABA, which fits with the results obtained from HSM. No additional peaks are 
observed in the DSC results indicating that PABA does not decompose as the system 
is exposed to ethyl acetate for 18 hours but remains in the stable state (alpha form).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.10. DSC plots for PABA re-crystallized from ethyl acetate as the system 
is kept at 45 °C during the experiment in which no crusting formed on vessel 
walls. Heat flows for each plot are shifted for clearer plotting 
 
 
XRPD patterns for the crystal samples obtained from the experiment in which no 
crusting formed on vessel walls is shown in Figure 6.11. Patterns for samples 
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similar to the alpha form of PABA indicating the presence of this form. All of the 
SSA techniques provide evidence that the alpha form of PABA nucleates from ethyl 
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Figure 6.11. XRPD patterns for raw material PABA (alpha form) and crystal 
samples obtained after the first nucleation event (45 
o
C) during the experiment in 
which no crusting formed on vessel walls. Intensities for each pattern are shifted 
by 2000 for clearer plotting 
 
6.5 Conclusions   
 
The chapter investigates the cooling crystallization of p-amino benzoic acid (PABA), 
under conditions when crusting can accumulate on the walls of the vessel. PAT tools 
including the FBRM probe and turbidity meter showed a decrease in counts and 
turbidity as the system was kept at constant temperatures of 45 and 5 °C. In closed 
metal industrial vessels the change occurring during the crystallization process could 
be misinterpreted as a polymorphic transformation or decomposition however the 
UV/Vis spectrometer provided evidence that the change is due to crusting (solid 
deposition on vessel walls) increasing with time. SSA techniques including the use of 
XRPD, DSC, HSM and optical microscopy provided supporting evidence that the 
alpha form of PABA nucleates from the first and second nucleation events during the 
cooling crystallization experiments. No additional crystal forms were identified 
providing supporting evidence that the decrease in FBRM counts and turbidity during 
the cooling crystallization experiment in which crusting formed on vessel walls is not 
due to a polymorphic transformation but due to crusting increasing with time. 
Previous research mentions the important factors, including rate of supersaturation 
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generation, level of impurities and mixing conditions, which affect measurements of 
MSZW and can result in product failure. This research highlights the importance of 
crusting as an additional factor that leads to errors in MSZW measurements and 
crystallization operation. Combination of PAT tools with SSA techniques identifies 
common problems such as crusting forming on vessel walls highlighting the need for 
improvement within vessel design, for example by indicating the need to be able to 
operate the industrial vessel at partially filled jacket levels. These tools can save both 
time and money that would have been spent in researching the possibility of the 
presence of different polymorphic forms of a compound due to misinterpretation of 
results and can lead to better crystallizer design and optimised operating conditions.    
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Chapter 7. PAT used to examine the effect of mixing 
on the crystallization of pharmaceutical products                                                                                                                                                                                       
 
7.1 Introduction 
 
Batch cooling crystallization is a key unit operation used for producing 
pharmaceutical drug products (Davey and Garside, 2000). Each crystallization vessel 
is not designed to produce a particular product but instead small scale laboratory 
experiments are carried out to find the right conditions that will result in consistent 
crystal quality upon scale up from laboratory to pilot and then industrial scale (Yi and 
Myerson, 2006). Nucleation is a key parameter that needs to be controlled for a 
crystallization processing to ensure a quality product. For successful scale up a robust 
meta-stable zone width (MSZW) determination is required which takes into 
consideration variation in process parameters (Gillon et al., 2006; Barrett and 
Glennon, 2002). Operating within this region can be used to design the trade off 
between growth and nucleation and achieve good control (Parsons et al., 2003). 
Developed models containing nucleation kinetic parameters are used to predict 
growth, attrition, secondary nucleation and are used for controlling the crystallization 
process to follow a set cooling profile within the robust MSZW region (Nagy et al., 
2008c; Mersmann and Bartosch, 1998; Meadhra et al., 1996). Therefore it is of high 
importance that the nucleation kinetic parameters are accurate (Nagy et al., 2008c). 
Nucleation kinetics can be determined from accurate MSZW data (O‟Grady et al., 
2007). The most commonly used method is Nyvlt‟s correlation which involves 
plotting log (cooling rate) against log (MSZW) (Trifkovic et al., 2009). 
 
Crystallization behaviour is greatly affected by hydrodynamics, which can vary upon 
scale up. Hydrodynamic effects relate to changes in mixing conditions such as 
agitator speed and type, which affects the distribution of supersaturation within the 
crystallization vessel (Liang et al., 2004). This affects the point of nucleation leading 
to a variation in MSZW. Vessel size and agitator speed affect both the number of sub 
nuclei sites and the frequency of collisions between these sites required for nucleation 
(Yi and Myerson, 2006). Agitator type and speed can also have an effect on the size 
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of the final crystals as high frequency collisions between crystals can lead to breakage 
affecting the quality of the crystals (Gillon et al., 2006).  
 
A detailed investigation into the effect of mixing conditions within different vessel 
sizes of 1 mL (Crystal 16) and 1 L is carried out using a Mettler Toledo FSC402 
turbidity probe and focused beam reflectance measurement (FBRM) probe. These 
process analytical technology (PAT) tools are used to detect the point of spontaneous 
nucleation and hence the MSZW. Variations are made to a range of parameters 
including ramp (heating/cooling) rate, agitator speed and agitator type to examine the 
effect of the mixing conditions of the primary nucleation behaviour of the model 
systems para-amino benzoic acid (PABA), meta-amino benzoic acid (MABA) and 
ortho-amino benzoic acid (OABA) in water. Combining the effect of these parameters 
a robust MSZW region is obtained for the isomers of ABA. Nucleation kinetics and 
enthalpy/entropy of dissolution are obtained from the MSZW results and comparisons 
are made between the different crystallization vessel set-ups to corroborate the level 
in which these parameters are system specific. 
 
7.2 Experiments performed 
 
Cooling crystallization experiments were performed at the 1 mL and 1 L scale to 
investigate the effect of changes in mixing conditions on the MSZW. Other 
parameters were varied including ramp (heating/cooling) rate, agitator speed and type. 
A detailed range of experimental parameters used and the PAT tools used to measure 
the clear and cloud points at a range of concentrations is mentioned in section 3.3 and 
3.4.3 of chapter 3. A Figure of the crystallization set-up for the 1 L scale is shown in 
Figure 3.1 of chapter 3.  
 
7.3 Variation in key parameters on the MSZW and 
nucleation kinetics for isomers of ABA 
 
There are many parameters such as agitator speed, agitator type, ramp 
(heating/cooling) rate, dosing rate and point of addition of antisolvent, type of probe 
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used for measurement, size and shape of vessel and whether the vessel is baffled or 
not, all which can affect the clear and cloud curves resulting in changes to the MSZW. 
Significant differences in the MSZW can lead to the production of crystals with 
undesired properties resulting in failed batches and an increase in economic costs. 
This sub-section of research focuses on the effect of vessel size, agitator speed, 
agitator type and ramp (heating/cooling) rate of the MSZW region. The model 
systems used in this study are PABA and MABA in water.  Solubility data for PABA 
and MABA in water obtained from the literature can be found in Appendix D.  
 
7.3.1 MSZW determination using different size vessels 
 
This section of research investigates the affect of different mixing conditions within a 
1 mL and 1 L size vessel on MSZW measurements. Cooling crystallization 
experiments are performed using the model system PABA and MABA in water. For 
both scales a turbidity probe is used to detect the clear (solubility) points and cloud 
(nucleation) points for a range of concentrations using ramp rates of 0.5 and            
0.3 °C/min. The types of turbidity probes within each size vessel and measurement 
method is different, which could have some affect on the clear and cloud points. For 
the 1 mL scale 0% means no crystals dissolve and 100% means all the crystals 
dissolve. For the 1L scale the turbidity reading of 0% indicates all crystals dissolve 
and a positive number indicates crystals have nucleated.  A different measurement 
method is the point at which the reading of clear and cloud points is chosen. 
Variations in the agitator type and rotational speed of the agitator will affect the 
mixing conditions within the vessel and hence the point of spontaneous nucleation 
and rate of dissolution. For the 1 mL scale a magnetic flea is used for suspending the 
solids and for the 1 L scale a overhead 3 flat blade glass retreat curve is used. The 
agitator speed used within the 1 mL scale is 700 rpm while the value used in the 1 L 
scale is 300 rpm. The results for the cooling crystallization experiments for PABA in 
water are shown in Figures 7.1 and 7.2. The results highlight not only the affect of 
vessel size on the MSZW but also the affect of different mixing conditions created by 
different agitator speeds and types, different types of turbidity probes and 
measurement methods of turbidity.   
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Figure 7.1. Clear and cloud point curves for PABA in water at the 1 mL and 1 L 
scale using a ramp rate of 0.3 °C/min 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.2. Clear and cloud point curves for PABA in water at the 1 mL and 1 L 
scale using a ramp rate of 0.5 °C/min 
 
The MSZW is determined from the difference between the clear and cloud point 
curve for all concentrations values and the results for each scale using ramp rates of 
0.5 and 0.3 °C/min are shown in Table 7.1. 
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Table 7.1. MSZW values for the cooling crystallization of PABA in water using 
different ramp rate and vessel sizes 
 
Concentration 
(mg/mL) 
Ramp rate of 0.3 °C/min Ramp rate of 0.5 °C/min 
MSZW (°C) 
(1 L) 
MSZW (°C) 
(1 mL) 
MSZW (°C) 
(1 L) 
MSZW (°C) 
(1 mL) 
10 7.4 5.0 9.7 3.4 
15 5.7 3.0 8.9 4.3 
26 3.9 3.9 - - 
30 - - 3.6 2.9 
35 2.2 1.9 3.7 2.8 
 
Table 7.1 shows, for a ramp rate of 0.3 °C/min, the MSZW is wider at the larger scale 
(1 L) for all concentration values. The same behaviour is observed using a ramp rate 
of 0.5 °C/min. For the 1 mL scale the clear and cloud point temperatures are higher 
for all concentrations when compared with those obtained for the 1 L scale. The 
higher cloud (nucleation) temperature indicates enhanced mixing in the 1 mL vial. 
The poorer mixing in the 1 L scale was visually confirmed by observing solids 
settling at the bottom of the vessel. Yi and Myerson (2006) performed batch cooling 
crystallization experiments within vessel sizes of 50 mL and 500 mL. The results 
showed that for a larger size vessel using a lower agitator speed, nucleation occurred 
at a higher temperature leading to a narrower MSZW. However this was not found to 
be the case in the cooling crystallization experiments of PABA in water. The 
explanation for the different behaviour observed could be due to the different size 
vessels and types of agitators used to perform the cooling crystallization experiment 
affecting the mixing conditions within the vessel. Yi and Myerson (2006) used vessel 
sizes of 50 and 500 mL with  stainless steel overhead pitched blade turbines whereas 
in these studies vessel sizes used include the 1 mL with the use of the magnetic flea 
and vessel size 1 L using an overhead 3 blade glass retreat curve.  The higher 
nucleation temperature observed in the 1 mL scale could be due to the small vessel 
size and magnetic flea increasing the frequency of collisions between the solute 
molecules enhancing the likelihood of forming the critical size nucleus which is 
required for nucleation (O‟Grady et al., 2007). Additionally the MSZW based on 
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primary nucleation can significantly vary whether heterogeneous or homogeneous 
nucleation takes place.     
 
Repeats of the MSZW experiments were performed at the 1 mL scale and 1 L scale 
using the model system MABA in water with ramp rates of 0.1, 0.2, 0.3 and            
0.5 ºC/min. The results for the clear and cloud point curves using a ramp rate of      
0.3 ºC/min is shown in Figure 7.3. The clear/cloud point temperatures and MSZW 
values at both scale (1 mL and 1 L) and at all ramp rates of 0.5, 0.3, 0.2 and             
0.1 ºC/min is shown in Tables 7.2 and 7.3.  
 
For the 1 mL scale and the 1 L scale using a 3-blade glass retreat curve there is not 
much difference in the MSZW at high concentration (28-24 mg/ml) but the MSZW 
increases by 10 ºC at low concentration of 15 mg/ml for the 1 L scale. There is a shift 
in the clear and cloud point curves for the two scales. Clear and cloud point curves 
occur at higher temperatures for the 1 mL scale. Similar results were observed for the 
two scales when using a ramp rate of 0.5 ºC/min. This behaviour was also observed 
for the model system PABA in water. 
Figure 7.3. Clear and cloud point curves for MABA in water using different 
scales of 1 mL and 1 L (3-blade glass retreat curve) at a ramp rate of 0.3 ºC/min. 
Error bars included  
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Table 7.2. Clear/cloud point temperatures and MSZW values for MABA in 
water at the 1 L scale using a 3-blade glass retreat curve at different ramp rates  
 
Experiment 
type 
Concentration 
(mg/ml) 
Ramp 
rate 
(ºC/min) 
Temperature 
(clear point) 
Temperature 
(cloud point) 
MSZW 
(ºC) 
1 L 
 
( 3-blade 
glass retreat 
curve) 
28 0.5 73.2 49.7 23.5 
0.3 69.5 49.3 20.2 
0.2 67.4 46.5 20.9 
24 0.5 61.6 39.7 21.9 
0.3 61.2 39.9 21.3 
0.2 60.3 40 20.3 
20 0.5 56 30 26 
0.3 58.1 30.6 27.5 
0.2 58 29.8 28.2 
17 0.5 52.6 22 30.6 
0.3 54.8 23.2 31.6 
0.2 55.6 23.9 31.7 
14.5 0.5 51.7 16.1 35.6 
0.3 52.5 17.6 34.9 
0.2 52.7 17.7 35 
 
Table 7.3. Clear/cloud point temperatures and MSZW values for MABA in 
water at the 1 mL scale at different ramp rates 
 
Experimental 
type 
Concentration 
(mg/ml) 
Ramp rate 
(ºC/min) 
Temperature 
(clear point) 
Temperature 
(cloud point) 
MSZW 
(ºC) 
1 mL 12 0.5 53.7 25.6 28.1 
0.3 53.7 23.1 30.6 
0.1 52.3 31.5 20.8 
15 0.5 59.7 33.5 26.2 
0.3 58.9 33.8 25.1 
0.1 58.2 35.8 22.4 
17.9 0.5 63.9 40.8 23.1 
0.3 64.3 39.8 24.5 
0.1 63.4 43.4 20 
20 0.5 65 45.6 19.4 
22.1 0.5 69.4 47.3 22.1 
0.3 69.5 49.7 19.8 
0.1 69.5 52.3 17.2 
24 0.5 72 49 23 
0.3 70.8 49.7 21.2 
0.1 71 54.8 16.2 
26 0.5 73.5 55 18.5 
0.3 71.6 53.4 18.2 
0.1 72.4 55.4 17 
28 0.5 75.3 56.7 18.6 
0.3 75.2 55.3 19.9 
0.1 74.2 58.8 15.4 
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7.3.2 MSZW determination using different agitator speeds and type 
 
Cooling crystallization experiments were performed at the 1 L scale using different 
agitator types and agitator speeds to examine the effect of these parameters on the 
MSZW. The first set of experiments investigated the effect of agitator type on the 
MSZW using the model system MABA in water. The two types of agitator used in 
this study are the 3-blade glass retreat curve and a 4-pitched blade turbine. The FBRM 
was used to detect the clear and cloud points for the vessel with the 4-pitched blade 
turbine. The turbidity probe was used to detect the clear and cloud points for the 
vessel with the 3-blade glass retreat curve. The MSZW results using a ramp rate of 
0.3 ºC/min and an agitation speed of 300 rpm is shown in Figure 7.4. Three previous 
repeated experiments using a combination of FBRM and turbidity probe for cooling 
crystallization of PABA in ethyl acetate (Chapter 6) showed that there was no 
difference in the clear points and only a 1 ºC difference in the cloud points detected 
by the two PAT tools. Taking into account a 1 ºC difference in cloud points over the 
concentration used the MSZW shown in Figure 7.4 still varies by 2-7 ºC due to the 
effect of agitator types. This confirms that the significant differences in clear/cloud 
points and hence MSZW values shown in Figure 7.4 is mainly due to the effect of 
different agitator types.   
Figure 7.4. Clear and cloud point curves for MABA in water using different 
agitator types at the 1 L scale and ramp rate of 0.3 ºC/min. Error bars included 
for clear and cloud points for the 3-blade glass retreat curve agitator 
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Clear/cloud point temperatures and MSZW values for the 3-blade glass retreat curve 
can be found in Table 7.2 and those for the 4-pitched blade turbine can be seen in 
Table 7.4. 
 
 
Table 7.4. Clear/cloud point temperatures and MSZW values for MABA in 
water at the 1 L scale using a 4-pitched blade turbine at different ramp rates 
 
 
 
 
There is no significant difference in the MSZW for the 1 L scale using different 
agitator types of the 3-blade glass retreat curve and 4-pitched blade turbine. There is a 
shift in the clear and cloud point curves for the different agitator types indicating a 
variation in the mixing conditions. Higher clear and cloud points are observed at all 
concentration ranges (14.5-28 mg/mL) for the 4-pitched blade turbine.  
 
 
The second set of experiments investigated the effect of agitator speed on the MSZW. 
Cooling crystallization experiments were performed within a 1 L size vessel using a 
3-blade glass retreat curve and a constant ramp rate of 0.3 °C/min. The agitator speeds 
used were in the range of 250 to 400 rpm. Alterations to the agitator speed will vary 
the power input into the system. Variations in the power input will affect the mixing 
Experiment 
type 
Concentration 
(mg/ml) 
Ramp rate 
(ºC/min) 
Temperature 
(clear point) 
Temperature 
(cloud point) 
MSZW(ºC) 
1 L 
 
(4-pitched 
blade 
turbine) 
28 0.5 71.2 50.2 21 
0.3 72.9 52.4 20.5 
0.2 74.2 53.9 20.3 
24 0.5 66.9 43.5 23.4 
0.3 66.5 45.9 20.6 
0.2 70.4 49.1 21.3 
20 0.5 61.7 33.8 27.9 
0.3 62.3 35.9 26.4 
0.2 66.4 40.0 26.5 
17 0.5 57.8 28.3 29.5 
0.3 58.5 31.4 27.1 
0.2 61.8 33.3 28.5 
14.5 0.5 54.5 21.7 32.8 
0.3 54.7 22.6 32.1 
0.2 58.1 23.2 34.9 
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conditions within the vessel and hence the MSZW. The model system used in this 
study is PABA in water. The turbidity probe was used to detect the clear and cloud 
points for different concentration values and agitator speeds. The clear and cloud 
point curves are shown in Figure 7.5. The MSZW is determined for each 
concentration value at the different agitator speeds and the results are shown in Table 
7.5. 
 
 
Figure 7.5 shows that for all agitator speeds the clear and cloud point curves are very 
similar. The MSZW values stated in Table 7.5 show that for each concentration value 
the MSZW does not change significantly by changing the agitator speed from 250 to 
400 rpm. For each agitator speed, power number ( pN ), power input ( P ) and 
Reynolds number for impeller were calculated to provide a crude approximation of 
the variation in the flow regime by the change in the agitator speed within the range 
used. 
 
 
 
Figure 7.5. Clear and cloud point curves obtained using different agitator speeds 
within the 1 L size vessel 
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Table 7.5. MSZW values for the cooling crystallization of PABA in water using 
different agitator speeds 
Concentration 
(mg/ml) 
MSZW (°C) for different agitator speeds 
250 rpm 300 rpm 400 rpm 
10 8.1 7.4 7.9 
15 5.9 5.7 5.7 
22 4.3 4.0 4.2 
26 3.9 3.8 3.3 
30 3.1 2.1 2.2 
35 2.8 2.15 5.6 
 
The Reynolds number for impeller is defined as 
 
v
L ND

 2
Re                                                                                                             (7.1) 
 
where L is the fluid density, v  is the fluid viscosity, D  is the impeller diameter 
and N is the  agitator speed (Rielly et al., 2007). The power number is given as 
follows (Li et al., 2005): 
53DN
P
N p

                                                                                                            (7.2) 
 
where P  is the power input into the system. The power number remains constant for 
Re>10 4 (Li et al., 2005).  
 
For the calculations of the Reynolds number the properties of the fluid are assumed to 
remain constant for the temperature range used. The fluid properties are those 
obtained for water giving a fluid density constant at a value of 1000 kg/m 3  and fluid 
viscosity is 0.001 Ns/m 2 . The diameter of the retreat curve impeller is 0.05 m.  
 
A summary of the results for Reynolds number, power number and power input into 
the system for each agitator speed is shown in Table 7.6.  
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Table 7.6. Summary of Reynolds number, power number and power input for 
different agitator speeds 
 
 
Agitator speed 
(rpm) 
Reynolds number Power number Power input 
(J/s) 
250 10,417 0.7 0.016 
300 12,500 0.7 0.027 
400 16,666 0.7 0.06 
 
 
 
From the results in Table 7.6 it shows that the Reynolds number is in the region of 
10,000-17,000 for the agitator speeds used of 250-400 rpm. Given all values are 
Re> 410  the mixing conditions within the vessel is in the turbulent regime, indicating 
good mixing (Li et al., 2005). Within the range of agitator speeds used the Reynolds 
number and hence degree of turbulence does not change significantly indicating little 
change in the mixing conditions within the vessel which could explain why the cloud 
(nucleation) point curves are very similar as shown in Figure 7.5.   
 
Optical microscopy is used to analyse samples of crystals obtained from the cooling 
crystallization of PABA in water using different agitator speeds of 250, 300 and        
400 rpm. The optical microscope images are shown in Figure 7.6.  
 
The micrographs show long fibrous needles of size greater than 200 μm. The size of 
the crystals is not affected by the agitator speeds within range 250-400 rpm which 
indicates that the mixing conditions for these studies, using a 1 L vessel size and a 3-
flat blade glass retreat curve, does not affect the quality of the crystals. The increase 
in turbulence and power input resulting from the increase of the agitator speed from 
250 to 400 rpm was not large enough to generate the attrition of the crystals.  
 
 
 
 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates 
 
2011 
133     Chapter 7. PAT tools to monitor changes in mixing of the crystallization process  
        
              
 
 
 
 
 
 
 
Figure 7.6. Optical microscope images of crystals obtained during the cooling 
crystallization of PABA in water using different agitator speeds of (a) 250 rpm, 
(b) 300 rpm and (c) 400 rpm 
7.3.3 Evaluation of the effect of cooling rate on the MSZW and 
investigation of the variability of nucleation kinetics with different 
crystallization conditions 
 
Cooling crystallization experiments were performed within a 1 L vessel using a        
3-blade glass retreat curve and an agitator speed of 300 rpm. The cooling rate is 
varied using a range of values including 0.5, 0.3, 0.2 and 0.1 °C/min to investigate 
how this parameter affects the MSZW. The model systems used in this study are 
PABA and MABA in water.  The first set of experiments used the turbidity probe to 
detect the solubility (clear) point and nucleation (cloud) points for a range of 
concentrations using the model system PABA in water. From the turbidity results the 
true thermodynamic solubility curve was obtained by using an extrapolation method 
in excel to find the temperature corresponding to zero ramp rate and nucleation 
(cloud) curve for each cooling rate are obtained and the results are shown in Figure 
7.7. 
 
For each cooling rate the MSZW is determined by the temperature difference between 
the solubility and nucleation curves. A summary of the results are shown in Table 7.7. 
 
Figure 7.7 and Table 7.7 show that for a particular concentration the MSZW increases 
with the cooling rate, which is observed in many generic crystallization processes 
(Nagy et al., 2007). As the concentration is lowered the MSZW increases, which is 
true for all cooling rates. From these results nucleation kinetics are determined using 
the method proposed by Nyvlt (1968) and both the enthalpy and entropy of 
dissolution are calculated using the Van‟t Hoff solubility curve for PABA in water.  
200μm 
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200μm 200μm 200μm 
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Figure 7.7. Solubility and nucleation curves for PABA in water at cooling rates 
0.5, 0.3, 0.1 °C/min, using a 1 L size vessel 
 
Table 7.7. MSZW values for the cooling crystallization of PABA in water using a  
1 L vessel and different cooling rates 
 
Concentration 
(mg/mL) 
MSZW (ºC) at different cooling rates 
0.5 °C/min 0.3 °C/min 0.1 °C/min 
10 8.6 8.1 6.1 
15 4.7 4.6 3.2 
22 3.9 3.9 2.8 
26 3 2.7 1.9 
30 1.6 1.4 0.6 
35 1.7 1.7 0.9 
 
 
Various experiments have been prepared in the literature for nucleation rate (e.g. 
Mullin, 2001). However for modelling purposes the following power law type semi-
empirical expression is often used:  
 
b
b CCkB )(
*                                                                                                        (7.3) 
 
 
where B  is the rate of nucleation, bk  is the nucleation rate constant, b  is the 
nucleation order and ( )*CC   is the degree of supersaturation.                                                                            
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For the experimental determination of B , Nyvlt prepared a method that involves 
varying the rate of supersaturation generation and measuring the MSZW (Nyvlt, 
1968). This method involves cooling a solution down at a constant cooling rate using 
the same initial concentration. Nyvlt (1968) carried out a large number of experiments 
involving the cooling crystallization of aqueous solutions and found that a linear 
relationship by plotting ln (cooling rate) against ln (MSZW). The linear relationship is 
shown in Equation 7.4, 
 
KMSZWb  )ln()ln(                                                                                          (7.4) 
 
where   is the cooling rate, b is the nucleation order, MSZW is the meta stable zone 
width and K  is a constant.  
 
From the results shown in Figure 7.7, for the cooling crystallization experiments of 
PABA in water within a 1 L vessel, ln (  ) is plotted against ln (MSZW) for each 
concentration value and the results are shown in Figure 7.8.  
 
Figure 7.8 shows approximately liner relationships between the cooling rate and 
MSZW at all concentrations for the cooling crystallization of PABA in water at the     
1 L scale. From the slope of each line the nucleation order, b , is calculated. The 
results together with the constant K from equation 7.4 and R
2
 values, which represent 
how close the data points fit the linear line, are shown in Table 7.8. 
 
 
 
 
 
 
 
 
 
 
Figure 7.8. Linear dependence between cooling rate and MSZW according to 
Nyvlt (1968) for PABA in water at the 1 L scale 
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Table 7.8. Nucleation orders, contact K and R
2
 values obtained from the cooling 
crystallization of PABA in water within the 1 L vessel 
 
Concentration 
(mg/ml) 
Nucleation order ( b ) Constant ( K )  2R values 
10 4.4 ± 0.8 -10.34 0.98 
15 3.7 ± 0.4 -6.59 0.93 
22 4.1 ± 0.3 -6.51 0.90 
26 3.4 ± 0.5 -4.52 0.99 
35 3.4 ± 0.3 -2.65 0.97 
 
 
Nucleation order for the cooling crystallization experiments of PABA in water are in 
the range of 3.4-4.4 with confidence intervals of up to ± 0.8. Nagy et al. (2007) stated 
that the nucleation order for the cooling crystallization of caffeine in water is 3.18, 
which is lower than the values obtained within these experiments. Lower nucleation 
orders indicate a narrower MSZW and hence the system is more difficult to control.  
 
Further calculations involving the determination of the enthalpy and entropy of 
dissolution were performed using linearised van‟t Hoff relationship, which is shown 
in Equation 7.5, 
 
R
S
TR
H
C dd




1
)ln(                                                                                           (7.5) 
 
where C is the concentration, R is the gas constant, T is the temperature, dH  is the 
enthalpy of dissolution and dS  is the entropy of dissolution. Equation 7.5 represents 
a linear relationship between ln (C) and 1/T with slope dH / R and intercept dS / R. 
 
Based on the linearised van‟t Hoff solubility equation, ln (C) is plotted against ln 
(1/T) for the cooling crystallization experiments of PABA in water and the results are 
shown in Figure 7.9. 
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.  
Figure 7.9. Linearised van’t Hoff solubility curve for PABA in water at the 1 L 
scale 
 
The enthalpy of dissolution is obtained from the slope of the line plotted to the data 
points, giving a value of dH =37.2 J/mol. The entropy of dissolution is obtained 
from the intercept giving a value of dS =80.2 J/mol/K. These values are lower than 
the values obtained from the cooling crystallization of caffeine in water which has an 
enthalpy of dissolution of 40.8 J/mol and entropy of dissolution of 104.0 J/mol/K 
(Nagy et al., 2007). Due to the lower melting point of PABA compared to caffeine, it 
is expected that the enthalpy of dissolution would be lower as less energy is required 
in order to dissolve the solid. PABA is a less complex molecule in terms of the 
molecular structure when compared to caffeine and therefore a lower value for the 
entropy of dissolution is expected for PABA.   
 
The second set of experiments investigated the effect of ramp rate on the MSZW 
using the model system MABA in water. Cooling crystallization experiments were 
performed using a 3-blade glass retreat curve with agitator speed of 300 rpm. The 
ramp rates used includes 0.5, 0.3 and 0.2 ºC/min. The results showing the clear and 
cloud point curves at the different ramp rates are shown in Figure 7.10. 
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.  
 
Figure 7.10. Clear and cloud point curves for MABA in water at the 1 L scale 
using a 3-blade glass retreat curve and different ramp rates of 0.5, 0.3 and           
0.2 ºC/min 
 
From the results shown in Figure 7.10 there is no significant difference in the clear 
and cloud point curves at all ramp rates. Similar results were obtained when using a           
4-pitched blade turbine within a 1 L size vessel and using a magnetic stirrer at the      
1 mL scale.  Nucleation kinetics are obtained from the results of clear and cloud point 
curves at different ramp rates at the 1 L scale using a 3-blade glass retreat curve and 
4-pitched blade turbine and at the 1 mL scale. The same method is used to obtain 
nucleation kinetics as for the previous model system, PABA in water. However the 
true thermodynamic solubility temperature (zero heating rate) at all concentration 
values is replaced with the temperature at a ramp rate of 0.2 ºC/min for the 1 L scale 
and 0.1 ºC/min for the 1 mL scale. Results showing a linear relationship between 
ln(  ) and ln(MSZW) for the three different set-ups are shown in Figures 7.11, 7.12 
and 7.13. 
 
Nucleation orders were obtained from the slope of the lines in Figure 7.11, 7.12 and 
7.13. The results together with the constant K obtained from equation 7.4 and R
2
 
values, which represent how close the data points fit the linear line, are shown in 
Table 7.9.  
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Nucleation orders obtained from the 1 mL and 1 L scale using a 4-pitched blade 
turbine are within the range 3.9-6.3 with confidence intervals of up to ± 1. These 
values are similar to the nucleation order obtained for PABA in water of 3.4-4.4. 
Although these values are relatively similar the nucleation order for MABA in water 
at the 1 L scale using a 3-blade glass retreat curve is significantly higher, within the 
range of 15.6-16.9 with confidence intervals of up to ± 3. The results provide 
experimental evidence that the typical model parameters of the semi-empirical 
nucleation expression (Equation 7.3) often used in crystallization modelling are only 
valid for a specific crystallization vessel and mixing conditions. Therefore model 
based design and scale-up of crystallization processes must be used carefully, and 
considering more detailed mechanistic models and better incorporation of the effect of 
mixing in these mechanisms can improve the generality and applicability of 
crystallization models.  
 
Enthalpy and entropy of dissolution values are obtained for MABA within the three 
different vessel set-ups using the linearised van‟t Hoff solubility curve. Figure 7.14 
shows the van‟t Hoff solubility curve for each vessel set-up including the 1 L scale 
with the 3-blade glass retreat curve and the 4-pitched blade turbine and for the 1 mL 
scale.  
 
 
Figure 7.11. Linear dependence between cooling rate and MSZW according to 
Nyvlt’s (1968) method for the 1 mL scale of MABA in water 
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Figure 7.12. Linear dependence between cooling rate and MSZW according to 
Nyvlt’s (1968) method for the 1 L scale using a 3-blade glass retreat curve for 
MABA in water 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.13. Linear dependence between cooling rate and MSZW according to 
Nyvlt’s (1968) method for the 1 L scale using a 4-pitched blade turbine for 
MABA in water 
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Table 7.9. Nucleation orders obtained from cooling crystallization of MABA in 
water within a 1 L vessel using a 3-blade glass retreat curve and 4-pitched blade 
turbine and within a 1 mL vessel  
 
Vessel type Concentration 
(mg/mL) 
Nucleation 
order 
Constant 
( K ) 
2R values 
1 mL 12 4.9 ± 0.7 -17.11 0.84 
22.1 6.3 ± 1 -20.02 0.99 
28 5.9 ±0.6 -18.24 0.58 
1 L (3-blade 
glass retreat 
curve) 
14.5 16.9 ± 2.7 -61.51 0.85 
17 15.6 ± 3 -55.40 0.99 
1 L                                     
(4-pitched blade 
turbine) 
17 5.7 ± 0.5 -20.56 0.99 
20 4.3 ± 0.3 -15.78 0.92 
24 3.9 ± 0.6 -13.55 0.96 
28 5.4 ± 0.9 -17.76 0.99 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.14. van’t Hoff solubility curve for MABA in water  (a) at the 1 mL scale 
and 1 L scale using (b) a 3-blade glass retreat curve and (c) 4-pitched blade 
turbine 
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From the slope and intercept of the van‟t Hoff solubility curves the enthalpy of 
dissolution and entropy of dissolution are obtained for each crystallization set-up, and 
the results are shown in Table 7.10.  
 
 
Table 7.10. Enthalpy and entropy of dissolution values for MABA in water at the  
1 mL scale and the 1 L scale using a 3-blade glass retreat curve and a 4-pitched 
blade turbine 
 
Crystallization set up 
(vessel type) 
Enthalpy of dissolution 
(ΔH) (J/mol) 
Entropy of dissolution 
(ΔS) (J/mol/K) 
1 mL 35.7 73 
1 L (3-blade glass retreat 
curve) 
37.7 81.8 
1 L (4-pitched blade 
turbine) 
38.9 80.2 
 
 
Enthalpy of dissolution for MABA in water within all crystallization set-ups is very 
similar giving a value in the range 35.7-38.9 J/mol. As the melting point of PABA     
(189 ºC) is close to that of MABA (177 ºC) the enthalpy of dissolution would be 
predicted to be similar and this is found to be the case as the enthalpy of dissolution 
for PABA in water is 37.2 J/mol. The entropy of dissolution for MABA is within the 
range 80.2-81.8 J/mol/K. A slightly lower value of 73 J/mol/K is obtained at the 1 mL 
scale which could be due to the fact that the temperature values plotted in the 
vant‟Hoff solubility curve for the 1 L scales correspond to the clear points obtained at 
a heating rate of 0.2 ºC/min, whereas for the 1 mL scale correspond to the clear points 
obtained at a heating rate of 0.1 ºC/min. The entropy of dissolution for MABA is 
predicted to be similar to PABA, due to the similar complexity of the molecules since 
the compounds are isomers. The entropy of dissolution obtained for PABA from this 
report is 80.2 J/mol/K (see Figure 7.9), which as expected is similar to the values 
obtained for MABA.    
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7.4 Robust MSZW region for the isomers of ABA 
 
Controlling the crystallization process to follow a set profile within the MSZW is 
important to obtain quality crystals with the desired properties. This sub-section 
investigates the differences in MSZW values for the three isomers of ABA (ortho, 
meta and para) and uses the results obtained from sub section 7.2 to obtain a robust 
MSZW region for PABA and MABA. The robust MSZW region can be used to 
design a crystallization system at larger scale (pilot to manufacturing) increasing the 
likelihood of producing a quality product.  
7.4.1 Variation in the MSZW between the three isomers of ABA 
 
Cooling crystallization experiments were performed in a 1 L vessel using a 4-pitched 
blade turbine at a rotation speed of 255 rpm and ramp rate of 0.5 ºC/min for the three 
isomers of ABA (ortho, meta, para). The FBRM probe was used to detect clear (all 
crystal dissolve) and cloud points (first detection of crystals) for a range of 
concentrations of the three isomers and the results are shown in Figure 7.15.  
Solubility data for PABA and MABA in water obtained from the literature can be 
found in Appendix D.  
Figure 7.15. Clear and cloud point curves for the three isomers of ABA (ortho, 
meta and para) using a ramp rate of 0.5 ºC/min and 1 L vessel (4-pitched blade 
turbine) 
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From the difference in the clear and cloud points in Figure 7.15 the MSZW is 
determined for each isomer of ABA and the results are given in Table 7.11. 
 
Table 7.11. MSZW results for the three isomers (ortho, meta, para) of ABA 
 
Isomer of ABA  Concentration (mg/mL) MSZW (ºC) 
ortho  10 35.9 
14 30 
18 24.7 
22 18.2 
25 17.8 
meta 14.5 32.8 
17 29.5 
20 27.9 
24 23.4 
28 21 
para 14 10.6 
18 7.5 
22 5.5 
26 4.6 
30 4.3 
 
The MSZW for each isomer of ABA increases in width as the concentration is 
lowered. The isomer para-ABA has a narrower MSZW ranging from 4.3-10.6 ºC 
compared to the other two isomers ortho and meta-ABA, with MSZW values in the 
range 17.8-35.9. As the MSZW becomes narrower the crystallization process is more 
difficult to control. ortho- and meta-ABA isomers have similar MSZW ranges but 
meta-ABA has a slightly larger MSZW over the concentration range 10-28 mg/mL 
(see Table 7.11). The three isomers of ABA have significant differences in the clear 
and cloud point curves. ortho-ABA has the highest clear (solubility) points and para-
ABA has the lowest temperature clear points over the concentration range               
10-30 mg/mL. Based on the cloud point data for the three isomers para-ABA would 
be the first to nucleate from a mixed isomer solution and meta-ABA would be the 
final form of isomer to nucleate as the cloud points occur at the lowest temperature 
values as shown in Figure 7.15. The differences in the clear and cloud point curves of 
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any molecular compound with isomers would be important information for the design 
of experiments involving the separation of isomers via crystallization.  
In the previous sub-section 7.2 the nucleation order, enthalpy and entropy of 
dissolution are obtained for the meta- and para-ABA isomers. A summary of these 
parameters for the three isomers are highlighted in Table 7.12. 
 
Table 7.12. Summary of results for nucleation order, enthalpy/entropy of 
dissolution para- and meta-ABA  
 
Isomer-ABA Nucleation 
order 
Enthalpy of 
dissolution (J/mol) 
Entropy of 
dissolution 
(J/mol/K) 
PABA 3.4-4.4 37.2 80.2 
MABA ( 1 mL) 4.9-6.3 35.7 73 
MABA (1 L) 
(3-blade glass retreat curve) 
15.6-16.9 37.7 81.8 
MABA (1 L) 
(4-pitched blade turbine) 
3.9-5.7 38.9 80.2 
 
7.4.2 Robust MSZW region for PABA and MABA 
 
Determination of the robust MSZW region is important in the design of crystallization 
processes. The robust MSZW is defined as the distance between the thermodynamic 
solubility curve and the lower limit curve through the cloud points. Often in industry 
for new active ingredient (AI) compounds the thermodynamic solubility curve is 
unknown. So an alternative way that will be used in this research to define the robust 
MSZW is the distance between the lower limit curve through the cloud points and 
upper limit curve through the clear points (free point zone). This method is a quick 
way of obtaining a robust MSZW when the thermodynamic solubility curve is 
unknown and with the high demands in the pharmaceutical industry this will help 
them achieve their targets of project timelines. Considering all the parameters 
mentioned in section 7.2, including ramp rate, scale, agitator speed and type, a robust 
MSZW region is obtained for PABA and MABA and the results are shown in Figures 
7.16 and 7.17.   
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Figure 7.16. Robust MSZW region for PABA in water at the 1 L scale with 
variations in clear and cloud point curves for different ramp rates, agitator types 
and agitator speeds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.17. Robust MSZW region for MABA in water with variations in clear 
and cloud point curves for different ramp rates, agitator types and scale of vessel 
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Figure 7.16 shows a robust MSZW region for the model system PABA in water. This 
region is obtained by the limits of the clear (all crystals dissolve) and cloud (first 
appearance of crystals) curves as represented by the red and black points respectively. 
The robust MSZW region takes into consideration variations in process parameters 
including cooling rate (0.5, 0.3 and 0.1 ºC/min), agitator speed (250, 300 and 400 
rpm) and agitator type (3-blade glass treat curve and 4-pitched blade turbine). The 
general MSZW for PABA in water is narrow resulting in a narrow robust MSZW 
region ranging from 0.9-5.4 ºC. This robust MSZW region provides the experimental 
conditions for seeding and the degree of supersaturation required to control the 
crystallization process at large scale so as to produce crystals with the desired 
properties. However this robust MSZW region does not apply at the 1 mL scale due to 
overlaps of the clear and cloud point curves as a result of a narrow MSZW.  
 
Figure 7.17 shows the robust MSZW region for MABA in water. This robust MSZW 
takes into consideration variations in cooling rate (0.5, 0.3, 0.2 and 0.1 ºC/min), 
agitator type (3-blade glass retreat curve and 4-pitched blade turbine) and scale (1 mL 
and 1 L). The robust MSZW region varies in width from 5.5-20.8 ºC which provides a 
suitable candidate for a model system involving the design of larger scale 
crystallization experiments in which a supersaturation profile is followed within the 
robust MSZW region for obtaining quality crystals.   
 
These results indicate that for compounds with broader MSZW, such as MABA, it is 
possible to determine the robust MSZW by performing automated MSZW 
experiments under various operating conditions (e.g. heating/cooling rates, agitator 
speed, agitator type, etc) and at different scales (e.g. 1 mL and 1 L). The robust 
MSZW identified can then be extrapolated for larger scale operations. However if the 
compound has a narrow MSZW (such as in the case of PABA) this approach may not 
be applicable, due to the overlapping boundaries of the MSZW‟s determined under 
various conditions. 
 
   
 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates 
 
2011 
148     Chapter 7. PAT tools to monitor changes in mixing of the crystallization process  
7.5 Conclusions 
 
Cooling crystallization experiments were performed with the use of the turbidity and 
FBRM probes to investigate the effect of ramp rate, scale, agitator type and speed on 
the clear and cloud point curves and hence MSZW for isomers of ABA.  Larger 
MSZW values were observed for the 1 L scale compared to the 1 mL scale for PABA 
and MABA in water. These results have significant practical relevance as they 
indicate that at larger scale the MSZW can be broader, hence the laboratory scale 
design of crystallization condition can be conservative enough to provide consistent 
product properties at the larger scale. Also these results highlight the careful usage of 
the Crystal 16 data (1 mL scale) for the design of larger scale (pilot and industrial) 
experiments as there is a large variation in the MSZW at the 1 mL and 1 L scale. 
Clear and cloud point curves occur at higher temperatures for the 1 mL scale 
indicating enhanced mixing, which could be due to the small vessel size and magnetic 
flea increasing the frequency of collisions between the solute molecules.  
 
Changes in agitator types (including the 3-blade glass retreat curve and 4-pitched 
blade turbine) did not have significant effect on the MSZW values, but clear and 
cloud point curves occurred at higher temperatures when using the 4-pitched blade 
turbine. Agitator speeds within the range 250-400 rpm showed no significant effect on 
the clear and cloud point curves and hence the MSZW, for the 3-blade glass retreat 
curve at the 1 L scale. Optical microscope images showed that the quality of crystals 
is not affected within the studied agitator speed range of 250-400 rpm.  
 
Nucleation orders, MSZW, enthalpy and entropy of dissolution values were obtained 
from results of cooling crystallization experiments at different ramp (cooling/heating) 
rates for model system meta- and para-ABA in water. MSZW values were found to 
increase with the cooling rate for PABA in water. Enthalpy and entropy of dissolution 
values are similar for PABA and MABA isomers. Nucleation orders were found to 
vary for the model system MABA within different crystallization set-ups involving 
different size vessels and mixing conditions, highlighting that crystallization models 
containing nucleation parameters are only valid for a specific crystallization set-up. 
Therefore model based design and scale-up of crystallization processes must be used 
carefully and more detailed mechanistic models, which take into consideration the 
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effect of mixing need to be designed to improve the generality and applicability of 
crystallization models.   
 
MSZW values for the three isomers (ortho, meta and para) of ABA are obtained at 
the 1 L scale, which showed that PABA has a narrow MSZW while MABA and 
OABA have wide MSZWs. A robust MSZW region, which takes into consideration 
variation in operating conditions (ramp rate, agitator speed and impeller type) and 
different scales (1 mL and 1 L), is obtained for MABA. However this robust MSZW 
does not apply for PABA at the 1 mL scale due to an overlap of clear and cloud point 
curves. This research shows that a robust MSZW can be obtained for compounds with 
broad MSZWs, which can then be extrapolated for the design of larger scale 
operations increasing the likelihood of producing a quality product.
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Chapter 8. Crystallization and characterisation of 
salts of o, m, p-amino benzoic acid isomers 
8.1 Introduction 
 
Crystallization of salts is a method used to change the structure of pharmaceutical 
products resulting in drugs with enhanced physicochemical properties (Reutzel-Edens 
et al., 2003, Forbes et al., 1992, Haynes et al., 2005, Jones et al., 2005, Stephenson 
and Diseroad, 2000). Salt formation is used to overcome problems with solubility, 
dissolution rate, stability and hygroscopicity (Forbes et al., 1992, Haynes et al., 
2005). Reports state that 50% of pharmaceutical drug products are crystallized as salts 
(Kumar et al., 2009). A common morphology of crystals is needles, which results in 
problems in downstream processing such as long filtration times due to blockage of 
filter. To overcome this problem often compounds are crystallized as salts producing 
large crystals with a well defined shape. There are a number of variables that can 
affect whether a salt nucleates from solution and the type of salt including solvent, pH 
of solution and acid/base used to achieve the desired pH (Towler et al., 2004, Jones et 
al., 2005).  
 
Many active pharmaceutical ingredients are organic compounds containing both 
amino and carboxyl groups (e.g. amino acids) as is the case of the model system 
PABA and MABA. Due to the presence of these groups within the molecule four 
forms of the compound are known to exist. These forms consist of the neutral form 
(no charge), zwitterion which contains both negative charge on the (COO
-
) group and 
positive charge on the (NH3
+
) group, single positive charge (-NH3
+
) and single 
negative change (COO
-
).  Figure 8.1 shows the four different forms of PABA and the 
equilibrium between each form.  
 
Variations in pH and temperature will alter the solubility of the compound and the 
percentage ionisation of the different species in solution. Figure 8.2 (a) shows the 
solubility curves for pH range 1-11 for the model system of PABA in ethanol 
solution. These curves were obtained using the equations (8.1) and (8.2). The iso-
electric point of PABA is 3.6 and the pKa values are 2.5 and 4.8 (Seok et al., 1995). 
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Figure 8.1. Four different forms of PABA and the equilibrium between each 
form 
 
 
For the neutral form of the compound the solubility has a minimum at pH within the 
range 3 to 6. At low pH (acidic conditions) and high pH greater than 8, there is a large 
increase in solubility. Figure 8.2 (b), shows how changing the pH affects the 
percentage ionisation of the different species in solution. At pH values below 3 the 
(NH3
+
) species is 100% ionising, pH in the range 3-6 the neutral form of the 
compound is most likely to nucleate from solution and at high pH the (COO
-
) species 
has 100% ionisation. This confirms that at low pH the acidic salt is likely to form and 
at high pH the basic salt is likely to form when an acid or alkali is added to the 
solution. The relationship between the solubility and pH can be expressed as: 
 
 








oL
o
SS
S
pKapH log  ,                                                                                    (8.1)    
 
where oS  is the intrinsic solubility at specific temperature and LS  is the calculated 
solubility at specific pH and temperature (Florence and Attwood, 1981); and  
Zwitterions 
Neutral form 
-ve species 
+ve species  
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Equation (8.1) applies for pH values below the iso-electric point and equation (8.2) 
applies for pH values above the iso-electric point (Florence and Attwood, 1981). A 
derivation of Equations (8.1) and (8.2) can be found in Appendix G.  
 
 
 
 
Figure 8.2. Change in pH with (a) solubility and temperature for PABA in 
ethanol and (b) % ionisation of certain species of PABA  
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are produced using the software package Mercury (version 2.2; Macrae et al., 2008). 
The predicted morphology of salt crystals is obtained by Bravais, Friedel, Donnay and 
Harker (BFDH) crystal morphologies method using the software package Mercury 
(version 2.2; Macrae et al., 2008). This method predicts the crystals morphology 
assuming crystal growth occurs within a vacuum and therefore it does not take into 
account any bonding interactions between solvent molecules or impurities with the 
crystal surfaces. The model system used in this study is meta-amino benzoic acid 
(MABA) and para-amino benzoic acid (PABA). Salts of MABA and PABA are 
characterised using SSA techniques providing information on properties on the 
crystals that have not yet been reported in the literature.   
 
8.2 Experiments performed  
 
 
Cooling, precipitation and evaporation experiments were performed using a range of 
acids and bases as mentioned in section 3.2 of Chapter 3, to produce salts of the 
model systems. Vessel size used for the cooling crystallization experiment is 750 mL. 
The PAT tools used to monitor the crystallization process and a detailed methodology 
of the all experiments is within section 3.4.4 and 3.6 of Chapter 3. A schematic set-up 
of the crystallization rig for the cooling crystallization experiments is similar to the 
one shown in Figure 3.3 but does not include the ATR-UV/Vis probe. The range of 
SSA techniques used and the operating conditions for each technique is described in 
section 3.7 of Chapter 3.    
 
8.3 Acidic salts of PABA and MABA by cooling 
crystallization 
8.3.1 Introduction 
 
Compounds are often crystallized as salts to overcome problems with solubility and 
stability. The most common method used to crystallize the salts is cooling 
crystallization as it is a simple and slow process that allows growth of the crystals 
resulting in large crystals, which is a desirable characteristic. To produce acidic salts 
the pH of solution must be below 3. The acids used include hydrochloric acid and 
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hydrobromic acid. These acids are classified as strong acids resulting in 100% 
ionisation in solution and are therefore likely to produce the salt when mixed with the 
compound. These acids are the top two acids in salt formation with compounds 
(Haynes et al., 2005).   
8.3.2 Solid state characterisation of the hydrochloric salt of MABA 
 
Cooling crystallization experiments were performed for MABA in ethanol by using a 
3M solution of hydrochloric acid to crystallize the salt under very acidic conditions of 
pH=2.5. FBRM results for the cooling crystallization experiment are shown in Figure 
8.3. A single nucleation event is detected by a sudden increase in FBRM counts 
followed by a gradual increase in counts indicating additional nucleation. 
                                                                                                                                                                
 A range of solid state analytical techniques were used to characterise the crystalline 
product. Optical and scanning electron microscope images of MABA re-crystallized 
from ethanol at pH=2.5 using HCl acid are shown in Figure 8.4. Images show 
rectangular rod shape crystals which are different to the two polymorphic forms of 
MABA of needle morphology (Svard et al., 2010). Differences in the morphology 
provide evidence that the hydrochloric salt of MABA forms when re-crystallized from 
ethanol under very acidic conditions (pH=2.5). The crystals are fine particles, which 
are yellow in colour with a sparking tint as shown in Figure B1 of appendix B. 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3. FBRM results for the cooling crystallization of MABA from ethanol 
at pH=2.5 using HCl acid 
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Figure 8.4(a) Optical microscope and ( b, c ) scanning electron microscope 
images of MABA re-crystallized from ethanol at pH=2.5 using HCl 
 
 
Further solid state analysis involving the use of XRPD, DSC and solid state IR 
spectroscopy are used to characterise the crystals. XRPD patterns for the sample re-
crystallized from ethanol at pH=2.5 using HCl acid and the raw material form of 
MABA are shown in Figure 8.5. XRPD patterns for the two samples are completely 
different indicating the presence of the hydrochloric (HCl) salt of MABA.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.5. XRPD pattern for raw material form of MABA and MABA re-
crystallized from ethanol at pH=2.5 using HCl acid 
 
There is only one form of the chloride salt of MABA known to exist which is 
anhydrous (Cambridge Structural Database (Version 5.30; Allen, 2002) refcode 
MAMBZA (Arora and Sundaralingam,1973)). The simulated XRPD pattern of the 
anhydrous chloride salt of MABA and the crystals produced experimentally are 
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shown in Figure 8.6. These patterns are very similar indicating that the salt crystals 
produced experimentally are indeed the anhydrous form.  
     
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6. Simulated and experimental XRPD patterns for the chloride salt of 
MABA 
 
The unit cell dimensions of the chloride MABA salt crystals reported by Arora and 
Sundaralingam (1973) can also be used to predict the morphology of the crystals. The 
predicted morphology of the chloride salt of MABA is rod shaped as shown in Figure 
8.7. The crystals produced experimentally from ethanol as shown in Figure 8.4 are a 
similar morphology to the prediction but are much longer indicating that solvent 
interacts with certain crystal faces preventing growth in one direction.  
 
Figure 8.7. Predicted morphology of the chloride salt of MABA using the BFDH 
method 
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The DSC result for a sample of MABA re-crystallized from ethanol at pH=2.5 using 
hydrochloric acid is shown in Figure 8.8. A sharp peak appears at a temperature of 
291 °C which is the melting point of hydrochloride salt of MABA. A single peak 
indicates the formation of the pure salt.  
                
Figure 8.8. DSC plot of the hydrochloride salt of MABA 
 
 
IR spectrum for a sample of the hydrochloride salt of MABA and the raw material 
form of MABA are shown in Figure 8.9. There are many differences in the IR 
spectrums of the two forms. Two significant peaks at wavenumbers of 2548 and   
2804 cm
-1
 appear in the IR spectrum for the hydrochloric salt of MABA and a peak at 
wavenumber 2950 cm
-1
 appears in the spectrum for the raw material form of MABA. 
These peaks are due to the stretching of (O-H) bonds within the molecules. 
Wavenumbers in the range 1580-1650 cm
-1
 are due to the bending of the (N-H) 
bonds. As the HCl salt of MABA forms an ionic compound with a positive charge on 
the amine (NH3
+
) group this affects the (N-H) bending resulting in variations in the 
peak pattern of this wavelength range. In-plane bending of the (C-O-H) bond appears 
at wavenumber 400 cm
-1
 and for out-of-plane bending of the (C-O-H) bond a peak 
appears at wavenumber 900 cm
-1
.  There is a slight shift in both the in-plane and     
out-of-plane bending of these bonds for both the HCl salt of MABA and the raw 
material form as shown in Figure 8.9.   
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Figure 8.9. IR spectrum for the hydrochloric (HCl) salt of MABA and the raw 
material form of MABA  
 
Combining PAT tools with SSA techniques provided the experimental conditions 
required to produce the hydrochloride salt of MABA.  This salt forms when using an 
organic solvent (ethanol) and at very low pH conditions of 2.5 (highly acidic). A 
combination of solid state analytical techniques were used to characterise the crystal 
product showing that the hydrochloride salt of MABA forms large rectangular rod 
shape crystals of size greater than 500 μm with a melting point of 291 °C.  Simulated 
and experimental XRPD patterns confirmed that the salts produced experimentally are 
the same anhydrous form as those reported in the Cambridge Structural Database. 
BFDH predicted morphologies confirmed that solvent interacts with the surface 
affecting the final morphology of the salt crystals.  
 
8.3.3 Solid state characterisation of the hydrobromic salt of MABA  
 
The cooling crystallization experiment is performed using hydrobromic acid (HBr) to 
crystallise the HBr salt of MABA under low pH conditions of 1.5. FBRM results for 
the cooling crystallization experiments are shown in Figure 8.10. A single nucleation 
event is detected by a sudden increase in FBRM counts. 
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Figure 8.10. FBRM results for the cooling crystallization of MABA from ethanol 
at pH=1.5 using HBr acid  
 
 
Once nucleation occurred solid samples were filtered and dried. Solid state analyses 
of the crystals were carried out using a range of SSA techniques. Optical microscope 
image of the crystal samples are shown in Figure 8.11. The morphology of the 
crystals is diamond shaped of size greater than 50 μm. The morphology of the crystals 
are different to the raw material form of MABA which consists of needles indicating 
the possible formation of the HBr salt of MABA. 
 
         
 
Figure 8.11. Optical microscope images of MABA re-crystallized from ethanol at 
pH=1.5 using HBr acid 
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 XRPD patterns for the crystal sample of MABA re-crystallized from ethanol at 
pH=1.5 using HBr acid and the raw material form of MABA are shown in Figure 
8.12. The patterns of the two samples are significantly different providing evidence of 
the formation of the hydrobromic (HBr) salt of MABA from ethanol at pH=1.5 using 
HBr acid.     
     
Figure 8.12. XRPD pattern for the raw material form of MABA and MABA re-
crystallized from ethanol at pH=1.5 using HBr acid 
 
There is only one form of the bromide salt of MABA known to exist which is 
anhydrous (Cambridge Structural Database (Version 5.30; Allen, 2002) refcode 
DIWLIF (Cincic and Kaitner, 2008b)). The simulated XRPD pattern of the anhydrous 
bromide salt of MABA and the crystals produced experimental are shown in Figure 
8.13. These patterns are very similar indicating that the salt crystals produced 
experimentally are anhydrous.  
 
The unit cell dimensions of the bromide MABA salt crystals reported by Cinci and 
Kaitner (2008b) can be used to predict the morphology of the crystals. The predicted 
morphology of the bromide salt of MABA is rectangular plate like shaped crystals, as 
shown in Figure 8.14, which is different to the crystals produced experimentally from 
ethanol, as shown in Figure 8.11, with diamond morphology. The difference in 
morphology indicates that solvent interacts with certain crystal faces forming bonds 
and preventing growth.  
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Figure 8.13. Simulated and experimental XRPD patterns for the bromide salt of 
MABA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.14. Predicted morphology of the bromide salt of MABA using the 
BFDH method 
 
 
DSC results for crystals which nucleated from ethanol solution at pH=1.5 using HBr 
acid are shown in Figure 8.15. A single sharp peak appears at a temperature of 301°C 
which is the melting point of the HBr salt of MABA. No other peaks appear in the 
DSC results indicating a pure form of the salt.   
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Figure 8.15. DSC results for the hydrobromic (HBr) salt of MABA 
 
 
IR spectrum for HBr salt of MABA and the raw material form of MABA is shown in 
Figure 8.16. Two broad peaks at wavenumbers of 2536 and 2824 cm
-1
 appear in the 
IR pattern of the salt but not for the raw material form of MABA. These peaks are due 
to the stretching of the (O-H) group in the molecule. The presence of charges on the 
ionic HBr salt of MABA and the addition of a hydrogen bond attached to the nitrogen 
atom in the molecule may affect the intermolecular hydrogen bonding between the 
molecules resulting in variations in the stretching of the (O-H) group.  An additional 
peak appears in the IR pattern for the salt at 1674 cm
-1
 which is  due to the stretching 
of the carbonyl (C=O) group. The fingerprint region for the two forms are different 
showing three sharp peaks at wavenumbers in the range 1400-1500 cm
-1
 for the salt 
which does not appear in the IR pattern of the raw material providing evidence of 
different forms of the compound. A sharp peak at 900 cm
-1
 appears in the IR pattern 
of the salt, which is due to the out-of-plane bending of the (C-O-H) bond. The 
bending vibrations of this bond are altered in the raw material form of MABA which 
shows two peaks at wavenumbers of 885 and 918 cm
-1
. The clear differences between 
two the IR patterns provides supporting evidence that the HBr salt of MABA re-
crystallizes from ethanol at low pH conditions of 1.5.  
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Figure 8.16. IR spectrum for hydrobromic (HBr) salt of MABA and the raw 
material form of MABA 
 
DVS analysis is a useful technique for studying whether compounds are hygroscopic 
in nature and the tendency of compounds to form hydrates. DVS results for the 
hydrobromic salt of MABA are shown in Figure 8.17. As the relative humidity is 
increased from 40 to 90% there is a small increase in mass of 0.2% which suggests 
that the salt is not hygroscopic in nature. A similar behaviour occurs during the 
desorption cycle and the process is repeated during cycle 2, indicating that the salt is a 
highly crystalline solid (Hilfiker, 2006) There are no large step changes in mass or 
small and gradual changes in mass indicating that the salt does not have a tendency to 
form hydrates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.17. DVS results for the hydrobromic salt of MABA showing (a) 
isothermal plot and (b) change in mass (Dry) plot 
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Combining PAT tools with SSA techniques provides the experimental conditions 
required to produce the hydrobromic salt of MABA.  This salt forms when using an 
organic solvent (ethanol) and at very low pH conditions of 1.5 (highly acidic). A 
combination of solid state analytical techniques were used to characterise the crystal 
product showing that the hydrobromic salt of MABA forms large diamond shape 
crystals and the melting point of the salt is 291 °C. Simulated and experimental 
XRPD patterns confirmed that the crystal produced experimentally are anhydrous. 
BFDH predicted morphologies confirmed that the solvent (ethanol) interacts with the 
crystal surface affecting the final morphology. IR analysis showed that the salt affects 
the stretching and bending vibration of bonds within the molecule. DVS results 
provided evidence that the hydrobromic salt of MABA is a highly crystalline solid 
that does not have a tendency to form hydrates.  
 
 
8.3.4 Solid state characterisation of the hydrobromic salt of PABA   
 
Cooling crystallization of PABA from an ethanol solution is performed using 
hydrobromic acid to achieve a solution of pH=1. FBRM results for the cooling 
crystallization experiment are shown in Figure 8.18. A single nucleation event is 
detected as shown by a sharp increase in FBRM counts.  
 
 
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.18. FBRM results for the cooling crystallization of PABA from ethanol 
at pH=1 using HBr acid 
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Solid samples were removed from the process stream after nucleation and crystals are 
characterised using a range of solid state analytical techniques.  Optical microscope, 
scanning electron microscope and PVM images of the crystals are shown in Figure 
8.19. Crystals appear as rod shape with longest dimension of size greater than 100 μm 
and a hexagonal face. The crystals are fine particles, which are white in colour with a 
sparking tint as shown in Figure B1 of appendix B. Further solid state analysis is 
required to identify the crystal form. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.19. PABA re-crystallized from ethanol using the (a) optical microscope, 
(b) PVM image during nucleation, (c and d) SEM images  
 
XRPD patterns for the sample re-crystallized from ethanol at pH=1 using 
hydrobromic acid and the raw material form of PABA are shown in Figure 8.20. The 
XRPD pattern for the raw material shows additional peaks at angles of 9, 14 and 15. 
The clear differences between the two patterns provide evidence of the formation of 
the hydrobromic salt of PABA.  
 
There is only one form of the bromide salt of PABA known to exist which is 
anhydrous (Cambridge Structural Database (Version 5.30; Allen, 2002) refcode 
WIZLOH (Cincic and Kaitner, 2008a)). The simulated XRPD pattern of the 
anhydrous bromide salt of MABA and the crystals produced experimental are shown 
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in Figure 8.21. These patterns are very similar indicating that the salt crystals 
produced experimentally are the anhydrous form. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.20. XRPD pattern for raw material form of PABA (alpha) and PABA 
re-crystallized from ethanol at pH=1 using HBr acid  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.21. Simulated and experimental XRPD patterns for the bromide salt of 
PABA 
 
The unit cell dimensions of the bromide PABA salt crystals reported by Cinci and 
Kaitner (2008a) can be used to predict the morphology of the crystals. The predicted 
morphology of the bromide salt of PABA is rod shape crystals with a hexagonal face 
as shown in Figure 8.22. The predicted morphology is similar to the salts produced 
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experimental as shown in Figure 8.19, indicating that the solvent (ethanol) does not 
interfere with the growth of the individual crystal faces. 
 
 
 
 
 
 
 
 
Figure 8.22. Predicted morphology of the bromide salt of PABA using the BFDH 
method 
 
DSC results for the HBr salt of PABA are shown in Figure 8.23. The single sharp 
peak at 267 
o
C is the melting point of the salt. As no other peaks are detected this 
indicates a pure salt sample. 
 
DVS results for the hydrobromic salt of PABA are shown in Figure 8.24. During the 
sorption step the relative humidity is increased from zero to 90 % which results in a 
0.18 % increase in weight. The process is reversible and repeatable as shown from 
both cycles 1 and 2. As the weight % change in mass is very low this suggests the 
salts are highly crystalline solids (Hilfiker, 2006).   
 
  
 
 
 
 
 
 
                     
 
 
 
 
Figure 8.23. DSC results for the hydrobromide  (HBr) salt of PABA 
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Figure 8.24. DVS results for hydrobromic (HBr) salt of PABA showing (a) 
isotherm plot and (b) change in mass (Dry) plot  
 
IR patterns of PABA / HBr salt and the raw material form of PABA are shown in 
Figure 8.25.  PABA contains a primary amine (NH2) and a carboxylic acid (COOH) 
functional groups. Two sharp peaks appear at wavenumers of 3360 and 3459 cm
-1
 in 
the IR pattern for the raw material form of PABA, which is due to the stretching of 
the N-H bond within the primary amine functional group. Bending of the N-H bond 
occurs at wavenumbers in the range 1580 to 1650 cm
-1
.  Significant differences 
appear in the patterns of the two samples within this range indicating that the positive 
change on the amine group within the HBr salt molecule of PABA affects the N-H 
bending vibrations. Stretching of the hydrogen bond (O-H) in the carboxyl acid 
functionally group occurs at wavenumbers in the range 2500 to 3300 cm
-1
. A much 
broader peak appears in this wavelength range for the raw material compared to the 
HBr salt of PABA. There is a slight shift in the peak due to the stretching of the 
carbonyl group within the two samples.  This peak appears at wavenumber 1700 cm
-1
 
for the salt and 1658 cm
-1
 for the raw material form of PABA. The differences in the 
IR patterns for the two samples indicates that the HBr salt of PABA affects the 
bending and stretching vibrations of the  bonds within  the amine and carboxylic 
functional group. The IR pattern of the salt has not yet been reported in the literature 
providing a novelty aspect to the characterisation of the salt.  
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Figure 8.25. IR results for PABA /HBr salt and raw material form of PABA 
(alpha) 
 
Combining PAT tools with SSA techniques provided the experimental conditions 
required to produce the hydrobromic salt of PABA.  This salt forms when using an 
organic solvent (ethanol) and at very low pH conditions of 1 (highly acidic). A 
combination of solid state analytical techniques were used to characterise the crystal 
product showing that the hydrobromic salt of PABA forms large rod shape crystals 
with a hexagonal face. Simulated and experimental XRPD patterns are similar 
indicating that hydrobromic salt crystals produced experimentally are anhydrous. 
BFDH predicted morphology is the same as those produced experimentally indicating 
that the solvent (ethanol) does not interfere with the crystal surface during growth. 
DSC shows that the melting point of the salt is 267 °C. DVS analysis confirmed that 
the salt is a highly crystalline solid and IR analysis confirmed that the salt affects the 
bending and stretching vibrations of the amine and carboxyl functional groups within 
the molecules.  
8.3.5 Solid state characterisation on the hydrochloride salt of PABA  
 
PAT tools including the use of the FBRM, PVM, pH and ATR-UV/Vis spectroscopy 
are used to monitor the cooling crystallization of PABA from an ethanol solution at 
pH=2.5. Excess hydrochloric acid (HCl) was added to ensure all the PABA reacted to 
form the hydrochloric salt. UV/Vis data shows a peak absorbance for the HCl salt of 
PABA at 295 nm and for PABA (alpha form) at 301 nm as shown in Figure 9.21 
(Chapter 9).  
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Figure 8.26. FBRM results for the cooling crystallization of PABA from ethanol 
solution at pH=2.5 using HCl acid 
 
 
 
Figure 8.26 shows the FBRM and UV/Vis results for the cooling crystallization 
experiment of PABA at pH=2.5 in which excess acid (HCl) was added to the solution. 
The sharp increase in both FBRM signal and absorbance at the start of experiment is 
due to the addition of solid to solution. FBRM and UV/Vis detects two dissolution 
events. At the moment acid (HCl) is added the crystals dissolve as shown by a sharp 
decrease in the FBRM signal and sharp increase followed by a sharp decrease in 
absorbance at wavelength range 295-301 nm (see point (1) on Figure 8.26). The 
increase in absorbance is due to the PABA dissolving. As acid is added to solution 
this reacts with PABA to form the salt which has a lower absorbance within the 
wavelength range 295-301 nm compared to PABA causing the absorbance to decrease 
during acid addition. Sodium hydroxide (NaOH) is added at point (2) on Figure 8.26 
to dissolve all the crystals forming a clear solution of pH=2.5. The system is then 
cooled down at a ramp rate of 0.6 
o
C/min. FBRM detects a single nucleation event 
shown by a sharp increase in FBRM signal followed by a gradual change indicating 
additional nucleation. During nucleation the UV/Vis absorbance signal should 
decrease however there is no significant change in the absorbance within wavelength 
range 295-301 nm. This is thought to be due to a combined effect of crystals sticking 
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to the probe window, which occurs when water is present in solution, resulting in an 
increase in absorbance and as the temperature decreases the absorbance increases.  
 
A range of solid state analytical techniques including optical microscope, XRPD, 
DSC and IR spectroscopy are used to characterise the crystal product. Optical 
microscope images of the crystals from the first nucleation event show large rod 
shape crystals as shown in Figure 8.27. These images are different to the raw material, 
with needle morphology, indicating the possible formation of the salt. The crystals are 
fine particles, which are pink in colour with a sparking tint as shown in Figure B1 of 
appendix B. 
      
 
                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.27. Optical microscope image of PABA re-crystallized from ethanol at 
pH=2.5 using HCl acid  
 
Further solid state analytical techniques including DSC, XRPD and IR spectroscopy 
were used to analyse the crystals obtained from the experiment in which a single 
nucleation event occurred during cooling as shown in Figure 8.26.  
 
XRPD patterns for the raw material form of PABA and the sample obtained from the 
first nucleation event are shown in Figure 8.28.  Additional peaks appear in the 
pattern at angles 9, 14, 15 and 22 degrees for the raw material form of PABA 
compared to the sample re-crystallized from ethanol at pH=2.5, indicating clear 
structural differences between the two crystal forms and providing evidence of the 
formation of the salt. 
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Figure 8.28. XRPD pattern for the hydrochloride salt of PABA and the raw 
material PABA (alpha form) 
 
There is only one form of the chloride salt of PABA known to exist which is an 
anhydrous form (Cambridge Structural Database (Version 5.30; Allen, 2002) refcode 
PAMBZA (Colapietro and Domenicano, 1980)). The simulated XRPD pattern of the 
anhydrous bromide salt of MABA and the crystals produced in the experiment are 
shown in Figure 8.29. These patterns are very similar indicating that the salt crystals 
produced experimentally are the anhydrous forms.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.29. Simulated and experimental XRPD patterns for the chloride salt of 
PABA 
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The unit cell dimensions of the chloride PABA salt crystals reported by Colapietro 
and Domenicano (1980) can be used to predict the morphology of the crystals. The 
predicted morphology of the chloride salt of PABA is rod shape crystals with a 
hexagonal face as shown in Figure 8.30. The predicted morphology is similar to the 
salts produced in the experiments as shown in Figure 8.27, indicating that the solvent 
(ethanol) does not interfere with the growth of the individual crystal faces.  
 
Figure 8.30. Predicted morphology of the chloride salt of PABA using the BFDH 
method 
 
Figure 8.31 shows the DSC results for the crystal sample obtained from the cooling 
crystallization experiment of PABA in ethanol at pH=2.5 using HCl acid. A single 
sharp peak occurs at a temperature of 235 °C, which is thought to be due to the 
melting point of the hydrochloride salt of PABA. The enthalpy of melting of the salt 
is 515 J/g.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.31. DSC results for hydrochloride (HCl) salt of PABA 
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Figure 8.32 shows the IR data for the hydro-chloride salt of PABA and the raw 
material PABA (alpha form). Figure 8.31 shows two peaks at wavenumbers 3459 and 
3360 cm
-1
 which are observed in both patterns. These peaks are due to the stretching 
of the amine group (-NH2). The IR pattern for the raw material shows an additional 
peak at wavenumber 3220 cm
-1
 which is thought to be due to the stretching on the     
(-O-H) group with hydrogen bonds present within the crystal (Stuart et al., 1998). 
This peak is not observed in the salt as ionic bonds are present between the molecules 
of the salt due to charges on the molecules. Additional peaks appear in the spectrum  
of the salt at wavenumbers 2850 and 2599 cm
-1
 indicating a difference in the 
stretching of the (–O-H) bond of the carboxylic group of the two samples (Stuart et 
al., 1998). A sharp peak at wavenumber 1700 cm
-1
 observed in the spectrum for the 
salt is due to the stretching of the carbonyl group.  Figure 8.31 shows the fingerprint 
region within wavenumber range 1500-600 cm
-1
 which is different for the two 
samples indicating the presence of different crystal forms. Bending vibration of the (–
N-H) group in the amine occurs at wavenumbers within the range 1630-1500 cm
-1 
(Stuart et al., 1998). Two peaks at 1505 and 1550 cm
-1
 are only observed in the peak 
pattern of the salt providing evidence that the formation of the salt affects these 
vibrations. The clear differences between the bending and stretching vibrations within 
the two samples indicate the formation of the HCl salt of PABA. 
 
  
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.32. IR results for the HCl salt of PABA and the raw material PABA 
(alpha) 
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Combining PAT tools with SSA techniques provided the experimental conditions 
required to produce the hydrochloric salt of PABA.  This salt forms when using an 
organic solvent (ethanol) and at very low pH conditions of 2.5 (highly acidic). A 
combination of solid state analytical techniques were used to characterise the 
crystalline product showing that the hydrochloric salt of PABA forms large rod shape 
crystals. Simulated and experimental XRPD patterns confirm that the hydrochloric 
salt of PABA produced experimentally is the anhydrous form. BFDH predicted 
morphology is the same as the experimentally produced crystals indicating that the 
solvent does not interfere with the crystal surface during crystal growth. The melting 
point of the salt is 235 °C. IR patterns provided evidence that the salt affects the 
stretching and bending vibrations of the amine and carboxyl functional groups. Also 
an addition peak appears in the IR pattern for the raw material which is due to the 
stretching of the hydrogen (O-H) bond. This peak would not be expected to appear in 
the IR pattern for the salt as this contains ionic bonds, provided evidence of the 
formation of the HCl salt of PABA. 
 
8.3.6 Structural comparison of the bromide and chloride salts of 
PABA 
 
The bonding arrangement between individual atoms within a molecule affects the 
structure of the crystal form resulting in crystals with specific physico-chemical 
properties, such as solubility, stability, dissolution rate and bioavailability. 
Crystallizing the compound with the desired properties is important to obtain a quality 
product. Previous reported literature (Cincic and Kaitner, 2008a) states that the 
chloride and bromide salts of PABA are isostructural indicating that the structures are 
very similar in which the bromide ions replace the chloride ions in the bromide salt. 
However this statement was based on studies which did not take into account all the 
hydrogen bonds and more up to date literature reported different values of bond 
angles resulting in variations in the unit cell dimensions (Cincic and Kaitner, 2008a). 
This is an important parameter in crystal structure determination (Byrn, 1982). XRDs 
of the chloride and bromide salts of PABA are shown in Figure 8.33 showing clear 
differences in the peak positions, indicating that the chloride and bromide salts of 
PABA are not isostructural. 
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Figure 8.33. Comparison of XRPD patterns for the chloride and bromide salts of 
PABA 
 
Previous literature (Cincic and Kaitner, 2008b) reported the chloride and bromide 
salts of MABA are also isostructrual but more up to date literature has reported a 
different sequence in unit cell dimensions (Cincic and Kaitner, 2008b). XRPD results 
for the chloride and bromide salts of MABA are shown in Figure 8.34. Clear 
differences in the peak positions indicate again that the two salts are not isostructural.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.34. Comparison of XRPD patterns of the chloride and bromide salts of 
MABA 
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8.4 Acidic salts of PABA formed by precipitation 
8.4.1 Introduction 
 
Acids are classified into groups according to the number of hydrogen atoms available 
for dissociation. Monoprotic acids can dissociate one hydrogen atom, diprotic can 
dissociate two and triprotic can dissociate three hydrogen atoms resulting in the 
formation of a number of salts. So far, in chapter 8.2, research has focused on the 
crystallization of acidic salts of PABA using strong monoprotic acid. This section 
focuses on the crystallization of salts of PABA using diprotic and triprotic acids.  
Crystallization experiments are performed using sulphuric acid (H2SO4) to crystallize 
the sulphate salt of PABA and phosphoric acid to crystallize the phosphate salt of 
PABA. Crystallization in these cases occurs by a process known as precipitation due 
to the formation of insoluble salts in the organic solvent ethanol. A range of solid state 
analytical techniques including the optical microscopy, scanning electron microscopy, 
XRPD, DSC, solid state IR spectrum and DVS are used to characterise the crystal 
product.   
 
8.4.2 Solid state characterisation of the sulphuric salt of PABA  
 
Crystallization experiments involved adding sulphuric acid to a PABA/ethanol 
solution. At the moment acid is added to the solution, crystals precipitate from 
solution. The pH of the solution as crystallization occurs is 1.2. Sulphuric acid is a 
strong diprotic acid and can dissociate two hydrogen atoms resulting in the possible 
formation of two salts. Optical and scanning electron microscope images of crystals 
obtained from the precipitation experiment in which PABA re-crystallized from 
ethanol/H2SO4 solution are shown in Figure 8.35. Optical microscope images of 
crystals obtained from mobile slurry show rod shape morphology. Vacuum filtration 
results in the crystals agglomerating together as shown by the SEM images in Figure 
8.35 (b). The morphology of the crystals is different to the needle morphology of the 
raw material form of PABA indicating the presence of a different form. Further solid 
state analysis is required to characterise the crystal product.  
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Figure 8.35. PABA re-crystallized from an ethanol/ H2SO4 solution showing (a) 
optical microscope image from mobile slurry and (b) scanning electron 
microscope image after filtration 
 
XRPD patterns for the sample re-crystallized from an ethanol/H2SO4 solution at    
pH=1.2 and the raw material form of PABA are shown in Figure 8.36. The XRPD 
pattern for the raw material form of PABA shows additional peaks at angles of 14, 15 
and 22. The sample re-crystallized from ethanol/H2SO4 solution at pH=1.2 shows an 
additional peak in the XRPD pattern at an angle of 5. The differences in XRPD 
patterns of the two samples indicate structural differences providing evidence of the 
formation of the sulphuric salt of PABA from the precipitation experiment.  
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.36. XRPD patterns for sample re-crystallized from ethanol/H2SO4 
solution at pH=1.2 and the raw material form of PABA (alpha) 
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There are two anhydrous forms of the sulphate salt of PABA known to exist 
(Cambridge Structural Database (Version 5.30; Allen, 2002) with refcodes RICDOX 
and WEPVET. The molecular formula of the anhydrous form (RICDOX) is 
C7H8NO2+.HO4S
-
 whereas the molecular formula of the anhydrous form (WEPVET) 
is 2C7H8NO2+.SO4
2-
. The simulated XRPD pattern of the anhydrous sulphate salt of 
PABA (refcode: WEPVET (Athimoolam and Natarajan, 2006)) and the crystals 
produced experimentally are shown in Figure 8.37. These patterns are very similar 
indicating that the salt crystals produced experimentally are anhydrous form with 
refcode WEPVET. 
  
        
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.37. Simulated and experimental XRPD pattern for the sulphate salt of 
PABA 
 
The unit cell dimensions of the sulphate salt of PABA crystals reported by 
Athimoolam and Natarajan, (2006) can be used to predict the morphology of the 
crystals. The predicted morphology of the sulphate salt of PABA is rod shape crystals 
with a diamond shape point at both ends of the crystal as shown in Figure 8.38. The 
crystals produced experimentally were crystallized from ethanol and those reported by 
Athimoolam and Natarajan, (2006) were crystallized from water. The predicted 
morphology is similar to the salts produced experimentally as shown in Figure 8.35 
but those produced experimentally are longer and thinner. The slight differences in 
morphology indicate that the solvent interacts with certain crystal faces affecting the 
growth.  
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Figure 8.38. Predicted morphology of the sulphate salt of PABA using the BFDH 
model 
 
DSC results for the sulphuric salt of PABA are shown in Figure 8.39. A single sharp 
endothermic peak occurs at a temperature of 235 °C which is the melting point of the 
salt. No other peaks are detected in the DSC pattern indicating the formation of the 
pure salt.  
 
  
                          
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.39. DSC results for the sulphuric salt of PABA 
 
 
IR patterns for the sulphuric salt of PABA and the raw material form of PABA are 
shown in Figure 8.40. Two additional sharp peaks appear at wavenumbers of 3459 
and 3360 cm
-1
 in the pattern for the raw material, which is due to the (N-H) bending 
in the amine group. Stretching of the carbonyl group (C=O) occurs at wavenumbers in 
0 
Temperature ( 
o
C )  
H
e
a
t 
fl
o
w
 E
n
d
o
 u
p
 (
 m
W
 )
 
5 
10 
15 
20 
25 
140 100 60 180 220 260 300 
30 
235 
o
C 
20 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates 
 
181 Chapter 8.  Solid state characterisation of salts of ABA isomers 
2011 
the range 1650-1830 cm
-1
 (Stuart et al., 1998). A slight shift in the stretching of the 
carbonyl group occurs between the two samples. For the salt this peak appears at 
wavenumber of 1688 cm
-1
 and for the raw material it appears at 1658 cm
-1
. The 
fingerprint region of the IR spectrum is in the range of 600 to 1500 cm
-1
. Different 
forms of a compound can be identified due the differences in the finger region of the 
IR spectrum. The fingerprint region of the salt shows a large peak at 1020 cm
-1
 which 
does not appear in the IR pattern of the raw material. This peak is a characteristic 
peak for the sulphuric salt of PABA. 
 
 
 
 
 
 
 
                    
               
 
 
 
 
Figure 8.40. IR results for the sulphuric salt of PABA and the raw material form 
of PABA 
  
Crystal samples from the precipitation experiment are analysed using DVS to 
determine whether the sulphuric salt of PABA is hygroscopic in nature and to 
examine the tendency of the salt to form hydrates. DVS results for the sulphuric salt 
of PABA are shown in Figure 8.41. As the relative humidity is increased from 0 to 
90% there is a small increase in mass of 0.45% indicating that the salt is not 
hydroscopic. The compound‟s affinity for moisture sorption is repeatable and 
reversible as shown by the decrease in mass of 0.45% as the RH is decrease from 90 
to 0 %.  This type of behaviour is typically for highly crystalline solids (Hilfiker, 
2006). The sulphuric salt of PABA does not form stoichiometric hydrates as there are 
no large step changes in the DVS data.  
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Figure 8.41. DVS results for sulphuric salt of PABA showing (a) isothermal plot 
and (b) change in mass (Dry) plot 
 
A combination of solid state analytical techniques was used to characterise the 
sulphuric salt of PABA. XRPD patterns and IR spectrum provided evidence of the 
formation of the sulphuric salt of PABA. Simulated and experimental XRPD patterns 
for the sulphuric salt of PABA are similar providing evidence that the crystals 
produced experimentally are anhydrous. The crystals produced experimentally are 
similar to those predicted using the BFDH model but are longer in length indicating 
that the solvent (ethanol) interferes with certain crystal faces affecting growth. The 
melting point of the salt is 235 °C as shown from the DSC analysis. DVS results 
showed that the sulphuric salt of PABA does not form a hydrate when exposed to a 
maximum relative humidity of 90% and that the salt is a highly crystalline solid.  
8.4.3 Solid state characterisation of the phosphoric salt of PABA   
 
The choice of acid used to lower the pH of solution and form the acidic salt is 
important as weak acids do not fully ionise in solution and therefore are less likely to 
form a salt. However these acids may produce salts that have properties which are 
more desirable than other forms of salts. Therefore a full investigation and 
characterisation of salts is important before deciding the most suitable candidate for 
the next stages of manufacture from laboratory to pilot plant scale production.  
Literature data (Haynes et al., 2005) reported 2874 known hydrochloric acid salts, 
1403 hydrobromic acid salts, 161 sulphuric acid salts and 134 phosphoric acid salts of 
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pharmaceutical compounds. Crystallization experiments are performed using PABA 
and phosphoric acid to investigate the likelihood of salt formation using a weak acid. 
Solid state analytical techniques are used to characterise the phosphoric salt of PABA 
and to determine whether crystallizing a weak salt gives more suitable characteristics, 
such as morphology, for drug manufacturing.  
  
Crystallization experiments involved forming a mobile slurry solution of PABA in 
ethanol and then adding phosphoric acid to achieve a low pH of the solution. The size 
of the crystallization vessel used is 750 mL and a stirrer speed of 300 rpm was used.  
Excess moles of phosphoric acid are added to the solution compared to the moles of 
PABA to increase the likelihood of the formation of the pure salt. At the moment the 
acid is added to the solution, crystallization occurs by a process known as 
precipitation. Optical and scanning electron microscope images of the crystal samples 
are shown in Figure 8.42.  Images show rod shape crystals that form agglomerates due 
to precipitation. These images are different to the raw material form of PABA (alpha) 
which has needle morphology. Crystallization occurred before all the raw material 
dissolved and therefore these crystals act as a seed which is thought to have an 
influence on the morphology of the crystals produced. Further solid state analysis is 
performed on the crystal sample to identify the crystal form.  
 
          
 
Figure 8.42. Crystal images of PABA re-crystallized from ethanol/H3PO4 
solution at pH=3.3 showing (a) optical microscope images and (b) scanning 
electron microscope  
 
DSC analysis was performed on the crystal sample from the precipitation experiment 
and the results are shown in Figure 8.43. 
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Figure 8.43. DSC results for the sample re-crystallized from ethanol solution at 
pH=3.3 using phosphoric acid  
 
A sharp peak appears at a temperature of 205 °C which is thought to be the melting 
point of the phosphoric salt of PABA. Crystals precipitated from a mobile slurry 
solution in which not all of the raw material (PABA) had dissolved and therefore a 
small peak at 189 °C appears in the DSC results which is the melting point of the 
alpha form of PABA.  
 
The crystallization experiment is repeated in a beaker using a magnetic stirrer to 
achieve mixing. All of the raw material (PABA) dissolved before acid is added to the 
solution. Optical microscope images of the crystals are shown in Figure 8.44. The 
morphology of the crystals is plate like, but a few rod shaped crystals also form. 
Mixing with a magnetic stirrer created a vortex resulting in poor mixing. This affects 
the mass transfer which can result in crystallization of the same form but with a 
different morphology due to the high local supersaturation values. An alternative 
explanation to the different crystal morphologies obtained from the reactor and beaker 
precipitation experiments could be due to the formation of different phosphoric salts 
of PABA. Phosphoric acid can dissociate and donate three hydrogen ions to form 
three different salts. Insufficient mixing in the beaker experiment can result in 
localised regions of high concentration of acid forming the higher form of the salt 
(one hydrogen ion dissociates to form ( 
-
H2PO4 )). Further solid state analysis 
involving the use of DSC and XRPD is required to characterise the crystals produced.  
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Figure 8.44. Optical microscope image of crystals obtained from the beaker 
precipitation experiment of PABA in an ethanol/H3PO4 solution in which all the 
raw material dissolved 
 
DSC results for the sample of crystals re-crystallized from a clear ethanol/H3PO4 
solution (beaker experiment) are shown in Figure 8.45. Fluctuations in peaks occur 
within the temperature range of the melting point of the raw material (189 °C) and the 
melting point of the phosphoric salt of PABA (205 °C). The fluctuation in peaks 
signifies decomposition. The sharp peak at 257 °C is thought to be due to the melting 
point of the decomposition products.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 8.45. DSC results for the sample re-crystallized from a clear 
ethanol/H3PO4 solution 
 
100 μm 
0
10
20
30
40
50
60
70
80
90
100
0 50 100 150 200 250 300
H
e
a
t 
fl
o
w
 E
n
d
o
 u
p
 (
m
W
)
Temperature ( oC ) 
PABA/H3PO4 (All dissolved)
257
o
C 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates 
 
186 Chapter 8.  Solid state characterisation of salts of ABA isomers 
2011 
XRPD patterns for the raw material form of PABA and the compound re-crystallized 
from the beaker experiment (all of the raw material dissolved) and reactor experiment 
(raw material present in the slurry) are shown in Figure 8.46.  The XRPD pattern of 
the raw material is significantly different to the patterns obtained from the beaker and 
reactor precipitation experiments. Additional peaks in the raw material pattern appear 
at angles of 9, 14 and 15. The two XRPD patterns of samples from the precipitation 
experiments with phosphoric acid are very similar, suggesting the same crystal salt 
form. This provides evidence that the difference in morphology from the beaker and 
reactor experiment is due to the difference in mixing conditions and not the formation 
of different salts.  
              
 
Figure 8.46. XRPD patterns for the crystal samples obtained from the 
precipitation experiments of PABA in an ethanol/H3PO4 solution and the raw 
material form of PABA (alpha)  
 
 
There are two forms of the phosphate salt of PABA known to exist including a mono-
hydrate and an anhydrous form (Cambridge Structural Database (Version 5.30; Allen, 
2002). The simulated XRPD pattern of the anhydrous phosphate salt of PABA 
(refcode: RIBWAB (Benali-Cherif et al., 2007)) and the crystals produced 
experimentally are shown in Figure 8.47. These patterns are very similar indicating 
that the salt crystals produced experimentally are anhydrous. 
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Figure 8.47. Simulated and experimental XRPD pattern for the phosphate salt of 
PABA 
 
The unit cell dimensions of the anhydrous phosphate salt of PABA crystals reported 
by Benali-Cherif et al., (2007) can be used to predict the morphology of the crystals. 
The predicted morphology of the anhydrous phosphate salt of PABA is plate like 
shaped crystals with a hexagonal face as shown in Figure 8.48. The crystals produced 
experimentally were crystallized from ethanol and those reported by Benali-Cherif et 
al., (2007) were crystallized from water. The predicted morphology is similar to the 
salts produced from the precipitation beaker experiment as shown in Figure 8.44 but 
those produced experimentally form thinner plates and are irregular. The slight 
differences in morphology indicate that the solvent interacts with certain crystal faces 
affecting the growth.  
 
Solid state IR analysis is performed on the phosphoric salt of PABA and the raw 
material form of PABA. IR results are shown in Figure 8.49. Two additional peaks 
appear at wavenumbers of 3360 and 3459 cm
-1
 in the IR pattern of the raw material 
form of PABA, which is due to the stretching of the (N-H) bond in the amine group. 
The bending vibrations of the (N-H) bond occur at wavenumbers within the range 
1580 to 1650 cm
-1
. The peak pattern at this wavenumber varies for the two samples 
indicating that the formation of the salt affects the bending vibrations of the (N-H) 
bond.  The fingerprint regions of the two samples are completely different indicating 
the presence of two different forms. The salt shows additional peaks at wavenumbers 
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around 1000 cm
-1
 and a sharp peak at wavenumber 1214 cm
-1
 which is characteristic 
for the phosphoric salt of PABA. 
 
 
Figure 8.48. Predicted morphology of the anhydrous phosphate salt of PABA 
using the BFDH model 
 
 
 
.   
           
 
 
 
 
 
 
 
 
    
 
 
 
Figure 8.49. IR spectrum of the phosphoric salt of PABA and the raw material 
form of PABA 
 
 
A combination of solid state analytical techniques is used to characterise the 
phosphoric salt of PABA. DSC results showed that the melting point of the salt is  
205 °C. XRPD patterns confirmed that the same form of phosphoric salt of PABA  
can crystallize with different morphologies due to differences in mixing conditions. 
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Simulated and experimental XRPD patterns for the phosphoric salt are very similar 
indicating the crystals produced experimentally are anhydrous. The predicted 
morphology of the crystals, using the BFDH model, is similar to those produced 
experimentally but thinner and more irregular crystals are produced from the beaker 
experiment, indicating that solvent (ethanol) interferes with the crystal surface during 
growth. IR analysis showed that the phosphoric salt of PABA affects the bending 
vibrations on the (N-H) bond in the amine group and a characteristic peak appears 
around 1000 cm
-1
 and 1214 cm
-1
 for the salt. A combination of SSA techniques 
confirmed a weak acid such as phosphoric acid can be used to form salts of PABA.   
 
8.5 Basic salts of PABA formed by evaporation  
8.5.1 Introduction 
 
The production of alkali salts requires crystallizing under high pH conditions above a 
value of 8 in which the –COO- group is 100% ionised. The presence of the –COO- 
group increases the likelihood of hydrate salt formation by 35% (Infants et al., 2007). 
The size of vessel that is used in these studies to carry out cooling crystallization 
experiments is 750 mL which can hold a total of four PAT tools including the FBRM, 
pH, ATR-UV/Vis and PVM probe. As the solubility of the compound is very high at 
pH values above 8, operating at the 750 mL scale would require very large amounts of 
materials for a cooling crystallization experiment to be successful. Due to this reason 
an alternative method of evaporative crystallization in a beaker is used to crystallize 
the hydrated sodium and potassium salts of PABA. This required forming an 
undersaturated solution of PABA in ethanol at high pH values of 8.1 to 10.7 by 
adding the desired alkali and then the beaker was left in a fume cupboard for solvent 
evaporation. Crystal samples were analysed using a range of solid state analytical 
techniques to characterise the alkali salts. 
8.5.2 Hydrated forms of the sodium salt of PABA  
 
Optical microscope images of the sodium salt of PABA are shown in Figure 8.50. The 
morphology of the crystals is rod shape with a diamond shape end which is very 
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different to the raw material form of PABA of needle morphology. The difference in 
morphology provides evidence of the formation of a salt.   
 
   
 
 
                                        
 
 
 
 
Figure 8.50. Optical microscope image of PABA re-crystallized from ethanol at 
pH=10.7 using NaOH  
 
XRPD patterns for the sample re-crystallized from ethanol solution at pH=10.7 and 
the raw material form of PABA (alpha) are shown in Figure 8.51. The raw material 
shows an additional sharp peak at an angle of 15 and the sample re-crystallized from 
ethanol at pH=10.7 shows additional peaks at angles 16-18, 27 and 33.  The clear 
difference between the two XRPD patterns indicates the formation of the sodium salt 
of PABA from the evaporation crystallization experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.51. XRPD pattern for the sodium salt of PABA and the raw material 
form of PABA 
 
There is only one form of the sodium salt of PABA known to exist which is a 
pentahydrate (Cambridge Structural Database (Version 5.30; Allen, 2002) refcode 
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NAABZH (Salas-Cimingo, 1968a)). The simulated XRPD pattern of the pentahydrate 
sodium salt of PABA and the crystals produced experimentally are shown in Figure 
8.52. These patterns are different indicating that the salt crystals produced 
experimentally are a different hydrate form to the pentahydrate.  
 
DSC results for the sodium salt of PABA are shown in Figure 8.53. Four endothermic 
peaks occur at temperature of 67 °C, 118 °C, 328 °C and 396 °C. The first peak at    
67 °C is thought to be due to moisture of the surface of the crystals. The peak at     
118 °C is due to dehydration of a hydrate. As this peak is wide it is thought that this 
may consist of two separate peaks indicating the formation of two hydrates. Repeats 
of the DSC showed two peaks occurring within this temperature range at 120 °C and 
136 °C.  The peak at 328 °C is the melting point of the anhydrous sodium salt of 
PABA which has not yet been reported in the literature.  Previous studies on sodium 
benzoate, which contains the sodium ion showed a very high melting point of 440 °C. 
A higher melting point of 328 °C is observed for the sodium salt of PABA compared 
to other salts, which is thought to be due to the presence of the sodium ions. Heating 
the crystal sample up to a very high temperature resulted in decomposition as shown 
by a peak at 396 °C. Black solid deposits form on the outside of the DSC pan 
providing further evidence of decomposition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.52. Simulated and experimental XRPD pattern for the sodium salt of 
PABA 
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Figure 8.53. DSC results for the sodium salt of PABA 
 
TGA is used to determine the formation of hydrate or solvates of a compound from 
the weight decrease in mass as the crystals are heated. TGA results for the sodium salt 
of PABA are shown in Figure 8.54. A large weight decrease of 33.5 % occurs as the 
system is heated to 110 
o
C which is due to water removal from the internal structure 
of the crystal.  DSC and DVS results confirmed that there are two hydrate forms of 
the sodium salt of PABA, which have close stability. Due to this reason it is thought 
that the loss in water as shown by a single step in the TGA results represents the loss 
of water from both hydrates so the final form is anhydrous. The molecular ratio of 
sodium salt to water is calculated from the weight loss which gives a molecular ratio 
of salt to water of 1:4.4 for the highest hydrated form of the salt. A sample calculation 
can be found in Appendix E. These results support the prediction from the simulated 
XRPD results shown in Figure 8.52, which states that a different hydrate form other 
than the pentahydrate sodium salt of PABA crystallizes from ethanol solution. 
 
DVS is a useful tool in determining whether the material under investigation is 
amorphous, highly crystalline or the type of hydrate formation (channel or 
stoichiometric hydrate) by the extent of water uptake and how significant the mass 
changes with respect to RH. A large step change in mass indicates the formation of a 
stoichiometry hydrate whereas a small and gradual increase in mass indicates the 
formation of a channel hydrate (Hilfiker, 2006). DVS results for the sodium salt of 
PABA re-crystallized from ethanol solution are shown in Figure 8.55. These results 
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Figure 8.54. TGA results for the sodium salt of PABA 
 
show two step changes in mass as the RH is increased above 30-50% and 80%. The 
first step change as represented by point (1) on Figure 8.55 (a and b) is due to the 
formation of a stoichiometric metal co-ordinated hydrate. This type of behaviour is 
observed in other sodium salt compounds (Stephenson and Diseroad, 2000). The 
second step change at 80% relative humidity (see point (2) on Figure 8.55 (a and b))  
is thought to be due to layers of water building on the surface of the crystal. At high 
relative humidity of 80% it is assumed that the crystals deliquesce. During both 
sorption and desorption cycles there is a small and gradual increase in mass between 
the two step changes as shown by point (3) in Figure 8.55 (b) which is due to sharp 
changes in relative humidity.  
 
For the first step change the molecular ratio of sodium salt of PABA to water is 
calculated from the change in mass assuming that zero mass % indicates the 
anhydrous form of the compound. A sample calculation is shown within Appendix E. 
At point 1 on Figure 8.55 (b) the molecular ratio of sodium salt of PABA to water is 
calculated as 1:11 indicating the formation of a stochiometric metal co-ordinated 
hydrate. 
 
As the RH is decreased below 40% during the desorption cycle there is a step change 
in mass as shown by point 4 to 5 on Figure 8.55 (b). This step change is thought to be 
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due to the formation of a hydrate. The molecular ratio of sodium salt of PABA to 
water is 1:2.4 indicating the formation of a channel hydrate. As the molecular ratio of 
salt to water is lower than values obtained from TGA analysis this hydrated salt is 
thought to be the formation of the lower hydrate state as represented with a 
dehydration temperature of 118 °C from the DSC analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.55. DVS results for sodium salt of PABA showing (a) isothermal plot 
and (b) change in mass (Dry) plot  
 
 
A combination of SSA techniques including the use of the optical microscope, XRPD, 
DSC, DVS and TGA were used to characterise the crystalline product obtained from 
the evaporation experiment of PABA in an ethanol/NaOH solution of pH=10.7. 
XRPD patterns provided evidence of the formation of the sodium salt of PABA. The 
melting point of the anhydrous sodium salt of PABA is provided from DSC data 
giving a value of 328 °C. DSC, DVS and TGA confirmed the formation of two 
channel hydrate forms of the sodium salt of PABA from the evaporation experiment. 
The highest hydrate state has a molecular ratio of salt to water of 1:4.4 and lower 
hydrate state of 1:2.4. The sodium salt reported from the Cambridge Structural 
Database is a pentahydrate indicating that the lower hydrate states crystallized from 
ethanol by evaporation are new reported forms. DVS confirmed the formation of a 
higher stoichiometric hydrate state (molecular ratio salt to water of 1:11) when 
exposed to high RH showing the high tendency of the sodium salt of PABA to form 
hydrates.   
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8.5.3 Hydrated forms of potassium salt of PABA 
 
Optical microscope image of PABA re-crystallized from ethanol/KOH solution of 
pH=8.1 is shown in Figure 8.56. The image show crystals of rod shape morphology 
with a diamond shaped end. The sizes of the crystals are greater than 300 μm in 
length. Crystals of this shape and size are suitable candidates for minimising the 
problems in further downstream processing. The morphology of the crystals is 
different to the raw material form of PABA which consists of long needles. Further 
solid state analysis is required to identify the crystal form.  
 
                             
                                      
 
 
 
 
 
 
 
 
 
Figure 8.56. Optical microscope image of PABA re-crystallized from ethanol at 
pH=8.1 using KOH 
 
XRPD patterns of the sample re-crystallized from ethanol/KOH solution at pH=8.1 
and the raw material form of PABA (alpha) are shown in Figure 8.57. The raw 
material form of PABA shows additional angles in the XRPD patterns at values of 9, 
14-15, 22 and 30. The clear difference between the two patterns provides evidence of 
the formation of the potassium salt of PABA. This compound is used in fibrotic skin 
disorders (Swislocka et al., 2006).  The XRPD for the potassium salt of PABA has not 
yet been reported in the literature.  
 
There is only one form of the potassium salt of PABA known to exist, which is a     
tri-hydrate (Cambridge Structural Database (Version 5.30; Allen, 2002) refcode 
KAMBZH (Salas-Cimingo, 1968b)). The simulated XRPD pattern of the tri-hydrate 
potassium salt of PABA and the crystals produced experimental are shown in Figure 
5.58. These patterns are different indicating that the salt crystals produced 
experimentally are a different hydrate form to the tri-hydrate. 
100 μm 
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Figure 8.57. XRPD patterns for the potassium salt of PABA and the raw 
material form of PABA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.58. Simulated and experimental XRPD patterns for the potassium salt 
of PABA 
 
 
DSC results for the potassium salt of PABA are shown in Figure 8.59. Three 
endothermic peaks appear at temperatures of 44 °C, 105 °C and 205 °C.  The peak at 
44 °C is thought to be due to moisture on the surface of the crystals. Repeats of DSC 
analyses showed that the broad peak at 105 °C consisted of two peaks indicating the 
dehydration of two hydrate forms. The peak at 205 °C could be the dehydration of a 
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third hydrate state or the melting of anhydrous potassium salt of PABA. As the 
temperature is low compared to the melting point of other salts the peak at 205 °C is 
thought to be due to dehydration of a third hydrated form of the potassium salt of 
PABA.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                        
      Figure 8.59. DSC results for the potassium salt of PABA 
 
Solid state analyses including DVS and TGA were performed on the crystal samples 
re-crystallized from an ethanol/KOH solution to study the number and type of hydrate 
formation of the potassium salt of PABA.  
 
TGA analysis is a useful tool in identifying the formation of hydrates and the type of 
hydrate by the extent of weight loss and the temperature range over which this occurs. 
Step changes in weight loss indicate the presence of more than one form of hydrate. 
TGA results for the potassium salt of PABA are shown in Figure 8.60. Two step 
changes in weight loss occur over the temperature range 20 to 210 °C.  A 20.26 % 
weight loss occurs for the first step change until a temperature of 110 °C is reached. 
This weight loss is thought to represent the loss in weight of the two highest hydrated 
forms of the potassium salt of PABA. This prediction correlates with the results 
obtained from DSC analysis, which provided evidence of the dehydration of two 
hydrates at this temperature range. A second step change occurs over the temperature 
range of 160 to 210 °C showing a weight loss of 2.6%. The loss in weight is thought 
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to be due to the third hydrate state of the potassium salt of PABA. These results 
support the results obtained from DSC analysis, which showed a peak at 205 °C 
representing dehydration of a hydrate. From the % loss in weight the molecular ratio 
of salt to water is calculated for the lowest and highest hydrated forms of the salt. A 
sample calculation can be found in Appendix E. The lowest hydrated form of the 
potassium salt of PABA has a molecular ratio of salt to water of 1:0.26 indicating the 
formation of a channel hydrate and the highest hydrated form has a molecular ratio of 
salt to water of 1:3 (tri-hydrate). The hydrated form of the crystals reported by Salas-
Cimingo (1968b) is a tri-hydrate. However, the simulated and experimental XRPD 
patterns as shown in Figure 8.58 are different, indicating that a different polymorphic 
form of the tri-hydrate crystallizes from ethanol solution (Tian et al., 2010).   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.60. TGA results for the potassium salt of PABA 
 
DVS results for the potassium salt of PABA are shown in Figure 8.61. At point 1 on 
Figure 8.61 there is a step change in mass indicating the formation of a hydrate. The 
molecular ratio of the potassium salt of PABA to water is calculated from the weight 
increase during the step change assuming that zero % in mass indicates the anhydrous 
form of the salt. A sample calculation can be found in Appendix E. The molecular 
ratio of the potassium salt to water is 1:1.2. This value is in between the lowest and 
highest hydrated form calculated from TGA analysis confirming that this hydrate is 
the intermediate meta-stable hydrate form of the salt. At point 2 on Figure 8.61 there 
is a step change during the desorption cycle indicating the formation of a 
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stochiometric hydrate which forms at 60% relative humidity. The molecular ratio of 
potassium salt of PABA to water is 1:7. The step changes at points 3 and 4 on Figure 
8.60 are thought to be due to water molecules building up on the surface of the crystal 
and not due to the formation of higher hydrates, as the system‟s mass does not reach a 
steady state before the relative humidity increases further.  DVS analysis confirms 
that the potassium salt of PABA has a high tendency to form hydrates.  
 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         Figure 8.61. DVS results for the potassium salt of PABA 
 
A wide range of solid state analytical techniques including the use of the optical 
microscope, XRPD, DSC, TGA and DVS were used to characterise the crystal 
samples re-crystallized from an ethanol/KOH solution by evaporation. XRPD 
confirmed the formation of the potassium salt of PABA. Microscopic images showed 
large salt crystals that would minimise the problems in downstream processing. DSC 
and TGA provided evidence of the formation of three hydrate forms of the potassium 
salt of PABA. The molecular ratio of the potassium salt to water for the three hydrates 
starting from lowest to highest hydrate is 1:0.26, 1:1.2 and 1:3 (tri-hydrate) 
respectively. The tri-hydrate produced experimentally from evaporation in ethanol is a 
different polymorphic form to the tri-hydrate reported in the Cambridge Structural 
Database, as shown from the differences in XRPD patterns, providing evidence of a 
new undiscovered tri-hydrate. The DVS confirmed that the potassium salt of PABA 
has a tendency to form higher hydrates.  
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8.6 Conclusions  
 
A range of acidic and basic salts of PABA and MABA were produced using the 
method of evaporation, precipitation and cooling crystallization. The most suitable 
method for producing the salts is cooling crystallization which is a slow controlled 
process resulting in large crystals and prevents the formation of agglomerates, which 
was observed in the case of the precipitation experiments. PAT tools used to monitor 
the cooling crystallization experiments include the FBRM, ATR-UV/Vis, PVM and 
pH probes. Combining these tools enables the crystallization process to be designed to 
produce the desired form of the compound. Strong monoprotic acids including HCl 
and HBr were used to crystallize salts by cooling crystallization whereas the strong 
diprotic acid (H2SO4) and the weak triprotic acid (H3PO4) resulted in the salt crystals 
precipitating from solution. Acidic salts were found to crystallize at pH values below 
3 and when using an organic solvent (ethanol). Strong and weak acids were used in 
each experiment to see whether the strength of the acid has any affect of the formation 
of salts. Hydrobromic salts of PABA and MABA form highly crystalline solids that 
are not hygroscopic in nature and do not have a tendency to from hydrates. 
Phosphoric acid which is the weakest of acids used in these experiments resulted in 
the crystallization of salts. Variation in mixing conditions using a 3-blade glass retreat 
curve in a 750 mL vessel and a magnetic stirrer in a beaker resulted in the crystals of 
the phosphoric salt of PABA with different morphologies. Comparison between 
predicted and experimental morphologies of salt crystals showed that the solvent 
(ethanol) affected the morphology of 4 out of a total of 6 salt crystals, indicating that 
solvent is an important parameter for designing a crystallization experiment. Alkali 
salts produced by evaporation at pH values above 8, including the sodium and 
potassium salts of PABA, were found to have a high tendency to form hydrates.  
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Chapter 9. pH controlled polymorphic crystallization  
 
9.1 Introduction 
 
Crystallization is a critical unit operation in the late stage of development of an API 
which is used for the separation and purification of the desired crystal form 
(Thompson et al., 2005). Purity of the compound is an important property to control 
(Braatz et al., 2002). pH and solvent are parameters that can affect the crystal form 
which nucleates from solution (Varshney et al., 2007; Braun et al., 2008; Reddy et al., 
2009).  
 
 
The research presented in this chapter focuses on using PAT tools and SSA 
techniques to examine the effect of solvent and pH on the crystal form, which 
nucleates from solution. The model system used in this study is PABA and MABA. 
PABA is known to contain two polymorphic forms (alpha and beta) (Gracin and 
Rasmuson, 2004; Gracin et al., 2005).  Very limited data exists on the crystallization 
of MABA. It has been reported that MABA has a tendency to form hydrates (He et 
al., 2005). From this thesis research work solid state analytical techniques including 
the use of the optical microscope, XRPD and solid state IR spectroscopy provided 
evidence that salts of PABA and MABA do not form when using water as a solvent or 
when using an ethanol solution at pH value above 3. DSC provided data on the 
melting point of crystal forms and detected a new undiscovered meta-stable form of 
MABA. PAT tools used to monitor the crystallization process include FBRM, ATR-
UV/Vis, PVM and pH probe. PVM provided in-situ images of the crystals in real-
time, indicating the formation of different forms of the crystalline compound. FBRM 
and ATR-UV/Vis detected changes occurring during the crystallization process which 
were originally thought to be due to a polymorphic transformation. Further analysis 
using a range of solid state analytical techniques confirmed that two different forms of 
the compound PABA crystallized resulting in an impure product. Combined PAT 
tools and SSA techniques have been used to increase process understanding that can 
prevent misinterpretation of results and provide the experimental conditions to 
produce the desired pure form of the compound.  
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9.2 Experiments performed  
 
Cooling crystallization experiments were performed within a 750 mL vessel using the 
model systems PABA and MABA. Variations were made to both pH and solvent to 
examine the effect of these parameters on the formation of salts. Section 3.2 of 
Chapter 3 lists the material used including acids/bases, solvents and the molarities of 
each acid/base used. The experimental conditions including all PAT tools used and a 
detailed experimental methodology are discussed in Section 3.4.4 of Chapter 3. A 
schematic of the crystallization rig is shown in Figure 3.3 of Chapter 3. Only 
experiments discussed in Section 9.6 use the ATR-UV/Vis probe.  
 
9.3 Evaluation of pH sensitivity and effect of solvent on the 
crystallization of MABA and the discovery of a new 
polymorphic form of MABA   
 
Cooling crystallization experiments were performed for MABA in water at pH=3 and 
in ethanol at pH=4.1. The acid used to achieve the desired pH of solution is 
hydrochloric acid. PAT tools used to monitor the crystallization experiment include 
the FBRM, pH and PVM probe. A single nucleation event is observed during both 
experiments by an increase in the FBRM counts. When using water as a solvent 
nucleation occurs after the system was cooled to 5 °C and kept at this temperature 
overnight. Nucleation is a slow process as represented by a gradual increase in FBRM 
counts as shown in Figure 9.1. Nucleation occurs very rapidly when using ethanol as a 
solvent, which is represented as a sharp increase in FBRM counts as shown in Figure 
9.2. 
 
PVM images of crystals during the cooling crystallization of MABA from ethanol at 
pH=4.1 are shown in Figure 9.3. The raw material form of MABA consists of small 
fine needles and once HCl acid is added to solution this forms star shape agglomerates 
as shown by Figure 9.3 (a). Nucleation at conditions of pH=4.1 results in the form of 
long fibrous needles as shown in Figure 9.3 (b). These images are similar to the raw 
material which suggests possible the formation of the same polymorphic form. 
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Figure 9.1. Results for the cooling crystallization of MABA from water at pH=3 
 
 
 
 
 
 
 
      
       
 
 
 
 
 
 
 
 
 
 
Figure 9.2. FBRM results for the cooling crystallization of MABA from ethanol 
at pH=4.1 
 
 
After filtration the crystals form agglomerates, which appear grey in colour after re-
crystallizing from water and white when re-crystallized from ethanol. These crystals 
appear different to the raw material form of MABA, which is in a white powder form. 
A range of solid state analytical techniques were performed on crystal samples to 
identify the crystal form which nucleated from solution.  
 
 
0
2000
4000
6000
8000
10000
12000
14000
16000
18000
20000
0 5 10 15 20 25 30
Time (hours)
C
o
u
n
ts
 /
 s
e
c
  
  
  
0
5
10
15
20
25
30
35
40
45
p
H
, 
 T
e
m
p
e
ra
tu
re
 (
 o
C
 )
, 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
A
c
id
 a
n
d
 B
a
s
e
 a
d
d
it
io
n
 (
g
) 
FBRM (1-1000 microns)
pH
Temperature ( deg C )
Acid addition (g) 
Base addition (g)
Nucleation 
0
5000
10000
15000
20000
25000
30000
35000
0 1 2 3 4
Time (hours)
C
o
u
n
ts
 /
 s
e
c
0
10
20
30
40
50
60
70
80
90
100
p
H
, 
T
e
m
p
e
ra
tu
re
 (
 o
C
 )
, 
 A
c
id
 a
n
d
 B
a
s
e
 a
d
d
it
io
n
 (
g
)
FBRM (1-1000 microns) pH
Temperature ( deg C ) Acid addition (g)
Base addition (g)
Nucleation  
1
st
 dissolution 
event 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates 
 
2011 
204 Chapter 9. pH controlled polymorphic crystallization 
 
 
      
     
 
 
 
 
 
 
 
 
 
Figure 9.3. PVM images of (a) MABA crystals during the first dissolution event 
(see Figure 9.2) showing the formation of agglomerated needles and (b) crystals 
nucleated from ethanol solution at pH 4.1  
    
 
The morphology of the crystals is an important parameter, which can affect the 
downstream processing including filtration and drying. The morphology of the raw 
material form of MABA and sample re-crystallized from water at pH=3 are in the 
form of fine needles as shown in Figure 9.4. Images of crystals re-crystallized from 
ethanol at pH=4.1 are similar to those shown in Figure 9.4 (b).  
        
 
Figure 9.4. Optical microscope images of (a) raw material form of MABA and 
(b) MABA re-crystallized from water at pH=3 
 
XRPD patterns for the raw material form of MABA, sample re-crystallized from 
water at pH=3 and sample re-crystallized from ethanol at pH=4.1 are shown in Figure 
9.5. Patterns for the three samples are very similar indicating that the samples re-
crystallized from water and ethanol are of the same form as the raw material. 
50 μm 50 μm   (b)   (a) 
100μm 100μm (a) (b) 
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Figure 9.5.  XRPD patterns for the raw material form of MABA, sample re-
crystallized from water at pH=3 and ethanol at pH=4.1 
 
 
IR spectra for the raw material form of MABA, samples re-crystallized from water at 
pH=3 and ethanol at pH=4.1 are shown in Figure 9.6. The board peak at 2950 and 
2962 cm
-1 
is due to the vibrations of the (O-H) bond of the carboxylic acid within the 
molecule. The sample of MABA re-crystallized from water forms agglomerates 
resulting in water molecules trapped on the surface of the crystals. The broader peak 
observed at 2962 cm
-1
 for MABA re-crystallized from water is thought to be due to 
the presence of hydrogen bonds formed between water and MABA molecules, which 
absorb in the range of 2500 and 3500 cm
-1
 (Stuart et al., 1998). The fingerprint region 
of wavelength range 400-1500 cm
-1
 is very similar for all samples indicating that the 
samples are of the same form. A recent report on MABA states the IR spectra for two 
different polymorphic forms including Form I which is stable and Form II which is 
meta-stable at ambient temperature (Svard et al., 2010). The IR spectra of all samples 
from these experiments are similar to Form I indicating the nucleation of the stable 
form (Svard et al., 2010).  
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Figure 9.6. IR spectrum for raw material form of MABA, sample re-crystallized 
from water at pH=3 and sample re-crystallized from ethanol at pH=4.1  
 
 
DSC analysis is performed on the raw material for of MABA and the samples re-
crystallized from water at pH=3 and ethanol at pH=4.1 to provide data on the melting 
point of the crystals. DSC results for two different batches of raw material form of 
MABA were performed using different ramp rates and the results are shown in Figure 
9.7 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.7. DSC results for the raw material form of MABA 
 
For both repeats two peaks are observed at temperatures in the range of 150-157 °C 
and 173-177 °C. The first small peak at 150-157 °C is thought to be due to a 
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polymorphic transformation from stable to meta-stable form, which then melts at a 
temperature in the range 173-177 °C. The two polymorphic forms of MABA are 
enantiotropic with a transition temperature of approximately 156 °C. The raw material 
form of MABA at room temperature is the stable form and is in the form of a very 
fine powder, which results in complete conversion from stable to meta-stable form at 
a transition temperature 150-157 °C.  
 
Differential scanning calorimetry results for repeated samples of MABA re-
crystallized from water are shown in Figure 9.8. Sample preparation required grinding 
the crystals from light grinding to intense grinding, in which the consistence was 
similar to the raw material (powder form). Both DSC plots show a small peak at     
157 °C which is due to the polymorphic transformation from stable to meta-stable 
form. As the filtered and grinded crystals are in the form of small agglomerates only a 
proportion of the sample transforms at the transition temperature (157 °C) resulting in 
a mixture of stable and meta-stable form. This stable form then melts at 170 °C. An 
exothermic peak at 172 °C appears in the DSC results for the sample that was lightly 
grinded, which is due to the re-crystallization of the meta-stable form. This form then 
melts at a peak of 177 °C. Similar results are reported in previous literature (Bernstein 
2002). Grinding the sample from lightly to intense (powder form) resulted in a larger 
percentage of conversion from stable to meta-stable form, which is shown in the DSC 
results by a decrease in melting enthalpy from 75 to 43 J/g at the melting of the stable 
form (170 °C) and an increase in melting enthalpy from 149 to 186 J/g at the melting 
of the meta-stable form (177 ºC). The melting points of the two forms are very close 
and therefore due to kinetics an exothermic peak (re-crystallization of meta-stable 
form) does not appear in the DSC results for the intense grinded sample or the 
presence of the stable form is very low and therefore there is not enough 
supersaturation available for the meta-stable form to re-crystallize from the melt. 
 
DSC analysis is performed on crystal samples re-crystallized from ethanol at pH=4.1 
and very similar results are observed as for the case when water was used as the 
solvent. Three endothermic peaks occur at temperatures of 148, 171 and 178 °C as 
shown in Figure 9.9. The peak at 148 °C is thought to be due to a polymorphic 
transformation from stable to meta-stable form, which does not undergo complete 
conversion due to the formation of agglomerates, resulting in a mixture of two forms. 
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The stable form melts at 171 °C and the meta-stable form melts at 178 °C. A recent 
report on MABA (Svard et al., 2010) showed similar findings to these results, 
supporting the predictions and confirming the existence of two polymorphic forms of 
MABA.  
 
 
 
 
 
 
 
 
 
 
Figure 9.8. DSC results for samples of crystals re-crystallized from water at 
pH=3 for lightly and intense grinding 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.9. DSC results for MABA re-crystallized from ethanol at pH=4.1 
 
 
TGA results for the raw material form of MABA, sample re-crystallized from water at 
pH=3 and ethanol at pH=4.1 are shown in Figure 9.10. As the samples are heated 
from room temperature to 150 °C there is no change in weight loss indicating the 
presence of the anhydrous form. There is a significant decrease in weight percentage 
at the transition temperature of the two polymorphs of MABA at 155 °C, which is 
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below the melting point of the two polymorphic forms. At this point the stable form 
transforms to the meta-stable form and a process of sublimation occurs resulting in a 
large decrease in weight. This is in correlation with results in the literature stating that 
MABA sublimes before melting (Rotich et al., 2001). 
 
 
 
                    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.10. TGA plots for (a) raw material form of MABA and (b) MABA re-
crystallized from water at pH=3 
 
 
Process analytical technology tools were used to monitor the crystallization process. 
FBRM detected the experimental conditions for which each system nucleated. A pH 
probe was used to monitor and control the pH of the system, so that nucleation 
occurred at a low pH (acidic conditions). Solid state characterisation of the crystals 
provided evidence that a salt does not form when using water as a solvent or when an 
organic solvent (ethanol) is used at pH=4.1. DSC analysis provided evidence that 
there are two different polymorphic forms of MABA which are enantiotropic related 
with a transition temperature of 157 °C. TGA confirmed that at the transition 
temperature sublimation occurs. XRPD and solid state IR analysis provided evidence 
that the stable form of MABA nucleated from solution when using water at pH=3 and 
ethanol at pH=4.1. These results are in correlation with results obtained from Svard 
(2010) who also confirmed the nucleation of the stable form from solvents of water 
and methanol.  
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9.4 Application of PVM for identifying the crystallization 
conditions of different forms of compounds of MABA  
 
 
PVM probe captures images of the crystals during the crystallization process while 
the optical microscope is an off-line solid state technique requiring sample removing 
from process stream. Changes in conditions of temperature and relative humidity can 
affect the stability order of different polymorphic forms of a compound which may 
have a different morphology. Transformations between the different forms after 
removal of samples from process stream can lead to misinterpretation of results 
obtained from the optical microscope images. PVM and optical microscope images of 
MABA re-crystallized from ethanol solution at pH=1.5 using hydrobromic acid (HBr) 
are shown in Figure 9.11. PVM shows a diamond shape crystal forms upon nucleation 
which is similar to the optical microscope images as shown in Figure 9.11b. The 
morphology of the crystals are different to the raw material, which has a needle shape 
(see Figure 9.4a), providing supporting evidence that possibly a salt forms under very 
acidic conditions (pH < 2.5). FBRM data which support these results is shown in 
Figure 8.10 of Chapter 8. 
 
       
Figure 9.11. (a) PVM and (b) optical microscope image of MABA re-crystallized 
from ethanol at pH=1.5 using HBr acid 
 
 
PVM images of MABA re-crystallized from ethanol at pH=2.5 using HCl acid are 
shown in Figure 9.12. PVM images show a change in morphology from fine needles 
to small rod shape crystals forming agglomerates once acid is added to solution. 
Images 9.12c and d show long rod shape crystals during nucleation. These images are 
100 μm 50 μm (a) (b) 
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similar to the optical and scanning electron microscope images as shown in Figure 8.4 
of Chapter 8. PVM images provide supporting evidence of the formation of the HCl 
salt of MABA under acidic conditions of low pH of 2.5 when using an organic solvent 
(ethanol). FBRM data which supports these results is shown in Figure 8.3 of Chapter 
8.  
 
 
    
       
Figure 9.12. PVM images of (a) raw material form of MABA, (b) crystals after 
HCl acid has been added to solution and (c,d) crystals after nucleation  
 
 
PVM images provide supportive information on the experimental conditions required 
to produce different salts forms of MABA. Differences in morphology from the 
starting material, indicates the presence of the salt. HCl salt of MABA shows long rod 
shape crystals while HBr salt of MABA is a diamond shape. Both these morphologies 
are desirable for further scale up, eliminating the problems in downstream process 
such as blockage of filter due to very fine crystals or needles.  
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9.5 Evaluation of pH sensitivity and effect of solvent on the 
crystallization of PABA  
 
Crystallization experiments were performed using the pH swing method and cooling. 
Crystallization of PABA using the pH swing method involved the addition of a base 
(NaOH) to dissolve the crystals and then acid (HCl) was added to the solution 
resulting in re-crystallization of the compound. Water was used as the solvent. The 
temperature was kept constant at 20 ºC. Nucleation occurred at pH=4.7 and the pH of 
the final solution in which crystals were suspended in solution was 3.6. FBRM results 
of the pH swing crystallization experiment are shown in Figure 9.13. A single 
nucleation event is detected by the FBRM probe as shown by a sudden change in the 
FBRM counts followed by a gradual increase in counts indicating additional 
nucleation.  
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.13. FBRM results for the pH swing crystallization experiments using 
water solution 
 
 
 
Cooling crystallization experiments were performed using water as the solvent. HCl 
and NaOH were added to solution to control the pH at a value of 2.6 in which 
nucleation occurred. The process was repeated at a higher pH value of 5.9. FBRM 
results show a single nucleation event during crystallization, at the desired pH values 
of 2.6 and 5.9, indicated as a sudden increase in FBRM counts as shown in Figure 
9.14.  
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Figure 9.14. FBRM results for the cooling crystallization of PABA from water at 
pH=5.9 using HCl  
 
Samples from both pH swing and cooling crystallization experiments were removed 
from the process stream after nucleation and analysed using a range of solid state 
techniques to identify the crystal form. Optical microscope images of the crystals are 
shown in Figure 9.15. Images show long needles which are similar to the raw material 
form of PABA (alpha form).    
     
            
 
 
 
 
 
 
Figure 9.15. Optical microscope images of PABA re-crystallized from water at 
different values (a) pH=2.5, (b) pH=3.6 and (c) pH=5.5 using hydrochloric acid  
 
XRPD patterns of the sample re-crystallized from water at pH=2.6, 3.6, 5.9 and the 
raw material form of PABA (alpha) are shown in Figure 9.16. The XRPD patterns are 
very similar indicating the formation of the alpha form of PABA from water within 
the pH range 2.6-5.9. 
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Figure 9.16. XRPD patterns for PABA re-crystallized from water within pH 
range of 2.6 to 5.9 using hydrochloric acid (HCl) and the raw material form of 
PABA. Intensities are shifted for clearer plotting  
 
Solid state characterisation of the crystals which nucleated from water at pH ranges 
2.6-5.9 provided evidence of the formation of the alpha form of PABA. At pH values 
below 3 the (NH3
+
) species within the molecule are 100% ionising indicating the 
likelihood of acidic salt formation (see Chapter 8). However for the cooling 
crystallization experiment of PABA from water using a pH value of 2.6 the salt does 
not form indicating that water is not a suitable solvent to crystallize salts. Cooling 
crystallization experiments were repeated using an organic solvent such as ethanol at 
pH value of 5.5.  The acid and base used to achieve the desired pH of solution were 
HCl and NaOH. FBRM results for the cooling crystallization of PABA from ethanol 
solution at pH=5.5 are shown in Figure 9.17. FBRM results show a large decrease in 
counts at the start of the experiment which is due to a combination of heating and 
diluting the system with the addition of acid and base to maintain the pH of solution at 
a set point value of 5. Once a maximum temperature of 70 
o
C is reached the FBRM 
counts decrease to 1300 indicating the presence of crystals in solution. Fluctuations in 
pH around the set point value of 5 results in the continuous addition of acid and base 
to the solution, which causes a fluctuation in FBRM counts as the system is kept at a 
constant temperature of 70 
o
C.  The increase in counts occurs as acid is added to the 
solution, which is thought to be due to the formation of the NaCl salt or HCl salt of 
PABA. As base (NaOH) is added to solution this results in a decrease in counts, 
which is due to diluting the system and increasing the solubility. The cycle was 
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repeated, resulting in the fluctuation in FBRM counts, until the system becomes 
undersaturated and all the crystals dissolve as shown by the zero counts in the FBRM 
reading. A single nucleation event is detected by a sudden increase in FBRM counts 
after 4 hours from the start of the experiment followed by a gradual increase in counts 
indicating additional nucleation. PVM probe is used to monitor the crystallization 
process providing images of the crystals in real time. These images are shown in 
Figure 9.18.  
 
The raw material form of PABA is in the form of small needles, which forms 
agglomerates due to the high density of solution as shown in Figure 9.18 (a). During 
heating the crystals start to dissolve and the solution becomes less dense. Figure     
9.18 (c) shows images of very fine particles which form agglomerates. These images 
are obtained as the system is kept constant at 70 
o
C and there is a continuous addition 
of acid/base causing a fluctuation in FBRM counts. At this point it is thought that 
either the NaCl salt or HCl salt of PABA forms. The solubility of sodium chloride in 
water at 70 ºC is 378 g/L (Perry and Green, 1998). Calculations were made on the 
concentration of NaCl in water at an approximate time of 1.5 hours from start of 
experiment in which the fluctuation in FBRM counts occurred (see Figure 9.17). The 
calculation showing the individual steps can be found in Appendix F. As this point the 
concentration of NaCl in water is 174.4 g/L, which is below the solubility value of 
378 g/L indicating an undersaturated solution. This supports the prediction that the 
fluctuation in FBRM counts is due to the formation of the HCl salt of PABA and not 
the NaCl salt.    
 
 
 
         
 
 
 
  
 
 
 
 
 
Figure 9.17 FBRM results for the cooling crystallization of PABA from ethanol 
at pH=5.6 
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Figure 9.18. PVM images of crystals during different stages of the crystallization 
experiment for PABA in ethanol at set point pH=5 showing (a) raw material 
form of PABA (needle morphology), (b) dissolution of needles during heating 
phase, (c) salt formation at temperature 70 
o
C and (d) nucleation at pH=5  
 
Crystal samples are removed from the process stream after nucleation at pH=5.6 and 
analysed using a range of solid state techniques including the optical microscope and 
XRPD. Optical microscope images of the crystals are shown in Figure 9.19. The 
image shows large needles of size greater than 400 μm, which are similar to the image 
shown in Figure 9.18 (d). 
 
 
 
 
 
 
 
 
Figure 9.19. Optical microscope images of crystals nucleated from ethanol 
solution at pH=5.6 
100 μm 
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  (d) 100 μm 100 μm   (c) 
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Figure 9.20 shows the XRPD patterns for the sample nucleated from ethanol at 
pH=5.6 and the raw material form of PABA (alpha). Both patterns are similar 
indicating the formation of this form.   
 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.20. XRPD patterns for PABA re-crystallized from ethanol at pH=5.6 
and the raw material form of PABA (alpha). Intensities are shifted for clearer 
plotting 
 
 
Solid state analytical techniques provided evidence that the alpha form of PABA 
nucleates from ethanol solution at pH=5.6. Using a combination of PAT tools 
including the FBRM and PVM probe to monitor the crystallization process provided 
additional information to understanding the process. The starting solvent is pure 
ethanol but as diluted forms of acid and base are added to solution this results in a 
water/ethanol mixture. Due to this reason and as the pH is above a value of 3 this 
reduces the likelihood of the formation of a salt.  
 
Cooling crystallization experiments for the model system PABA were performed at 
different conditions of pH and solvent choice. A combination of PAT and SSA 
techniques were used to monitor the crystallization process and to characterise the 
crystal product. Single nucleation events were detected with the FBRM probe and the 
PVM provided images of crystals during the process. SSA of the crystals provided 
evidence that the alpha form of PABA nucleated from water at pH range 2.5-5.9 
indicating that this is not a suitable solvent for crystallizing the salt. Cooling 
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crystallization of PABA from ethanol at pH of 5.9 also produced that alpha form 
indicating that the pH must be low (below 3) for salt production.  
                                   
 9.6 Application of PAT tools for monitoring the pH 
mediated crystallization of mixtures of PABA and the HCl 
salt 
 
PAT tools including the use of the FBRM, PVM and ATR-UV/Vis spectrometry are 
used to monitor the cooling crystallization of PABA from an ethanol solution at  
pH=2.5. Excess moles of PABA are added to solution compared with the moles of 
HCl acid. UV/Vis data shows a peak absorbance for the HCl salt of PABA at 295 nm 
and for PABA (alpha form) at 301 nm as shown in Figure 9.21. FBRM and UV/Vis 
results for the cooling crystallization experiment are shown in Figure 9.22.  
 
       
                                        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.21. UV/Vis spectrum for PABA and the HCl salt of PABA 
 
 
The sharp increase in both FBRM signal and absorbance at the start of experiment is 
due to the addition of solid to solution. FBRM and UV/Vis detects two dissolution 
events. At the moment acid (HCl) is added, the crystals dissolve as shown by a sharp 
decrease in the FBRM signal and sharp increase followed by a sharp decrease in 
absorbance at wavelength range 294-301 nm (see point (1) on Figure 9.22). The 
increase in absorbance is due to the PABA dissolving. As acid is added to the solution 
this reacts with PABA to form the salt which has a lower absorbance within the 
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wavelength range 295-301 nm compared to PABA causing the absorbance to decrease 
during acid addition. This prediction is supported with PVM images which show a 
change in morphology from needles to rod shape during the first dissolution event as 
shown in Figure 9.23 (a) and (b). Sodium hydroxide (NaOH) is added at point (2) on 
Figure 9.22 to dissolve all the crystals forming a clear solution of pH=2.5. The system 
is then cooled down at a ramp rate of 0.6 
o
C/min. Two nucleation events were 
detected by the FBRM probe showing a gradual increase in counts followed by a 
sharp increase in counts. The first nucleation event is due to the formation of the HCl 
salt of PABA and the second nucleation event is due to the formation of PABA as 
there was not enough acid in solution for all of the PABA to react to form the salt.  
During the first nucleation event the absorbance should decrease but it increases. This 
is thought to be due to a combination of crystals sticking to the probe window as 
water is present in solution and the temperature decreasing having a greater effect on 
the absorbance than the crystal form that nucleates from solution. A significant 
decrease in absorbance was detected during the second nucleation event, which is 
justified due to PABA absorbing to a larger extent compared to the salt within 
wavelengths of range 295-301 nm. PVM images of the crystals during the two 
nucleation events are shown in Figure 9.23 which support the prediction based on the 
FBRM results. Rod shape crystals form from the first nucleation event as shown in 
Figure 9.23 (c) and needles form during the second nucleation event as shown in 
Figure 9.23 (d). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.22. FBRM and UV/Vis results for the cooling crystallization of PABA 
from ethanol at pH=2.5 in which the moles of PABA is greater than HCl acid  
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Figure 9.23. PVM images of (a) raw material PABA, (b) salt formation during 
the 1
st
 dissolution event, (c) salt formation during the 1
st
 nucleation event and (d) 
mixture of salt and PABA for the 2
nd
 nucleation event  
 
 
The morphology of the crystal samples obtained after the first and second nucleation 
events are viewed using the optical and scanning electron microscope. Figure 9.24 (a) 
shows the optical microscope image of the crystals obtained from the first nucleation 
event. The morphology of the crystals is rod shaped with longest dimension greater 
than 200 μm. The crystals are fine particles, which are pink in colour with a sparking 
tint as shown in Figure B1 of appendix B. Optical microscope images of the crystals 
obtained after the second nucleation event are shown in Figure 9.24 (b). The 
morphology of the crystals is similar to the alpha form of PABA with needles of size 
greater than 300 μm. The clear difference between the morphology of the two crystal 
samples indicates the formation of two different forms. The hydro-chloride salt of 
PABA shows a rod shape while the alpha form of PABA has needle morphology.  
Figures 9.24 (c) and (d) show SEM images of a mixture of the salt (rod shape with a 
hexagonal face) and the alpha form of PABA (needles) which is present on the 
surface of the salt. 
200 μm 
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Figure 9.24. Microscope images of (a) hydro-chloride salt of PABA, (b) alpha 
form of PABA and scanning electron microscope images of (c, d)  mixture of 
hydro-chloride salt of PABA and PABA (alpha form) 
 
XRPD patterns for the sample from the first nucleation event and the salt are very 
similar as shown in Figure 9.25 (a). This provides evidence that the HCl salt of PABA 
nucleates from the first nucleation event. XRPD patterns for the sample from the 
second nucleation event and the raw material form of PABA (alpha) are shown in 
Figure 9.25 (b). The two nucleation events as shown in the FBRM results in Figure 
9.22 are thought to be due to a polymorphic transformation or the nucleation of a 
second form resulting in a mixture of two forms. The second sample was taken from 
the process stream at the end of the process when the FBRM counts remained 
constant. The XRPD pattern for the second sample and the raw material form of 
PABA are not identical. The XRPD for the second sample shows peaks at angles of 9 
and 14-15 which are characteristic for the alpha forms of PABA and peaks at angles 
of 27-29 which are characteristic of the HCl salt of PABA. This indicates that a 
mixture of salt and PABA (alpha form) crystallize from the second nucleation event, 
which confirms that the two nucleation events as shown in the FBRM results are due 
to the nucleation of two different forms and not a polymorphic transformation. 
 
Two repeats of DSC results for samples at the end of the second nucleation event are 
shown in Figure 9.26. Two endothermic peaks appear at 187 and 194 °C. The first 
peak at 187 °C is the melting of PABA (alpha form) and the second peak at 194 °C is 
thought to be due to the salt melting/dissolving in the melt. The third peak at 210 °C 
is exothermic which is thought to be due to re-crystallization of a compound from the 
melt which has a higher melting point than the range used in the DSC results, 
therefore no melting point is detected at high temperatures. The DSC results clearly 
   100 μm 
  (a)   (b)  (c)   (d) 
 100 μm    200 μm    100 μm 
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indicate that after the second nucleation event there is a mixture of salt and PABA 
providing further evidence that the two nucleation events are due to the nucleation of 
two separate forms and not a polymorphic transformation.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.25 XRPD patterns of (a) sample from 1
st
 nucleation and HCl salt of 
PABA  and (b) sample from 2
nd
 nucleation and raw material PABA. Intensities 
shifted for clearer plotting 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
Figure 9.26 DSC results for the sample nucleated from the second nucleation 
event during cooling crystallization of PABA from ethanol at pH=2.5 
 
A combination of the FBRM, PVM, ATR-UV/Vis and pH probe was used to monitor 
the cooling crystallization of PABA from ethanol at pH=2.5. The moles of PABA 
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(raw material) were in excess compared to the moles of HCl acid added. FBRM probe 
detected two nucleation events which were originally thought to be due to a 
polymorphic transformation. This statement was supported with the use of PVM 
images which shows a change in morphology during the two nucleation events. A 
range of SSA techniques were used to characterise the crystal product after the first 
and second nucleation events. Results showed supporting evidence that the salt 
nucleated from the first event and then the raw material (alpha) PABA nucleated from 
the second nucleation event. The two nucleation events were not due to a polymorphic 
transformation but the nucleation of two different crystal forms resulting in an impure 
product. These results show the importance of using a combination of PAT tools and 
SSA techniques in order to improve process understanding. PAT tools provide the 
conditions for which different forms crystallize from solution. This information can 
be use to design a robust process during scale up and prevent the crystallization of an 
impure product.  
 
9.7 Conclusions 
 
Combining PAT tools with SSA techniques provided the experimental conditions in 
which salts are most likely to crystallize from solution. PVM captures images of the 
crystals during the crystallization process which provides additional supportive 
information in identifying the nucleation of different crystal forms/salts. Salts do not 
form when using water as a solvent at pH values in the range 2.6-5.9 or in ethanol at 
pH values above 3. The HCl salt of PABA nucleated from ethanol at low pH value of 
2.5. FBRM detected two nucleation events which were originally thought to be due to 
a polymorphic transformation. However the SSA of crystal samples provided 
evidence that two different forms nucleated resulting in an impure product. These 
tools prevent misinterpretation of results and provide the experimental conditions to 
prevent the crystallization of an impure product, saving both time and money. PAT 
tools and SSA techniques also were used to discover a new polymorphic form of 
MABA. At room temperature the stable (raw material) form has a melting point of 
170 °C and the meta-stable form has a melting point of 177 °C. The two polymorphs 
are enantiotropic related with a transition temperature of 157 °C.    
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Chapter 10. Conclusions and future work  
 
10.1 Conclusions 
 
The aim of this research project is to apply a Quality-by-design (QbD) approach 
involving the use of PAT tools combined with SSA techniques to increase process 
understanding and knowledge for the design of robust crystallization processes. Within 
this section the conclusions about how PAT can be generally employed to understand 
how changes in the crystallization behaviour occur will be discussed and the 
conclusions of each chapter will be discussed together with how the key findings 
benefit industry. A summary table of all the compounds crystallized including new 
undiscovered forms and under what conditions nucleation occurred will be included in 
the conclusions.  
 
PAT tools are very useful for detecting changes occurring during the crystallization 
process, which could be a polymorphic transformation or the crystallization of an 
impure product. Combining a range of PAT tools to monitor the crystallization process 
provides additional supportive information to understand the process and prevents the 
misinterpretation of results, saving both time and money. 
 
The PVM probe is a useful tool for detecting changes in morphology of the crystals, 
which could indicate a polymorphic transformation or the crystallization of a impure 
product. This tool can identify the experimental conditions to produce crystals with the 
desired morphology, which will prevent problems in downstream processing such as 
long filtration times.  The FBRM probe has many statistics that can be used to monitor 
the crystallization process including total counts, fine counts, coarse counts, mean chord 
length and median. The fine counts, coarse counts and mean chord length are useful 
statistics for monitoring changes in morphology during the crystallization process, 
which could be a polymorphic transformation. Both the FBRM and turbidity probe are 
tools used for detecting the solubility (clear) points, nucleation (cloud) points and meta-
stable zone width (MSZW) measurements required for robust scale-up of the 
crystallization process. Both these tools have shown small differences in these 
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measurements. The turbidity probe provides less information about the process than the 
FBRM probe because it does not contain the additional statistics but the cost of the 
probe is cheaper and it provides good accurate results.  
 
There are benefits of using a combination of PAT tools, including the FBRM probe and 
ATR-UV/Vis spectrometer, to monitor the crystallization process. The FBRM probe 
may detect a fluctuation in counts (increase or decrease). This could be interpreted as 
sedimentation of crystals due to insufficient mixing, crystals sticking to vessel/probe 
walls, nucleation or a polymorphic transformation. If the ATR-UV/Vis probe detects a 
decrease in absorbance then this provides supporting evidence of nucleation or a 
polymorphic transformation. Combining these tools prevents the misinterpretation of 
results, saving both time and money. However within this research it must be noted that 
water was found to be not a suitable solvent to use for the ATR-UV/Vis as crystals stick 
to the probe and therefore result in an increase in absorbance during nucleation, which 
can lead to misinterpretation of results.    
 
Cooling crystallization experiments were performed using the model system sodium 
benzoate in water. The PAT tool used for monitoring the crystallization process is the 
FBRM probe. This tool detected a fluctuation in counts above a temperature of 65 ºC. 
Similar results were observed in different size vessels ranging from 750 to 1 L and 
using different ramp (cooling) rates of 0.5, 0.3 and 0.1 ºC/min. The repeatability of the 
results provided supporting evidence that the fluctuation in counts detected by the 
FBRM could be a polymorphic transformation. As hydrates tend to be stable at lower 
temperatures and anhydrates tend to be stable at higher temperatures the fluctuation at 
65 ºC is thought to be a polymorphic transformation from hydrate to the anhydrate 
form. Solid state characterisation of the crystals using a range of SSA techniques 
including optical microscopy, SEM, HSM, XRPD, DSC, TGA, DVS, NMR and IR 
spectroscopy confirmed the formation of a new undiscovered channel hydrate of 
sodium benzoate with molecular ratio SB to water of 1:0.28. This research highlights 
the usefulness of the FBRM probe in detecting polymorphic transformations and the 
importance of a combination of SSA techniques for the discovery of new polymorphs. 
Discovery of polymorphs earlier on in development can prevent late stage failures.  
 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates 
 
2011 
226 Chapter 10. Conclusions and future work 
Polymorphic transformations and new polymorphic forms were also discovered during 
the antisolvent crystallization experiments using the model system sodium benzoate in 
an IPA/water mixture. PAT tools used for monitoring the crystallization process include 
the FBRM probe, turbidity probe and ATR-UV/Vis spectrometer. Both the FBRM and 
turbidity probe detected a change occurring during the crystallization process once the 
volume ratio of IPA/water reached a value of 4:1. ATR-UV/Vis confirmed the change 
to be due to a polymorphic transformation and provided evidence that both solvent 
composition and kinetics had an influence on the behaviour of the system. Solid state 
characterisation of the crystals using a range of SSA techniques including SEM, XRPD, 
HT-XRPD, DSC, TGA, IR and NMR spectroscopy, confirmed the formation of a new 
undiscovered channel solvate. A combined DSC and HSM approach lead to the 
discovery of a new higher melting polymorphic form of sodium benzoate. This research 
reinforces the usefulness of using a combination of PAT tools including the FBRM, 
turbidity probe and ATR-UV/Vis in detecting polymorphic transformations during the 
crystallization process. The antisolvent crystallization experiments illustrated for the 
first time the capability of the ATR-UV/Vis instrument to detect polymorphic 
transformations. These results also demonstrate the importance of using a range of SSA 
techniques to discover new forms of crystalline compound.  
 
A combination of PAT tools and SSA techniques has also been used to investigate the 
problem of crusting (solid depositing on vessel walls) occurring within crystallization 
vessels. Cooling crystallization experiments were performed using the model system 
para-amino benzoic acid in ethyl acetate. The FBRM probe, turbidity probe and ATR-
UV/Vis spectrometer were used to monitor the crystallization process. SSA techniques 
including optical microscopy, XRPD and DSC were used to characterise the crystal 
product. The FBRM and turbidity probes detected a change occurring during the 
crystallization process. Repeats of the experiments using the ATR-UV/Vis confirmed 
that the change was due to crusting forming on vessel walls. This research highlights 
the importance of using a QbD approach involving the use of PAT tools and SSA 
techniques for gaining a deeper understanding of the crystallization process and to 
prevent misinterpretation of results, saving both time and money during the drug 
development process. This section provides the first comprehensive PAT-SSA based 
investigation of the important technological problem of crusting. An additional 
contribution to the field of knowledge highlights the need for improvement within 
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industrial scale vessel design, such as the use of vessels with variable jacket height, to 
prevent the problems of crusting.  
 
A QbD approach was also used during cooling crystallization experiments using the 
model system of ABA isomers in water to determine whether a robust MSZW can be 
obtained at lab scale and be used for the design of scale up experiments. The PAT tools 
used for measuring the solubility and nucleation curves, which is required for the 
determination of the MSZW, included the FBRM and turbidity probe. A robust MSZW 
ranging from 5.5 to 20.8 ºC was obtained for the model system meta-ABA in water, 
which takes into consideration variation in ramp rate, vessel size (1 mL and 1 L), 
agitator type and speed. This robust MSZW can then be used to design scale up 
experiments, increasing the likelihood of producing a quality product. The nucleation 
kinetics was determined for the ABA isomers corresponding to different vessel sizes 
and mixing conditions. The results shows that nucleation orders vary for different 
crystallization set-ups involving different size vessels and mixing conditions, 
highlighting that crystallization models containing nucleation parameters are only valid 
for a specific crystallization set-up. Therefore model based design and scale-up of 
crystallization processes must be used carefully and more detailed mechanistic models, 
which take into consideration the effect of mixing need to be designed to improve the 
generality and applicability of crystallization models.   
 
An alternative method used for designing a crystallization process to produce a quality 
product is through pH controlled polymorphic crystallization experiments, which were 
performed using the model systems meta/para-ABA in water and ethanol. A 
combination of 5 PAT tools was used in a single vessel to monitor the cooling 
crystallization process. PAT tools used include FBRM, ATR-UV/Vis, PVM, pH and a 
temperature probe. PAT tools detected a change occurring during the crystallization 
process, due to the formation of two products resulting in an impure product, confirmed 
by SSA methods.  These results reinforce that by using a QbD approach it can increase 
process understanding, preventing the misinterpretation of results. This approach 
enables better design of the crystallization process, preventing failed batches. Various 
parameters including solvent, pH of solution, strength and type of acid were varied to 
investigate the best conditions to produce pure salts. Cooling, evaporation and 
precipitation methods were used to produce salts. Results showed that water solution at 
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all pH values and an ethanol solution above a pH value of 3 are not suitable conditions 
to produce salts. Strength and acid type (mono, di and tri-protic) had no effect on the 
formation of salts but the di and tri-protic acids resulted in salt crystals precipitating 
from solution forming agglomerates, which is undesirable. PVM images showed that 
salt crystals improve the morphology of the crystals compared to the polymorphs. 
Solvent and variation in mixing conditions were found to affect the morphology of the 
salt crystals. Careful selection of design parameters is important for producing crystals 
of the desired morphology so as to prevent problems in downstream processing. Solid 
state characterisation of salts with the use of XRPD showed that by replacing different 
size ions within the same polymorph results in a change in structure of the salt. Salts 
containing the sodium and potassium ions have a high tendency to form hydrates. This 
research highlights that different salt crystals of the same compound have different 
structures and hence different physico-chemical properties. Therefore salt selection is 
important to consider when designing the crystallization process to ensure a quality 
product. 
 
The overall thesis presents research work that has contributed towards the field of 
knowledge of using a QbD approach involving the use of PAT tools and SSA 
techniques to design more robust crystallization processes. Key discoveries and new 
insights have shown that a QbD approach can overcome some of the problems that 
pharmaceutical industries face using PAT tools and confirmed with SSA techniques. 
New polymorphs were discovered during the crystallization process, which can prevent 
late stage failures and therefore reduce costs. The benefits of using a QbD approach, 
which increases process understanding and knowledge, has been shown to prevent the 
misinterpretation of results, speed up the crystallization process by highlighting key 
parameters that affect the quality of the product and identifies the experimental 
conditions to produce quality products. Results show the need for improvement within 
industrial vessel design and that the design of scale-up experiments involving the use of 
robust MSZW values obtained at lab scale can increase the likelihood of producing a 
quality product. These research findings show that a QbD approach can improve the 
quality of a product, prevent failed batches, speed up the time from drug discovery to 
market and reduce the costs of producing innovative medicines. This ultimately will 
improve profits by reducing essential costs of medicines and can have significant 
impact on our society by making new drugs available quicker and at a lower cost.  
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A summary table of all the crystal forms nucleated and isolated within this PhD thesis 
work including undiscovered new forms and the conditions of nucleation are listed in 
Table 10.1. 
 
 
Table 10.1. Summary of results for crystals forms produced during PhD thesis and 
experimental conditions  
 
Chapter Crystal form Method of 
crystallization 
Conditions of 
nucleation 
4 Sodium benzoate (SB) channel 
hydrate. (New undiscovered) 
Cooling water 
5 SB channel solvate. (New 
undiscovered) 
Anti-solvent IPA/water volume 
ratio of 2:1 
5 SB channel hydrate Anti-solvent IPA/water volume 
ratio of 4:1 
5 Higher melting polymorphic 
form of SB at temperatures 
above 437 ºC (melting point of 
anhydrous form) 
- DSC and hot stage 
microscopy analysis 
8 HCl salt of MABA  Cooling Ethanol at pH 2.5 
8 HBr salt of MABA Cooling Ethanol at pH 1.5 
8 HCl salt of PABA  Cooling Ethanol at pH 2.5 
8 HBr salt of PABA  Cooling Ethanol at pH 1 
8 H2SO4 salt of PABA 
 
Precipitation  Ethanol at pH 1.2 
8 H3PO4 salt of PABA  Precipitation Ethanol at pH 3.3 
8 Sodium salt of PABA (hydrates) Evaporation Ethanol at pH 10.7 
8 Potassium salt of PABA 
(hydrates) 
Evaporation Ethanol at pH 8.1 
9 Anhydrous alpha form of PABA pH swing and cooling Water at pH range 2.5 
to 5.9 and ethanol at 
pH 5.9 
9 Anhydrous form of MABA  Cooling Water at pH 3 and 
ethanol at pH 4.1 
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10.2 Recommendation for future work 
 
Recommendations for future work based on the research results presented in this thesis 
are mentioned in the following points:  
 
 
a) In the studies using the model systems of sodium benzoate in water and a 
water/IPA mixture (Chapter 4 and 5), PABA in ethyl acetate (Chapter 6) and 
PABA in a water/ethanol mixture (Chapter 9), crystallization experiments were 
performed using a range of PAT tools to monitor the process. PAT tools used 
include FRBM, PVM turbidity probe and ATR-UV/Vis spectrometer. In all 
cases the PAT tools detected a change occurring during the crystallization 
process, which was originally thought to be due to a polymorphic 
transformation. However in some cases after SSA of the crystal product this was 
found not to be the case. An additional PAT tool that would be recommended to 
monitor the crystallization process is the in-situ Raman probe. This technique 
will show a different spectrum for each polymorphic form and can be used to 
detect polymorphic transformation during the process. By using the Raman 
probe it would provide additional information that would prevent 
misinterpretation of results and speed up the time taken to design a robust 
crystallization process for the production of quality crystals.  
b) The problem of crusting (solid depositing on vessel walls) occurring during the 
crystallization process was identified during lab scale experiments with the use 
of PAT tools and SSA techniques. Crusting is a significant industrial problem 
since it can lead to large batch-to batch variation in product quality due to 
accidental seeding, formation of large lumps.  Additionally the product can be 
contaminated through solvent inclusion as due to degradation because of 
overheating of the solid deposited on the wall of the vessel. A suggestion of 
future research would involve the design of pilot and industrial size rigs with 
variable jacket height vessels or an alternative design that will eliminate the 
problems of crusting. Novel jacket designs could be developed and a 
crystallization system with automated jacket height adjustment based on level 
measurement in the vessel would be designed. Improved design of 
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crystallization rigs would increase the likelihood of producing a quality product 
and prevent failed batches.  
c) Robust MSZW values were obtained at the lab scale for the model system meta-
ABA in water. This robust MSZW takes into consideration variations in ramp 
rate, vessel size (1 mL and 1 L), agitator speed and type. Further research would 
involve the design of scale-up crystallization experiments (pilot plant and 
industrial scale) in which a supersaturation profile is followed within the robust 
MSZW region using a feedback loop for obtaining quality crystals with 
consistent properties. Additionally robust experimental design approaches could 
be used to determine the boundaries of the robust operating zone with a 
particular confidence interval, which would guarantee with a given probability, 
the consistency of certain product properties.      
d) The nucleation order, which is a parameter used within crystallization models 
was found to vary within different crystallization set-ups including variable 
vessel size and mixing conditions. A suggestion for further research would 
involve the design of mechanistic models, which take into consideration the 
effect of mixing in the mechanisms. These developed models can improve the 
generality and applicability of crystallization models and can be used for the 
model-based design and optimisation of the crystallization processes.   
e) Experiments involving MSZW measurements have been used to determine 
nucleation orders for the isomers meta and para-ABA. Further experiments 
involving MSZW measurements would be required to determine the nucleation 
order for the isomer ortho-ABA within the same crystallization set-up (vessel 
size and mixing conditions). Obtaining the nucleation order of all three isomers 
of ABA within the same crystallization set-up will provide new knowledge on 
how positional isomers influence the nucleation mechanism, and on whether 
crystallization models containing nucleation orders apply only to a particular 
isomer. This information could contribute towards better understanding of the 
nucleation mechanism and improving the future design of crystallization 
models.  
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Appendix A.   Avantium Crystal 16 equipment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (A1) Picture of the Avantium Crystal 16 equipment.  
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Appendix B. Pictures of salt crystals produced within Chapter 8 of 
thesis 
 
 
 
 
Figure B1 Picture of different colour salt crystals of PABA and MABA produced 
during cooing crystallization experiments.  
 
 
 
 
 
 
 
 
 
 
 
Pink crystals: 
hydrochloride 
salt of PABA  
Yellow crystals: 
hydrochloride salt 
of MABA  
White crystals: 
hydrobromide salt 
of PABA  
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Appendix C. Turbidity (solubility) results for sodium benzoate in 
organic solvents  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (C1) Turbidity (solubility) results for sodium benzoate (SB) in acetone, 
acetonitrile, methyl ethyl ketone and tetrahydrofuran   
 
Figure (C2) Turbidity (solubility) results for sodium benzoate (SB) in methanol, 
ethnaol, propan-2-ol (IPA) and butan-2-ol 
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Figures (C1 and  C2) show the turbidity results for sodium benzoate in organic solvents 
including methanol, ethanol, propan-2-ol (IPA), butan-2-ol, acetone, acetonitrile, 
methyl ethyl ketone and tetrahydrofuran.  A turbidity value of 100% represents a clear 
solution and a turbidity value of 0% represents a cloudy solution. For all organic 
solvents except methanol the turbidity value remains at zero % during both heating and 
cooling phases indicating that the solubility of sodium benzoate in organic solvents in 
very low.  
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Appendix D. Solubility graphs for para- and meta-amino benzoic acid 
in water obtained from the Literature 
 
Figure (D1) Solubility data for the two forms (alpha and beta) of para-amino benzoic 
acid in water. Date obtained from the literature (Gracin and Rasmuson) using a 
gravimetric method.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (D2) Solubility data for meta-amino benzoic acid in water. Data obtained from 
the literature (Stephen and Stephen, 1963).  
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Appendix E. TGA and DVS calculations on the molecular ratio of 
sodium benzoate in water and the sodium and potassium salts of PABA 
(see chapters 4, 5 and 8) 
 
A sample TGA calculation (based on results from Chapter 4) for the molecular ratio of 
sodium benzoate to water is shown below. For the TGA results based on the 1 mL scale  
for sodium benzoate that re-crystallized from water the initially sample weight was 
26.497 mg (dry weight and solvent). During the heating phase from 25 to 250 °C there 
is a 3.166% weight decrease. This is assumed to be loss of water from the internal 
structure of the crystal. Therefore the amount of water lost from the sample is: 
 
mgx 84.0497.26
100
166.3






. 
 
The amount of anhydrate form of sodium benzoate present is:  
 
26.497-0.84= 25.66mg . 
 
The molar ratio of sodium benzoate to water is calculated using the following formula:  
 
Moles= mass/molar mass.                                                                                            (E1) 
 
The molar mass of sodium benzoate is 144.11 and for water is 18.01. From these values 
the molar ratio is calculated as shown below: 
 
  Sodium benzoate (SB) to water: 
01.18
8388.0
:
11.144
66.25
    
 
Molar ratio of SB: water: 0.178: 0.0465 
 
Molar ratio of SB: water: 1: 0.26 
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The same method of calculation was applied for the DVS results expect the initial 
weight of solid for TGA analysis is that of the hydrate or solvate (anhydrous (dry) 
weight and solvent) and the initial weight of solid for DVS analysis is that of the 
anhydrous (dry) form.  
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Appendix F. Calculation on the concentration of sodium chloride in 
water during a pH controlled cooling crystallization experiment of PABA 
in water (See Figure 9.17 within Chapter 9) 
 
Key stages in these calculations are as follows: 
1) Calculation on the amount of sodium chloride and water formed  
2) Calculation on how much water is added from 5M hydrochloric acid (HCl) and 
5M sodium hydroxide (NaOH) solution 
3) Sum the total amount of water formed and added during crystallization process 
4) Concentration calculation of NaCl  is mass of NaCl / volume of water 
 
Stage 1 Calculation on the amount of sodium chloride and water formed 
Basic information:  
 Total amount of HCl acid added = 21.27g 
 Total amount of NaOH added= 26.4g 
 Density of NaOH is 1.5g/mL 
 Density of HCl is 1.18g/mL 
 Density of water 1 g/mL 
 Molarity of NaOH and NaCl is 5.  
 Molar mass of NaCl is 58.44 g/mol 
 Molar mass of water is 18 g/mol 
The moles of NaOH formed is calculated using the following equations: 
 
                   
                                                                                         (F1) 
 
 
 
                      
                                                                                             (F2) 
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The same method is used for calculating the moles of HCl acid formed 
 
Moles of HCl formed is 0.090  
 
 Reaction equation shows a 1 mole ratio:          
 
  ,                                                                         (F3) 
  
 
Mass of sodium chloride (NaCl) formed is calculated using the following equation: 
  
                                                                       (F4)         
 
m of sodium chloride formed =   0.088 x 58.44= 5.14g 
 
Mass of water formed =   0.088 x18= 1.584g 
 
Volume of water formed is calculated using equation B1 = 0.001584 L 
 
 
Stage 2 Calculation on how much water is added from 5M hydrochloric acid (HCl) and 
5M sodium hydroxide (NaOH) solution 
 
Within a 1 L solution of 5M HCl there is 506g of HCl and 571g of water 
Total mass of HCl and water in 1 L solution is 1077g 
 
Percentage of HCl is (506/1077)x 100= 47% 
Percentage of water is (571/1077)x 100= 53% 
 
Amount of 5M HCl solution added to process is 21.27g. Therefore the amount of 
water added from the HCl solution is: 
 
 
 PAT investigation of pharmaceutical crystallization polymorphs/ salts/ hydrates 
 
2011 
259 Appendix F 
 
Within a 1 L solution of 5M NaOH  there is 425.3g of NaOH and 716.5g of water 
Total mass of NaOH and water in 1 L solution is 1141.8g 
 
Percentage of NaOH is (425.3/1141.8)x 100= 37.2% 
Percentage of water is (716.5/1141.8)x 100= 62.7% 
 
Amount of 5M NaOH solution added to process is 26.4g. Therefore the amount of 
water added from the NaOH solution is: 
 
 
 
 
Stage 3 Sum the total amount of water formed and added during crystallization process 
 
Water formed =0.001584 L 
Water added= 11.27+16.6= 27.9g =0.0279 L 
 
Total water (formed and added)= 0.02948 L 
 
Stage 4 Concentration calculation of NaCl  is mass of NaCl / volume of water 
 
mass of sodium chloride formed =   5.14g 
 
Volume of water (formed and added)= 0.02948 L 
 
 
                                                                                             (F5) 
 
 
Concentration of sodium chloride in water = 5.14/0.02948= 174.4g/ L 
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Appendix G . Derivation of pH-solubility equations (This derivation 
can be obtained from Florence and Attwood, 1981) (see Chapter 8) 
 
Basic information 
 Total saturation solubility of the drug is S 
 Solubility of the undissociated species is So  
 S=So + (concentration of ionised species) 
 
First derivation based on acidic drugs.  
 
Acidic drugs are less soluble in acidic solutions than alkaline solutions. The acidic drug 
is represented as HA.  
 
The dissociation of the acid in water can be written as: 
 
                                                                                             (G1) 
  
 and the dissociation constant is given by  
 
  
                                                                                                        (G2) 
 
 
Rearranging Equation (G2) and substituting So for [HA]  
 
 
                                                                                                         (G3) 
 
     
   
Concentration of ionised species is 
 
          
                                                                                                                (G4)       
 
 
 
Substitution of Equation (G4) into (G3) gives the following:   
 
   
                                                                                                           (G5) 
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Taking logarithms of both sides of Equation (G5) gives the following: 
 
             
                                                                                            (G6)                         
 
 
Equation (G6) is used at pH values above the iso-electric point. 
 
 
Second derivation based on basic drugs 
 
Basic drugs are more soluble in acidic solution. The basic drug is represented as RNH2. 
The dissociation of the base in water is shown in the following Equation (G7): 
 
  
                                                                              (G7) 
 
 
The dissociation constant is given by  
 
                                                                                                     (G8) 
 
 
Equilibrium constant (Kw ) for water is given by the following Equation: 
 
        
                                                                                             (G9) 
 
 
Rearranging Equation (G9) gives the following: 
 
 
                                                                                                        (G10) 
 
 
Substituting Equation (G10) into (G8) and rearranging gives the following:   
 
 
                                                                                                          (G11) 
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Substituting So=RNH2  and S-So= RNH3
+   
 into Equation (G11) gives: 
 
 
                                                                                                          (G12) 
 
 
Taking logarithms 
 
 
                                                                                          (G13)                                                                                                                    
 
 
Equation (G13) is used at pH values below the iso-electric point. 
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